Prevention: an achievable goal in personalized medicine. by Cuijpers, P.
ear Colleagues,
In medicine, knowledge of the disease and an understanding of its mechanisms are required;
personalized medicine is aimed at determining to what extent the pathology, as well as its treatment,
is linked to the individual person.
The symptomatic expression of a disease can differ from one patient to the next; various inves-
tigative methods can lead to development of an individual typology, and to identification of partic-
ular groups in terms of clinical picture or treatment response.
Certain mechanisms are a function of background factors and environmental influences; it is
assumed that these aspects have a determinant influence on the disease, on its course, and possibly
on its reaction to various therapeutic approaches.
Finally, the course of the disease in response to treatment can vary from one subject to another
(genetic, enzymatic and metabolic aspects, etc).
The tools we have currently available for clinical and biological investigations, and for imag-
ing, allow us to characterize individuals more effectively, and to highlight particular profiles. These
specifications are the basis of personalized medicine, which can be applied in specific ways in a num-
ber of different fields, whether diagnostic, exploratory, or therapeutic. 
In terms of recent developments in modern medicine, it would be a huge task to cover all the
fields concerned. In the current issue we have chosen to give examples of possible applications of this
approach, without attempting to exhaustively cover all the aspects of this subject.
We would like to warmly thank Prof Barry Lebowitz, who coordinated this issue brilliantly, 
Dr Rajesh Parikh who assisted him in this, and all the authors of this complex review.
Sincerely yours,
Jean-Paul Macher, MD
E d i t o r i a l
D
357
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 357
C o n t e n t s
Page
359
357
405
417
427
435
447
455
464
363
397
389
377
361
Editorial
Jean-Paul Macher
In this issue
Barry D. Lebowitz, Rajesh Parikh
State of the art
The intersection of pharmacology, imaging, and genetics in the development of 
personalized medicine    
Philip Gerretsen, Daniel J. Müller, Arun Tiwari, David Mamo, 
Bruce G. Pollock (Canada)
Special article
Policy perspectives on the emerging pathways of personalized medicine 
Gregory J. Downing (USA) 
Translational research
The role of neuroimaging in diagnosis and personalized medicine—current position
and likely future directions 
Michael Brammer (UK) 
Stem cell approaches in psychiatry—challenges and opportunities 
Jens Benninghoff (Germany)
Pharmacological aspects
Pharmacogenetics of antipsychotic-induced side effects
Todd Lencz, Anil K. Malhotra (USA)
Major depression during interferon-α treatment: vulnerability and prevention
Francis E. Lotrich (USA)
Clinical research
Personalized medicine in psychiatry: ethical challenges and opportunities
Kathinka Evers (Sweden)
A new paradigm for the prediction of antidepressant treatment response
Andrew F. Leuchter, Ian A. Cook, Aimee M. Hunter, Alexander S. Korb (USA)
Prevention: an achievable goal in personalized medicine
Pim Cuijpers (The Netherlands)
Shared decision making in mental health: prospects for personalized medicine
Robert E. Drake, Delia Cimpean, William C. Torrey (USA)
Brief report
Personalized medicine: selected Web resources
Nancy F. Stimson (USA)
ISSUE COORDINATED BY: Barry D. Lebowitz
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 359
360
C o n t r i b u t o r s
Author affiliations: Pharmacogenetics
Research Clinic, Neurogenetics Section,
Centre for Addiction and Mental Health,
University of Toronto, Canada
Daniel J. Müller, MD
Author affiliations: Project Director, Per-
sonalized Health Care Initiative, Office of
the Secretary, Department of Health and
Human Services, Washington, DC, USA 
Gregory J. Downing, DO, PhD
Author affiliations: Centre for Neu-
roimaging Sciences, Institute of Psychia-
try, Kings College, London, UK
Michael Brammer, PhD
Author affiliations: Department of Psychi-
atry, Ludwig-Maximilian University,
Munich, Germany
Jens Benninghoff, MD
Author affiliations: Centre for Research
Ethics & Bioethics, Uppsala University,
Sweden  
Kathinka Evers, PhD
Author affiliations: Laboratory of Brain
Behavior, and Pharmacology, and the
Depression Research and Clinical Program,
Semel Institute for Neuroscience and
Human Behavior at UCLA, and the
Department of Psychiatry and Biobehav-
ioral Sciences, David Geffen School of
Medicine at UCLA, Los Angeles, Califor-
nia, USA
Andrew F. Leuchter, MD
Author affiliations: Department of Clinical
Psychology and EMGO Institute, VU Uni-
versity Amsterdam, The Netherlands
Pim Cuijpers, PhD
Author affiliations: Dartmouth Psychiatric
Research Center, Lebanon, New Hamp-
shire, USA
Robert E. Drake, PhD
Author affiliations: Biomedical Library,
University of California, San Diego, La
Jolla, California, USA  
Nancy F. Stimson, MLS
Author affiliations: Center for Translational
Psychiatry, Feinstein Institute for Medical
Research; Division of Psychiatry Research,
The Zucker Hillside Hospital, North Shore –
Long Island Jewish Health System, Glen
Oaks, NY, USA; Department of Psychiatry
and Behavioral Science, Albert Einstein Col-
lege of Medicine, Bronx, NY, USA
Anil K. Malhotra, MD
Author affiliations: Western Psychiatric
Institute and Clinic, Pittsburgh, Pennsylva-
nia, USA 
Francis E. Lotrich, MD, PhD
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 360
361
I n  t h i s  i s s u e . . .
“Every so often, a scientific advance offers new oppor-
tunities for making real advances in medical care.”1 The
clinical practice of medicine is facing dramatic change
and new opportunities. The worldwide investment in bio-
medical research by governments, foundations, and the
private sector, measurable in hundreds of billions of dol-
lars (US), have produced new tools and new approaches
that are truly transformational. For disorders of the brain,
new tools are yielding new hypotheses to guide treat-
ment discovery and for tailoring treatments to specific
patients. This transformation will change the focus of
medicine to a more proactive strategy. New structural
and functional imaging technologies, in combination
with genomic, proteomic, and many other “-omics”
methodologies, will create opportunities for selection of
“personalized” clinical approaches, rather than the
reliance on “one size fits all” treatment strategies. Stem
cell approaches have the potential for reversing the neu-
roanatomic foundation of brain disorders. 
Figure 1, generously provided by the Office of the Direc-
tor of the US National Institutes of Health (NIH), presents
the potential of personalized medicine in what has come
to be called the 4P model. In this approach, targets of
intervention are broadened beyond treatment response
and remission to disease prevention and disruption/rever-
sal of clinical course (preemption). The selection of treat-
ments is based upon predictive models and strategies that
yield a tailored (personalized) approach. The informed and
activated patient is a critical part of the transformation of
medicine. Thanks to advances in information technology,
and to greater acceptance of a “shared decision making”
approach to treatment, medicine is becoming more inter-
active. The participatory aspect of medicine is changing
the nature of the doctor-patient relationship. 
Personalized medicine is very much a work in progress.
We have assembled an outstanding group of interna-
tional scholars and policy makers to provide a snapshot
of this topic. The Editorial Board thanks each of the con-
tributors for their thoughtful papers. The papers as a
whole give us much to anticipate as this revolution in
medicine unfolds for the benefit of our patients.
The issue begins with an overview of the State of the
art by Prof Bruce Pollock and colleagues (p 363). The
paper contrasts the practice of “average” medicine with
a more tailored approach that uses brain imaging, phar-
macology, and genetics as markers of treatment response
and adverse events. They conclude that no single method
is optimal and that multimodal approaches have the
greatest potential for moving the field forward.
Interest in the development of personalized medicine is
a topic of interest for those at the highest levels of health
policy. It is a privilege for DCNS to present the first Spe-
cial article we have published. Dr Gregory Downing (p
377), Director of the Personalized Healthcare Initiative of
the US Department of Health and Human Services, char-
acterizes personalized medicine as a “disruptive” inno-
vation. He describes the essential role of information
technology (health IT) and discusses the substantive
thinking on US policy and regulation in personalized
medicine (see, for example, ref 2). 
Two papers on Translational research highlight some
of the complex methodological challenges being
addressed in the field. Prof Michael Brammer (p 389)
illustrates the potential applications of structural and
functional magnetic resonance imaging (MRI and fMRI)
in personalized medicine and proposes some innovative
analytic methods, based on machine learning approach-
es from the field of artificial intelligence that will facilitate
use of these approaches. The paper by Prof Jens Ben-
ninghoff (p 397) introduces approaches of stem cell biol-
ogy  and anticipates a future where processes of neuro-
genesis will become a standard of treatment. 
Two papers on Pharmacological aspects illustrate the
potential of pharmacogenetics. The first, by Profs Todd
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 361
362
Lencz and Anil Malhotra (p 405), examines the important
topic of pharmacogenomic correlates of antipsychotic-
induced side effects. They describe the limits of a candi-
date gene approach and describe new methodological
strategies to accelerate developments in the field. The
paper by Prof Francis Lotrich (p 417) provides another
example of the value of a pharmacogenetic approach in
its use in target identification for treatment development.
He concludes that identification of modifiable risk factors
that is made possible by pharmacogenetics opens the
opportunity for preventive intervention. 
The prospects of more personalized approaches to medi-
cine are exciting and challenging. At the same time, there
are very real possibilities of overpromising (see, for exam-
ple, ref 3) and misrepresenting the value of these
approaches. The Clinical research section begins with an
article by Prof Kathinka Evers (p 427) that explicates these
bioethical concerns. She concludes by alerting us to the
possibility of exaggeration of promises and to the need for
rigorous cost benefit evaluation of these proposed
approaches before adoption (see, for example, ref 4). Mov-
ing to clinical or patient-oriented research, Prof Andrew
Leuchter and colleagues (p 435) identify a set of clinical
and brain function (quantitative electroencephalographic)
predictors of treatment response and propose the concept
of “response endophenotypes” for this class of predictors.
Their approach illustrates many aspects of the possible
benefits of tailored approaches to personalized treatment
and suggests the possibility of revising the methodology of
the randomized clinical trial to establish treatment safety
and efficacy. Prof Pim Cuijpers (p 447) proposes a new
approach to prevention. A major focus of the paper is
innovative use of statistical methods to identify target
groups for preventive intervention. He concludes that pre-
vention is currently achievable and that Web-based
approaches may make such interventions accessible to
broad populations. Prof Robert Drake and colleagues (p
455) summarize their pioneering studies of shared decision
making. They make the convincing case for the essential
role of shared decision making in the development of per-
sonalized mental health care, and identify major barriers
that currently inhibit the full implementation of this
approach. They identify a number of important research
questions that could advance the field and describe the
needs for further development from the decision sciences
and in the areas of education of clinicians and patients.
Our understanding of personalized medicine and its var-
ious component parts is evolving rapidly. Contributions
are coming from all over the world and in many different
formats. The concluding paper in this issue, a Brief
report by Nancy Stimson, MLS (p 464), describes the
electronic resources that are available and provides guid-
ance on the selection of key words and search strategies.
Keeping abreast of this information is a great challenge
for the active investigator, teacher, and clinician. She con-
cludes with the recommendation that, when possible,
information professionals be involved in the development
of efficient search and update strategies.
We are very early in the development of personalized
medicine. Already there are a few examples around use
of medications.5-8 More will doubtless come. Right now,
the use of any of the genomic, imaging, or stem cell
approaches discussed in this issue is best seen as
exploratory research. We look forward to the time in the
not-so-distant future when we will be able to use the
technologies of personalized medicine to enhance our
research and to optimize our care of patients. 
I n  t h i s  i s s u e . . .
Barry D. Lebowitz, PhD; Rajesh Parikh, MD
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ince the serendipitous discoveries of chlorpro-
mazine and imipramine, the precursors of current
antipsychotics and antidepressants, respectively, we have
made arguably few strides towards the improvement of
clinical outcomes. Our major gains have been in the area
of pharmacotherapy acceptance and tolerability. The
development of serotonin reuptake inhibitors has dra-
matically reduced the side effects and lethality in over-
dose of commonly prescribed antidepressants. Similarly,
second-generation antipsychotics have significantly
decreased the incidence of extrapyramidal symptoms
(EPS), including tardive dyskinesia and parkinsonism,
but at the same time have increased the long-term like-
lihood of mortality and morbidity secondary to adverse
metabolic effects.
We remain in an era of uncertainty with regard to the
underpinnings of individual variability in order to pre-
emptively differentiate treatment responders from non-
responders. Our current evidence-based medicine relies
on large randomized control trials and meta-analyses—
average medicine, which ignores individual differences.
This dependence on large group analyses places us at a
risk of discarding subgroup-specific treatment options
owing to their failure to prove efficacious across entire
populations.1
There is a new era emerging in psychiatry of personalized
medicine that will focus on individual differences not evi-
dent phenomenologically. Much research is directed
towards the identification of genes, endophenotypes, and
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We currently rely on large randomized controlled trials
and meta-analyses to make clinical decisions; this places
us at a risk of discarding subgroup or individually specific
treatment options owing to their failure to prove effi-
cacious across entire populations. There is a new era
emerging in personalized medicine that will focus on
individual differences that are not evident phenomeno-
logically. Much research is directed towards identifying
genes, endophenotypes, and biomarkers of disease that
will facilitate diagnosis and predict treatment outcome.
We are at the threshold of being able to predict treat-
ment response, primarily through genetics and neu-
roimaging. In this review we discuss the most promising
markers of treatment response and adverse effects
emerging from the areas of pharmacogenetics and neu-
roimaging in depression and schizophrenia. 
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:363-376.
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biomarkers of disease that will facilitate diagnosis and
predict treatment outcome. Pharmacogenetic studies that
explore the role of an individual’s genetic makeup in
determining the effectiveness of pharmacotherapy are of
increasing interest. The rationale for the hypothesized
role of pharmacogenetics is based on observations made
in family and twin studies, where closely related relatives
tend to show similar response or side-effect patterns
(reviewed in ref 2). All proteins, including those involved
in the metabolism and central effects of pharmaceuticals,
can differ as a result of naturally occurring variability in
the DNA sequence of the associated gene. This has led
investigators to study gene variants for their association
with antipsychotic drug outcome. Gene variants (ie, alle-
les or polymorphisms) that code for the enzymes respon-
sible for drug metabolism can affect pharmacokinetics,
and therefore the amount of drug available in the body
to elicit a response. In addition, gene variants can affect
pharmacodynamics, the therapeutic effect of a drug in the
target organ (Figure 1, “PK and PD”). Representative
S t a t e  o f  t h e  a r t
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Selected abbreviations and acronyms
5-HT serotonin
5-HTTLPR serotonin transporter-linked polymorphic
region
ACC Anterior cingulate cortex
BDNF brain-derived neurotrophic factor
CYP cytochrome P450
PM poor drug metabolizer
UM ultrarapid drug metabolizer
Figure 1. The influence of pharmacokinetic, pharmacodynamic and environmental factors on pharmacotherapy response and side effects (source:
www.silvermedia.ca).
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examples in breast cancer research include the overex-
pression of the HER2 gene, a positive predictor of
response to the drug trastuzumab (Herceptin), and the
predictive value of active cytochrome P450 (CYP) 2D6
alleles in tamoxifen discontinuation.3
In psychiatry, we lack basic laboratory investigations to
diagnose mental illness, let alone genetic advances to
guide treatment. A primary goal of current research is
to characterize the etiologies and biological susceptibil-
ities of heterogeneous, complex conditions, such as
depression and psychosis. We are at the threshold of
being able to predict treatment response, primarily
through genetics and neuroimaging. 
Personalized medicine in psychiatry is a broad topic. As
such, we will confine our review to the most promising
markers of treatment response and adverse effects
emerging from the areas of pharmacogenetics and neu-
roimaging in depression and schizophrenia.
Genetics of antipsychotic drug metabolism,
response, and side effects in schizophrenia
Antipsychotic drugs remain the cornerstone of treat-
ment in schizophrenia. However, more than 20% of
patients do not initially respond to treatment with drug
therapy.4 In addition to lack of response, many patients
discontinue their medication due to side effects, which
can have serious and devastating consequences.5
In the following sections we discuss the genetics of
antipsychotic drug metabolism, response, and side effects
in schizophrenia.
Genetics of antipsychotic drug metabolism
The vast majority of antipsychotic drugs are metabolized
by the liver enzymes CYP2D6 and CYP2C19, which
play critical roles in determining plasma drug levels.
Gene variants that confer altered enzymatic activity
influence plasma drug levels, and therefore can predict
effective drug doses and potential side effects.
The CYP2D6 gene codes for an enzyme that is respon-
sible for metabolizing the majority of antipsychotic med-
ications.6 This enzyme shows genetic variability in activ-
ity and is highly polymorphic, with over 70 single
nucleotide polymorphisms (SNPs) and copy number
variations (CNVs).7 These variations can influence
antipsychotic drug activity and a patient’s ability to
metabolize them. Individuals can be classified, based on
their gene polymorphisms, as poor (PM), intermediate
(IM), extensive/normal (EM), or ultrarapid drug metab-
olizers (UM).8 The frequency of PMs, IMs, EMs, and
UMs varies across ethnicities. For example, Europeans
show the highest frequency of CYP2D6 PMs and
African-Americans show the highest frequency of
CYP2D6 UMs.9
In theory, the risk of side effects may be higher in indi-
viduals with compromised drug metabolism capabilities
because of higher drug plasma levels.10 Alternatively,
drug plasma levels may be lower and medications, as a
result, less efficacious in individuals with high enzymatic
activity.11 The vast majority of individuals will have no or
little impaired enzyme activity (ie, are IM or EM).
However, it may be extremely valuable for those indi-
viduals who show impaired (PM) or markedly increased
activity (UM) to have this information taken into con-
sideration when selecting antipsychotic medication,
determining appropriate dosage, or interpreting plasma
levels in the context of drug monitoring. 
Estimated dose adjustments for antipsychotics have
been described based on an individual’s metabolizer
status.12 CYP2D6 and CYP2C19 diagnostic testing is
FDA approved with the Roche AmpliChip®, but is
also available at decreasing costs every year through
other companies. Importantly, results from genotyping
analyses are only one factor affecting drug plasma lev-
els and should be considered in conjunction with other
important criteria, such as comedication, smoking, and
diet.6
Genetics of antipsychotic treatment response
Another important focus of investigation has been
antipsychotic drug response in schizophrenia. The first-
generation studies exploring the genetics of antipsy-
chotic treatment outcome were published in the early to
mid 1990s. They were performed with small sample sizes
and included patients treated mainly with clozapine, but
not exclusively. The most interesting findings, albeit
mixed, were obtained for the serotonin 2A (5-HT2A)
and the dopamine 2 (DRD2) receptor gene polymor-
phisms.13 These results suggested that the effect size of
these polymorphisms is low and that other factors,
including other genes and gene variants, are likely to be
involved. 
Second-generation studies have included larger samples,
more sophisticated analyses, and multiple polymor-
Pharmacogenetics and neuroimaging in personalized medicine - Gerretsen et al Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
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phisms, which allow for the investigation of haplotypes
and genome-wide associations. These continue to pro-
duce promising results for the 5-HT2A and DRD2 gene
polymorphisms. A comprehensive analysis which
included 12 DRD2 gene polymorphisms in a sample of
232 well-characterized subjects identified protective hap-
lotypes in both Europeans and African-Americans.14 A
review by Arranz et al concluded that the –141C/T poly-
morphism in the DRD2 gene is of particular significance
due to its association with treatment outcome in two
independent samples.2 A more recent meta-analysis of
almost 700 individuals supported the association
between the –141C/T polymorphism and antipsychotic
drug response.15 Intriguingly, this polymorphism is
located in the promoter region and could have regula-
tory effects in addition to functional relevance. Although
the role of the DRD2 gene in antipsychotic response is
not conclusive, these findings are of particular interest
since D2 is the main target of antipsychotics.16
5-HT2A is proposed to be involved in the unique ther-
apeutic action of clozapine.17 Two studies with sufficient
statistical power have demonstrated a role for the struc-
tural 5-HT2A His452Tyr polymorphism in predicting
clozapine response.18,19 Significant associations have also
been described in at least a dozen other genes, such as
DRD3, DRD4, 5-HT1A, 5-HT2C, 5-HT6, 5-HTT, BDNF,
COMT, GNB3, MDR1, MTHFR, NEF3, NRG1, RGS4
and TNF-alpha.2,20,21
Of note, the first whole genome-wide association study
of antipsychotic drug response was recently conducted
by Sullivan et al.21 This approach involves no a priori
hypotheses of candidate genes or gene variants, and as a
result makes it difficult to interpret the significance of
results in the context of adequately controlling for mul-
tiple variable testing. No significant findings have been
reported thus far. 
Also of note, only a few studies have tested for a direct
association between CYP450 gene polymorphisms and
drug response. These have yielded mostly negative
results.2,22
Overall, some interesting findings exist in the area of
genetics and antipsychotic response. However, many
associations are not conclusive and represent a small
fraction of the total variance of treatment outcome.
Because the entire genome and candidate gene variabil-
ity have not been fully explored, more robust observa-
tions are expected with the utilization of DNA sequenc-
ing techniques. The category “treatment response” may
be too broad an outcome measure in genetic studies of
heterogeneous conditions. Studies that target specific
symptoms, such as neurocognitive and verbal memory
scores, may yield more convincing findings.21,23
Genetics of antipsychotic-induced side effects
Antipsychotics can induce a variety of side effects, such
as involuntary movements (eg, tardive dyskinesia) and
weight gain, both of which appear to be genetically
determined.24,25 Compared with phenotypes like treat-
ment response, an analysis of genetic factors associated
with side effects may offer several advantages. First, side
effects are often more closely related to plasma levels,
which can sometimes be predicted by gene variants
involved in drug metabolism. Second, compared with
treatment response the occurrence of side effects may
be more closely related to specific pharmacodynamic
relevant receptors. Third, some side effects such as
weight gain can be assessed more easily and reliably as
compared with complex phenotypes, such as treatment
response. 
In a prototypical study of its time, Pollock et al26 prospec-
tively distinguished poor P450 2D6 metabolizers from
EM among a group of elderly patients suffering from
dementia treated with perphenazine. The poor metab-
olizers had significantly greater side effects than the 40
extensive metabolizers.
In the case of tardive dyskinesia, previous reports have
indicated that CYP1A2 may be of importance.27 Other
studies which focused on the Ser9Gly variant of the
DRD3 gene reported significant associations, which
were supported in two meta-analyses.28,29
Several interesting studies have now been published
regarding the genetics of antipsychotic-induced weight
gain. The CYP2D6 gene has been associated with
increasing weight. In pharmacodynamic analyses, the
most consistent findings involve the promoter polymor-
phisms of the 5-HT2C gene and the leptin gene. Both
genes are involved in energy and fat metabolism in stud-
ies of humans and animals (reviewed in ref 30, Figure 2).
Further interesting findings are reported in the
ADRA2A and SNAP-25 genes, with replications in
independent samples.31-35
In summary, studies assessing the genetic underpinnings
of side effects to antipsychotic medications have yielded
interesting findings, although effect sizes for single genes
(or gene variants) are small. 
S t a t e  o f  t h e  a r t
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Genetics of antidepressant response 
and drug metabolism in depression
Major depressive disorder (MDD) is one of the fourth
major causes of disability worldwide, with tremendous
socioeconomic consequences36 Adverse early life events
are major predictors of later development of MDD,
though genetic factors also appear to have a significant
influence (37% heritability in twin studies). Antidepres-
sants are the cornerstone in treating depression; how-
ever, only 50% to 70% of the patients respond to initial
therapy, and less than 40% patients achieve full remis-
sion.37 Furthermore, efficacy of an antidepressant is often
only apparent after treating for 4 to 8 weeks. A reliable
tool to predict antidepressant response would be of
great service to the clinician, leading to greater efficacy
Pharmacogenetics and neuroimaging in personalized medicine - Gerretsen et al Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
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Figure 2. The interaction between peripheral molecules and central pathways modulating food/energy intake. AgRP, Agouti related protein, GABA,
gamma aminobutyric acid, MC4, melanocortin receptor 4, NPY, neuropeptide, POMC, proopiomelanocortin, α-MSH, alpha melanocyte stim-
ulating hormone. (source: www.silvermedia.ca)
Adapted from ref 30: Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics. 2006;7:863-887.
Copyright © Future Medicine Ltd, 2006.
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and rapidity of response. Pharmacogenetics offers an
individually tailored alternative to the trial and error
prescription regime. Concordance for antidepressant
response has been observed in family studies implicat-
ing the role of genetic factors.38,39
Genetics of antidepressant drug metabolism 
The therapeutic level achieved by antidepressants is
heavily influenced by the metabolic activity of the
CYP450 enzymes. CYP2D6 is involved in the metabo-
lism of most tricyclic antidepressants (TCAs) and some
SSRIs. Functional polymorphisms lead to varying
degrees of metabolic activity that influence plasma drug
levels, and allow for the categorization of distinct phe-
notypes (see Genetics of antipsychotic drug metabolism
section above).6,40,41 The UM phenotype is associated with
increased clearance of antidepressants and lack of
response.42-44 Accordingly, the PM phenotype is reported
to lead to increased adverse events with antidepressant
treatment.45,46
Some evidence suggests that functional polymorphisms
in the CYP2C19 gene also influence serum levels of 
antidepressants metabolized by this enzyme. UM
(CYP2C19*17/*17) exhibited the lowest concentrations
of escitalopram, whereas patients with the PM genotype
(CYP2C19*2 or *3) exhibited the highest serum levels.47
Genetics of antidepressant treatment response
The selection of candidate genes for investigation is
based on the hypothesized association with pharmaco-
logical targets of antidepressants. The ability of earlier
antidepressants to increase the availability of
monoamines within the synapse by either blocking
monoamine reuptake (eg, imipramine) or inhibiting
monoamine oxidase (eg, iproniazid) led to the
monoamine-deficiency hypothesis of depression. As a
result, several genes from the monoaminergic systems
(eg, serotonin, noradrenaline, and dopamine receptors
and transporters) have been investigated for their asso-
ciation with response to antidepressant treatment.48
Among these, the serotonergic system is the most
widely investigated. Genetic variation within the sero-
tonin transporter (5-Hydroxytryptamin transporter, 5-
HTT; SLC6A4) is suspected of conferring a vulnerabil-
ity to anxiety and affective disorders. 5-HTT is the
principal site of initial action for several antidepressants,
including selective serotonin reuptake inhibitors
(SSRIs).49 Polymorphisms within the promoter region
were described shortly after the original isolation of the
SLC6A4 cDNA on chromosome 17q12 by Lesch et al.50
In particular, a site approximately1200 bp 5’ of the first
exon of the SLC6A4 gene involves a 22 bp repetitive
sequence consisting of two subtypes, a short (S) allele
with 14 copies and a long (L) allele with 16 copies.51 This
variation is frequently referred to as the serotonin trans-
porter-linked polymorphic region (5-HTTLPR). The S
allele is associated with a reduction of function as com-
pared with the L allele. Cells homozygous for the L
variant can have up to 66% more 5-HTT mRNA
expression, greater serotonin transporter density in
platelet and neuron cell membranes, and two times the
serotonin uptake than cells with the S/S genotype
(Figure 3). 52-57
The L variant is generally associated with a better anti-
depressant response in Caucasian patients.58 In a meta-
analysis by Serretti et al, L carriers had better response
and remission rates within 4 weeks of antidepressant
treatment when compared with subjects with the SS
genotype. Conversely, in an investigation of the
STAR*D sample treated with citalopram (total n=1659)
no association was observed between the 5-HTTLPR
polymorphism and treatment tolerance or outcome.59 In
another analysis of the STAR*D sample a significant
association was found between the L allele and remis-
sion in white nonhispanic patients.60
Recently, the Genome Based Therapeutic Drugs for
Depression (GENDEP) study61 found that the L allele
was associated with better response to escitalopram. A
significant interaction was identified between 5-
HTTLPR, drug and gender, with the effect concen-
trated in males. Of note, the single nucleotide polymor-
phism (SNP) rs2020933, found at the 5’ end of the
5-HTTLPR gene, also influenced treatment outcome in
this study.
A common A>G functional polymorphism within the L
allele has also been identified.51 The G variant of this
polymorphism (LG) shows transcription levels similar
to the S allele, whereas the A genotype (LA) shows
higher expression levels. In the STAR*D study they
reported a significant association between the LA allele
and reduced adverse events in the white nonhispanic
population, but not with treatment outcome.59
The influence of 5-HTTLPR on antidepressant response
is quite robust to ethnic differences although significant
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heterogeneity exists in Asian samples.62 In contrast to
Caucasian subjects, Asians carrying the S allele have
been reported to respond better to antidepressants,
although findings are mixed (see refs 37, 58, 63). 
Another gene of active investigation is HT2RA, which
codes for the 5-HT2A receptor, a target of both antide-
pressant medications and second-generation antipsy-
chotics. A polymorphism rs7997012 found in the second
intron was significantly associated with citalopram
response in the STAR*D study.64 In addition to this vari-
ant, the A1438G polymorphism also showed evidence of
association with treatment outcome. Participants who
were homozygous for the A allele had an 18% absolute
risk reduction of having no treatment response compared
with those homozygous for the G allele. This finding
appeared specific to white subjects. Conversely, the
GENDEP study61 failed to replicate this association with
rs7997012, and found that the G allele of another poly-
morphism, rs9316233, was associated with escitalopram
response. Inconsistent findings have also been reported
for the C allele of the T102C polymorphism.58 Despite the
lack of consistent findings for a specific polymorphism
moderating response, the HT2RA gene as a whole
appears to be of importance in depression outcome.
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Figure 3. Serotonin transporter gene (SLC6A4) and function. 5-HTTLPR x PFC/Amygdala endophenotype interaction. Allelic variation of the serotonin
transporter (5-HTT), including the serotonin-transporter-gene-linked polymorphic region (5-HTTLPR), the variable number of tandem repeats
(Intron 2 VNTR), rs25531 single nucleotide polymorphism (SNP), and the missense variant lle425Val (l425V). The long (L) allele (orange) of
5-HTTLPR produces significantly less 5-HTT mRNA and protein expression, than the short (S) allele (blue), leading to higher concentrations
of serotonin in the synaptic cleft. 5-HTTLPR s allele carriers show significantly less functional coupling between the amygdala and perigen-
ual anterior cingulate cortex than L/L individuals. MAOA, monoamine oxidase A. (source: www.silvermedia.ca)
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Many other genes associated with the different
monoaminergic systems that are either inconsistently
associated with antidepressant response or that have
produced contradictory results are reviewed in detail
elsewhere (see refs 58, 63). These include HTR1A,
TPH1, TPH2, MAOA, MAOB, COMT, DAT1, SLC6A3,
D2, D3, D4, NET1, SLC6A2, ADRA2A, ADRB1, G pro-
tein, beta polypeptide 3.
Brain-derived neurotrophic factor (BDNF) is an impor-
tant peptide abundantly expressed in limbic structures.
BDNF is critical for axonal growth, neuronal survival,
and synaptic plasticity. The observations of stress-induced
decrease in hippocampal BDNF levels and increase in
BDNF-mediated signaling following chronic treatment
with antidepressants suggest a possible role in depression
and its treatment.48,65,66 However, inconsistent and region-
specific effects have also been observed.48 A functional
coding SNP rs6265 causes a Valine to Methionine change
at codon 66, which leads to impaired intracellular traf-
ficking and secretion of the mature BDNF protein.
Carriers of the Met allele have significantly lower hip-
pocampal volume than subjects homozygous for the Val
allele.67 Although several studies have found an associa-
tion between the Met allele and antidepressant
response,63,68 the sample sizes were small, and the results
have been inconsistent.61 In addition to the Val66Met
allele, a polymorphism in the 5’ untranslated region of
the BDNF gene (rs61888800) was associated with anti-
depressant response in Mexican-American subjects.69
This observation requires replication.
Early life stress and dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis are also linked with depres-
sion treatment outcome.48,70 One of the important genes
that has emerged from the HPA axis is FKBP5 (FK506
binding protein 51), a cochaperone of 90 kDa heat shock
protein, which regulates glucocorticoid receptor sensi-
tivity. Carriers of the TT genotype of rs1360780 poly-
morphism in intron 2 of FKBP5 were demonstrated to
have a better treatment outcome than other genotypes.71
This observation was replicated in a separate sample in
the same study, and in two other independent studies.
Smaller investigations of Spanish and Korean popula-
tions failed to reproduce this association (see ref 72). 
Genetics of antidepressant-induced side effects
Side effects of antidepressant treatment have emerged as
important reasons for medication discontinuation and non-
compliance. The first-generation TCAs and monoamine
oxidase inhibitors (MAOIs) were primarily associated with
sedation, weight gain, and anticholinergic side effects,
including dry mouth, blurred vision, cardiac effects, and
death by overdose. The newer antidepressants, including
SSRIs and SNRIs, have better and safer side-effect profiles,
but tend to cause nausea, diarrhea, nervousness, agitation,
insomnia, and sexual side effects. 
Similar to studies of antidepressant response, the candi-
date genes extensively investigated in relation to anti-
depressant induced side effects are from the serotoner-
gic system. The presence of the 5-HTTLPR L allele is
generally associated with fewer treatment related side
effects. Negative studies are also reported in the litera-
ture. A recent meta-analysis found the L allele conferred
protection against antidepressant side effects for all anti-
depressants (OR 0.64),63 the significance of which
became more robust when analyzed with SSRI-induced
side effects only. The same meta-analysis found that the
presence of the -1438 G/G polymorphism of HTR2A
increased the risk of antidepressant side effects (OR
1.91). Several other pharmacodynamic genes were inves-
tigated with contradictory results.63
Although strongly related to drug plasma levels, few
important discoveries have been made linking pharma-
cokinetic associated genes and antidepressant-induced
side effects. CYP2D6 polymorphisms are reported to
influence the emergence of TCA and MAOI side effects,
but not the majority of the newer antidepressants (for
details see ref 72). Thus, the clinical utility of pharmaco-
kinetic genes predicting side effects remains limited. To
date, the most promising observations of an association
between genes and antidepressant side effects have
come from the 5-HTTLPR polymorphism. 
Personalized medicine and neuroimaging
A major barrier to progress in the study of complex dis-
eases, such as schizophrenia and depression, is the het-
erogeneity arising from etiological and phenotypic diver-
sity. A significant amount of neuroimaging research has
been conducted to identify biomarkers or endopheno-
types which may reduce the heterogeneity. Proximal
markers are presumed to be less genetically complex
than the clinical phenotype. The identification of inter-
mediary phenomena and specific gene-endophenotype
linkages may increase the individual variability
explained by candidate genes. The validity of biomark-
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ers and endophenotypes is contingent on their sensitiv-
ity and specificity for the disease in question.37
In the next sections we present the most promising neu-
roimaging markers of treatment response in depression
and schizophrenia.
Neuroimaging markers of antidepressant treatment
outcome
Anterior cingulate cortex
The most commonly reported finding in neuroimaging
studies of depression is that increased rostral anterior
cingulate cortex (rACC) activity predicts later response
to depression treatment, including antidepressants,73-75
CBT,76 and sleep deprivation.77 Structural MRI mea-
surements of the ACC have also demonstrated an asso-
ciation with treatment response.78 The ACC is implicated
in numerous brain functions, likely due to its neu-
roanatomical position as a bridge between frontal corti-
cal and subcortical structures.37 The rACC, primarily
Brodmann area 25, is consistently reported to be hyper-
active in depressed treatment responders.79 According to
Mayberg et al’s theory of depression, cortical-subcorti-
cal regulation shifts from the dorsolateral to the ventro-
lateral prefrontal cortex (PFC), which contributes to
rACC hyperactivity.75 It is this region that is a target of
deep brain stimulation (DBS) studies of treatment-resis-
tant depression.80 In further support of this theory, two
independent groups of researchers have identified
increased pretreatment activity in rACC theta activity
in responders using low-resolution electromagnetic
tomography.81,82
Functional neuroimaging studies during active task con-
ditions can facilitate distinguishing responders from non-
responders by targeting the neurocircuitry involved in
depression.37 The aim is to reduce unexplained back-
ground cerebral activity (“noise”) present during the rest-
ing state, thereby increasing the signal-to-noise ratio.
Common approaches involve comparing the brain regions
activated during the presentation of affectively laden or
sad facial expressions versus neutral or positive stimuli. In
an fMRI study by Chen et al,78 participants who displayed
greater pretreatment activation within ACC in response
to negative versus neutral stimuli displayed the greatest
response to treatment.73,74,83 Other fMRI studies have also
demonstrated a relationship between pretreatment ACC
activity and treatment outcome.73,74
Amygdala
Greater pretreatment amygdala activity is also associ-
ated with treatment response. Increased signal in the
amygdala following the presentation of negative facial
expressions is related to major depression severity84,85
and was demonstrated to predict improvement.86
Normalization of amygdala reactivity to affective stim-
uli is consistently reported to occur with antidepressant
treatment.74,87,88 The same study that reported an associ-
ation between PFC activity and response to CBT found
that heightened amygdala activity to negative words also
predicted response.76 Intriguingly, there is evidence to
suggest that the variability in amygdala and PFC activ-
ity is moderated, in part, by the serotonin transporter
gene 5-HTTLPR. 
5-HTTLPR x PFC/Amygdala endophenotype interaction
5-HTTLPR appears to have modulatory effect on emo-
tion89 via top-down cortico-amygdala regulation.1 On the
one hand, diminished cortical structure and function is
associated with depression and anxiety. Results from
functional brain imaging studies suggest that the S allele
contributes to increased amygdala reactivity via direct
anterior cingulate (ACC)-amygdala dysregulation,90,91
and indirect compensatory activation of the ventrome-
dial prefrontal cortex (Figure 3).91 Consistent with these
findings, the S allele was associated with peak gray-mat-
ter volume reductions in the subgenual ACC, a structure
implicated in both depression and anxiety.92 This theory
is substantiated by the dense serotonergic connections
between the ACC and amygdala in comparison with the
relatively few amygdala connections with the ventro-
medial PFC.91 On the other hand, the gain of function L
allele had the opposite effect of the S variant on cortico-
amygdala regulation.90,91 The LA/LA genotype confers a
modest risk of OCD,51 which is associated with hyper-
frontality, including increased ACC metabolic activity
and gray matter volume.93
Hippocampus
Lower hippocampal volume is associated with depres-
sion, frequency of episodes, and chronicity of illness.94
Hippocampal volume loss, as measured with structural
MRI, is also characteristic of late-life depression and
may be independently influenced by the val66met
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BDNF (See section Genetics of antidepressant drug
response) and 5-HTTLPR polymorphisms. 
5-HTTLPR appears to influence the pathogenesis of
depression depending on the age of onset.1 The S allele
was associated with reduced hippocampal volumes in
elderly subjects with early-onset depression (ie, first
episode 50 years or younger), while homozygosity for
the L variant predicted smaller hippocampal volumes in
depressed subjects with later onset.95 By contrast, the
L/L genotype appears to contribute to the relationship
between late-onset depression and dementia. Reduced
hippocampal volume in this context may represent the
effects of subcortical ischemia in vascular cognitive
impairment96 or the prodromal symptoms of depression
often seen in Alzheimer’s dementia.97
Although not consistently reported, some studies have
shown that antidepressant treatment may prevent or
even reverse hippocampal atrophy via neurogenesis.98,99
More research is required to determine the reliability of
hippocampal atrophy as a predictor treatment response.37
Other regions
White matter hyperintensities on structural MRI nega-
tively predict treatment response in late-onset depres-
sion.100,101 Fewer white matter lesions are associated with
remission and maintenance of remission in late-life
depression with antidepressant treatment.101 White mat-
ter disease commonly results in varied neuropsycholog-
ical deficits, primarily memory, executive, and language
function,102 which are associated with poor response to
antidepressants.37
Although the 5-HT transporter is widely believed to be
involved in the pathogenesis and treatment of depres-
sion, positron emission tomography (PET) studies have
shown both increased and decreased binding potential
of the 5-HT transporter in the context of depression.
These mixed results may reflect inter-study variation of
etiology or mood state leaving it as an unreliable bio-
marker at present.103
Neuroimaging markers of antipsychotic treatment 
outcome
Neuroimaging findings predicting treatment response to
antipsychotics are less robust than those for antidepres-
sants. Both brain atrophy by various measures (eg, sul-
cal width, ventricle size, etc.) and rate of gray matter loss
are associated with poorer treatment outcome.
Ventriculomegaly104 and cortical105 and cerebellar atro-
phy106 were found to predict response. More recently, the
extent of gray matter atrophy over time was a better
predictor of outcome than baseline abnormalities.107
Neurochemical (PET) imaging offers a minimally inva-
sive means of exploring distinct properties and cerebral
distribution of neurotransmitter systems in vivo through
the binding of receptor specific radiotracers. Binding
potential is a principal measure in PET imaging studies
that reflects both the density of available neuroreceptors
and the affinity of a radiotracer to a given receptor. PET
studies of dopamine 2 receptor (D2) binding potential
have shown that greater than 60% occupancy is associ-
ated with increased likelihood of antipsychotic response,
while greater than 80% robustly predicts EPS.108 The
clinical application of neurochemical PET imaging
remains limited by cost and availability, and while it has
been instrumental in the reduction of antipsychotic dos-
ing over the past decade and predicting dosing of sec-
ond-generation antipsychotic drugs, it has not been
applicable to the individual patients due to high inter-
subject variability. However, a recent line of investiga-
tion in older patients with schizophrenia has provided
new evidence from neuroreceptor PET imaging that
may have potential for bedside translation. These stud-
ies have suggested that measurable changes in receptor
reserve with aging is associated with antipsychotic med-
ication and that medicated older patients on a stable
dose of risperidone maintain individually consistent lev-
els of receptor occupancy, plasma concentration, and
psychopathology, supporting the use of this technology
in prospective studies.109 Presuming medication adher-
ence, PET imaging data may, in the future, be used to
facilitate the determination if worsening symptomatol-
ogy or side effects are either due to alterations in neu-
rochemistry or drug failure. Theoretically, this could be
performed with antidepressant radiotracers specific for
the serotonin transporter as well.110
In the future, PET imaging in conjunction with genetic
testing for CYP 450 metabolism may help define indi-
vidually tailored antipsychotic dosing schedules. UM
may require higher doses of an antipsychotic to achieve
the desired receptor occupancy, beyond the upper limits
of what is currently defined as the normal range.
Conversely, PM may require typically subtherapeutic
doses to avoid developing side effects, such as EPS.
Preliminary work directed towards age-specific dosing
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of antipsychotics has shown that EPS occurs at 50% to
70% D2 receptor occupancy in the elderly, which sug-
gests treatment efficacy occurs at even lower receptor
blockade (~40% to 50%).111 In the same study, a very
strong association was observed between D2 receptor
occupancy and antipsychotic plasma levels. Pending
replication, these results raise the possibility of predict-
ing individualized antipsychotic dosing. Using popula-
tion pharmacokinetic methodology in conjunction with
neuroreceptor PET data, our group is currently inves-
tigating the predictive validity of individualized antipsy-
chotic dosing using widely available bedside measures
including plasma drug levels, drug dose, demographic
factors, and concomitant medications.112
Conclusion
Personalized medicine promises the development of indi-
vidually designed treatments based on the integration of
all clinically relevant information, including data derived
from laboratory, genetic, and imaging investigations, etc.
The identification of pharmacogenetic and neuroimaging
biomarkers associated with side effects and treatment
response are active areas of research in psychiatry. The
question is, when will genetic testing and sophisticated
functional neuroimaging studies be implemented in clin-
ical practice? With regards to genetic testing, a relative
timeline can already be given. Genetic tests for critical
drug-metabolizing genes, such as CYP2D6 and CYP2C19,
are already available and can provide clinically useful
information, potentially improving response rates and
safety for those individuals who are poor or rapid metab-
olizers.113 It remains uncertain whether widespread geno-
typing prior to the onset of treatment therapy can con-
tribute substantially to therapeutic outcome. 
Challenges facing the field include phenotypic and etio-
logical heterogeneity, technological limitations, and con-
temporary research approaches. It seems that genetic
testing for side-effect prediction has the highest likeli-
hood of being incorporated into clinical practice.
Supporting this, a test for clozapine-induced agranulo-
cytosis is now available with satisfying sensitivity and
specificity.114 Computational models that include gene
variants and other factors associated with antipsychotic-
induced weight gain have yielded promising results.115
Tests related to treatment response may follow through
the inclusion of more sophisticated genotyping tech-
niques (eg, sequencing) and the analysis of refined
endophenotypes, such as specific symptoms or symptom
clusters. Future development of algorithm-based
approaches requires the integration of additional genetic
and nongenetic factors. 
Neuroimaging research has produced encouraging asso-
ciations between imaging endophenotypes and treat-
ment outcome, such as the 5-HTTLPR x PFC/amygdala
interaction. Nonetheless, these observations lack the pos-
itive and negative predictive value required to reliably
distinguish responders from nonresponders to be used
clinically. Based on current research, imaging markers
explain a significant, but modest, portion of the total
variance. More research is required with larger, less het-
erogeneous samples in conjunction with other markers,
eg, genotyping and electrophysiological measures. 
Most neuroscience research thus far involves the appli-
cation of various theoretical approaches (ie, neuroimag-
ing, genetics, neuropsychological, and physiological, etc)
in isolation. The next step in the development of per-
sonalized medicine is the formation of standardized mul-
timodal research models to better characterize markers
of treatment response. Now is a time for optimism in the
emerging ability of pharmacogenetics and neuroimag-
ing to provide meaningful help to the physician in devel-
oping individually tailored treatments for complex, het-
erogeneous psychiatric disorders. ❏
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La intersección de la farmacología, las 
imágenes y la genética en el desarrollo 
de la medicina personalizada
Actualmente se cuenta con numerosos ensayos con-
trolados, randomizados y meta-análisis para tomar
decisiones clínicas; lo que nos coloca en riesgo de
descartar opciones terapéuticas específicas para un
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en grandes poblaciones. En la medicina personali-
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tará el diagnóstico y la predicción de la evolución
terapéutica. Estamos en el umbral de la capacidad
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Croisement de la pharmacologie, de l’image-
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gique. Afin de faciliter le diagnostic et de prévoir
l’évolution des traitements, la recherche se dirige
vers l’identification des gènes, des endophénotypes
et des biomarqueurs de la maladie. Nous sommes
sur le point de pouvoir prédire la réponse au trai-
tement, en particulier grâce à la génétique et à la
neuro-imagerie. Cet article se propose d’examiner
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imply stated, for personalized medicine to
become a hallmark of mainstream modern medicine, the
attributes of precision and meaningful improvement in
quality of health care through technology and informa-
tion management must be obvious and unequivocal.
Throughout biomedical science, there has been much
anticipation of the potential impact of genomic, molec-
ular, and personalized medicine for health. The begin-
ning of 21st-century biomedical research was heralded
by the completion of the Human Genome Project, which
gave a great deal of momentum to new capabilities of
science and technology in the hands of medical practi-
tioners and the public. 
Across the spectrum of clinical neurosciences, many
advances are clearly being made toward understanding
the biological underpinning of disease. Applications of
new technology platforms in research are widely seen in
neurodegenerative disorders, neuropsychiatric condi-
tions, addiction, and developmental disorders. While the
impact of translation of these new research frontiers will
likely take many years to be measured, pressing impli-
cations requiring important policy considerations are vis-
ible today. 
Significant innovation and technological achievements
lie at the heart of the rapid pace of accrual of scientific
information to support personalized medicine. Dramatic
decreases in cost and increases in analytical throughput
have placed within reach the possibility of sequencing a
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Remarkable advances in the fundamental knowledge
about the biological basis of disease and technical
advances in methods to assess genomic information have
led the health care system to the threshold of personal-
ized medicine. It is now feasible to consider strategic
application of genomic information to guide patient
management by being predictive, preemptive, and pre-
ventive, and enabling patient participation in medical
decisions. Early evidence of this transition has some hall-
marks of disruptive innovation to existing health care
practices. Presented here is an examination of the
changes underway to enable this new concept in health
care in the United States, to improve precision and qual-
ity of care through innovations aimed at individualized
approaches to medical decision making. A broad range
of public policy positions will need to be considered for
the health care delivery enterprise to accommodate the
promise of this new science and technology for the ben-
efit of patients.  
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person’s entire genome for $1000. Broad applications of
genomic characterization of disease states in the phar-
maceutical, biotechnology, and diagnostic research sec-
tors have become mainstays of early- and late-stage
therapeutic development. Despite the robust invest-
ments in discovery research technologies to exploit
genomic variation of disease-related genes, personalized
approaches to disease management have raised chal-
lenges for industry because of the potential segmenta-
tion effect on diminishing the potential marketable pop-
ulation for new medical products. Nevertheless, there
remains strong interest among pharmaceutical and
biotechnology developers for clinical strategies to
employ diagnostic tests in combination with therapeutic
interventions. Whether this “codevelopment” approach
will be widely employed by industry to enhance clinical
development strategies, or is engaged in the clinical prac-
tice regimen as a personalized medicine tool, is largely
unknown. The pathway toward large-scale use of mole-
cular diagnostics in managing therapy decisions has sub-
stantial obstacles and misaligned incentives that will
require significant policy modifications before person-
alized medicine becomes commonplace in health care.1
While today’s view of the horizon for many aspects of
clinical practice remains unclear, some disciplines of
medicine, such as oncology, are rapidly adopting clinical
genomic analysis and individualization of therapies.
Some of the more relevant challenges are not the scien-
tific validity of the use of genomic tools, but rather the
capability to deploy and organize information in mean-
ingful ways in clinical practice. In addition, it is impor-
tant to recognize that all of the discovery research and
technological advancement is occurring in a highly
volatile climate of change in health care policy. Access
to health care, public financing of health care services,
moving away from fee-for-service reimbursement mod-
els, comparative effectiveness research, changing focus
on preventive health services, looming financing chal-
lenges accompanying dramatic shifts in demographics of
aging populations, and continued concerns regarding
security and privacy of health information are all part of
today’s policy framework, representing a cauldron of
change in health care. 
In this overview, the policy perspective of the translation
of genomic science into health care practice is examined
under the moniker of personalized medicine. The focus
through this lens addresses how advances in science,
technology, and health care in the United States come
together while recognizing that global influences in all
of these domains are increasingly relevant to the domes-
tic picture. Currently, personalized medicine addresses
two general advanced technology platforms; molecularly
targeted therapeutics which are selective for a specific
biological marker (biomarker—defined as a character-
istic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention2), and molecular diagnostics. The latter, rel-
ative to the neuroscience areas, can generally be consid-
ered to include genomic diagnostic tests, biobehavioral
testing measures, and imaging technologies. While rec-
ognizing the value of the contribution of many advanced
imaging technologies to drug discovery and develop-
ment and clinical disease state assessment, this report is
principally focused on genomic diagnostic technologies.
Currently, three broad medical applications of these
technologies are most frequently considered as person-
alized medicine approaches: to determine likelihood of
clinical response with molecularly targeted agents, to
determine polymorphisms likely to contribute to adverse
events or subtherapeutic response to drugs, and to assess
disease biomarkers as predeterminants for diseases and
conditions, such as heart disease, neurodegenerative dis-
orders, and cancer. 
In 2006, the US Department of Health and Human
Services (HHS) initiated a federal effort to coordinate
and facilitate steps across the agencies to establish path-
ways to enable genomic and personalized medicine to
enter health care. In recognizing potential obstacles that
predictive, preventive, and pre-emptive approaches to
health care may face, the Personalized Health Care
Initiative was launched to avoid unnecessary delays and
develop effective communication strategies for the
intended use of these technologies in health care. The
framework for this initiative was built on two funda-
mental tenets: that linkage of clinical and genomic infor-
mation would yield insights into human health and dis-
ease, and that the information gained from this linkage
would be used, and not misused, to benefit patients and
consumers.3 Recently, HHS published a report that
included an analysis of health systems changes that were
being undertaken in various institutions and through col-
laborative projects.4 The report also looked at the need
for changing roles of key stakeholders in successful
transformation of services in health care, required to suc-
cessfully implement personalized medicine practices.
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These analyses featured some of the implementation
issues associated with personalized medical care and
some of the solutions to overcome them. 
Definitions and context of 
personalized medicine
The use of the term “personalized medicine” in the lit-
erature predates the advances in clinical genomics that
have advanced the biological understanding of differ-
ences between individuals. Applications of this termi-
nology were often related to customized behavioral
approaches to management of health conditions. Prior
to the 1990s, the use of the term “personalized medicine”
was used to imply that there were sociological, educa-
tional, and psychological bases for alternative
approaches to patient management that led to more or
less successful practices. In the late 1990s, somewhat
simultaneously with the approaching completion of the
Human Genome Project, more common usage of the
term reflected genetic understanding for differences in
pharmacotherapy, ie, pharmacogenomics. This also coin-
cided with the market entry of several molecularly tar-
geted therapies in oncology that used genetically based
determinants for the development and subsequent clin-
ical application of novel therapeutic agents. Trastuzumab
(Herceptin®), a monoclonal antibody that serves as a
treatment for breast cancer, has often been heralded as
the first molecular therapy ascribed to personalized
medical applications through the use of an assay to
detect overexpression of the Her2 protein, thereby iden-
tifying patients who are most likely to respond. 
Since then, there have been many interpretations and
contexts applied to the term “personalized medicine.”
For the purposes of this discussion, the definition used
here will be based on one by Willard et al as “the deliv-
ery of health care in a manner that is informed by each
person’s unique clinical information; genetic, genomic,
and other molecular biological characteristics; and envi-
ronmental influences. The goals of personalized medi-
cine are to take advantage of a molecular understanding
of disease, combined with other individual factors, to
optimize preventive health care strategies while people
are still well or at the earliest stages of disease.”5
Increasingly, consumer interactions with the health care
system and engagement in proactive participation in
agenda setting and decision making are being applied to
new ends. The rise of advocacy organizations and their
involvement in therapeutic development, application of
social networking enterprises for patient connectivity (ie,
PatientsLikeMe), greater involvement of public members
in policy development, and growing public influences on
coverage and reimbursement policies add new context to
patient advocacy. Greater public awareness and growing
understanding of personal utilities afforded by informa-
tion technology, genomic analysis-assisted disease risk
assessment, and computer-assisted living devices all bring
a broader context to this discussion, which is referred to
here as personalized health care (as distinguished from
medical context of diagnosis and interventions).6
While much of the emphasis in discussions about per-
sonalized medicine has been focused on medical tech-
nologies, aspects of information technology are becom-
ing their equal in enabling individualization or mass
customization of health care schemes. This is not unlike
the disruptive innovation qualities that computers have
had in other industries, and will likely lead to wide-rang-
ing and equally disruptive change for the medical com-
munity.7 One key characteristic of change will be the
blurring of the lines between the established medical
community, the patient/consumer, and other community
members “linked” by information systems. In the future,
personalized health care will represent an amalgam of
patient experiences that will be customized, interactive,
less episodic in nature, and more of a continuum of care.
There will be many challenges ahead, in order for this
model to be accepted and demonstrated to provide a
higher quality of care, greater understanding by patients
of their condition and health care choices, and improved
efficiency and effectiveness of health care practices. 
Key catalysts on the pathways 
to personalized medicine
The pace at which discovery research in human genomics
enters translational research may be a trajectory unlike
past novel interventions. In looking at personalized med-
icine through the lens of clinically meaningful impact, it is
worthwhile to provide a context for some of the forces at
play in creating the foundation for personalized medicine. 
Genomic sequencing and related analytic platform
technologies
The establishment of the public domain as the key refer-
ence source for the Human Genome Project opened the
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door to discovery research that continues to pay dividends
in advancing scientific frontiers. Additionally, the substan-
tial investments in large-scale science included funding for
technology platforms and their applications in the project
itself. As a consequence, there was a surge in the develop-
ment of sequencing technologies yielding remarkably
higher throughput, dramatically reduced costs, and greatly
enhanced analytic capabilities. Government-supported
incentives for technology development created an eco-
nomically feasible environment that has expanded
genome-scale research capabilities from large sequencing
centers to the laboratory bench, and now, virtual discovery
research through computational analysis. These efforts
were first engaged to sequence targeted regions of the
genome, in order to understand polymorphisms in genes
and their contribution to genetic disorders. The HapMap
project, by building a widely diverse international public
genome database, rapidly accelerated the capability to
compare population-based genetic makeup, resulting in
highly annotated databases of disease genes.8 Evolutionary
aspects of genomic information for understanding biolog-
ical diversity came in the form of sequencing projects of
other species. These projects yielded tremendous public
resources that enabled biological understanding to be
gained in model organisms, leading to broader insights into
human development and disease mechanisms. 
Advances in genomic information were not based solely
on high-throughput sequence analysis. The development
of microarray technology enabled ease of use for per-
forming hybridization analysis on virtually any laptop
computer. A new basis for diagnostic tests has been pro-
vided by the vast amount of gene expression data now
available through large-scale measurement of mRNA
abundance. The platform greatly expanded the capabil-
ities to include comparative analysis of specimens for
gene expression and the volume of genomic data that
could be generated in hours of experimental time.
Coupled with the development of analytical software,
scientists are now armed with an adaptable platform to
evaluate polymorphisms, compare the effects of inter-
ventions on DNA analysis, and ultimately evaluate phar-
macologic impact on gene expression. Over the past 5
years, gene expression profiling has become a commonly
used quantitative method in molecular and systems biol-
ogy. In a short period of time, this technique has also
become a common translational research tool widely
applied in clinical medical laboratories, particularly in
oncology for assessment of tumor biomarkers. 
Genomic analysis platforms have had dramatic impact
on clinical research and therapeutic research and devel-
opment, and spawned a broad range of molecular diag-
nostic assays and devices. Meanwhile, medical applica-
tions remain unclear, as the clinical experience and
evidence is lacking for many potential uses.
Pharmacogenomics is viewed by many as a discipline of
clinical pharmacology which deals with the influence of
genetic variation on drug response in patients by corre-
lating gene expression or single-nucleotide polymor-
phisms with a drug's efficacy or toxicity. By doing so,
pharmacogenomics provides a rational means to opti-
mize drug therapy with respect to the patients' genotype,
to ensure maximum efficacy with minimal adverse
effects. This approach sets the stage for personalized
medicine, in which drugs and drug combinations are
optimized for each individual's unique genetic makeup.
The clinical impact of this has been primarily recognized
in the alteration of many drugs' biotransformation pro-
files as a result of polymorphisms that contribute to slow
or rapid metabolism. These manifestations are relevant
to a broad range of pharmaceuticals, leading to either
subtherapeutic responses in the case of enhanced activ-
ity of drug metabolizing enzymes, or adverse events
from toxicologic manifestations of slowed drug inacti-
vation. These studies have led to implications by the US
Food and Drug Administration (FDA) to notify pre-
scribing clinicians that pharmacogenomic testing may be
of value in dosing and therapeutic selection, in some
cases. The FDA maintains a list of drugs with labeling
requirements that under some circumstances require
pharmacogenomic testing of subpopulations for poly-
morphisms before the drug is prescribed.9,10
Analysis of pharmacogenomic data has become a sub-
stantial undertaking by the FDA. Among these steps in
developing the translational science for the future, the
FDA, together with the pharmaceutical industry and
academic investigators, has established a voluntary data
submission process to enable better understanding of the
interaction of developmental therapies with genes and
their clinical manifestations.11 Arguably, the largest num-
ber of patients with potential clinical application of a
pharmacogenetics test under consideration in medical
practice today are those who will be prescribed the anti-
coagulant warfarin. Several polymorphisms lead to the
abnormal metabolism of the drug, which has a narrow
therapuetic index fraught with medical complications.
Research continues on the clinical importance of routine
S p e c i a l  a r t i c l e
380
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 380
testing of the Cytochrome P450 2C9 locus, which is
involved in warfarin metabolism, and variants in Vitamin
K epoxide reductase (VKORC1). Several commonly used
drugs for neurologic conditions have FDA labeling for
pharmacogenomic implications. Carbamazepine-related
Stevens Johnson syndrome has been linked to polymor-
phisms in the HLA B haplotype. Individuals carrying
one or two *1502 alleles are advised to avoid carba-
mazepine. Labeling for pharmacogenetic assay consid-
eration is also present for fluoxetine and other selective
serotonin reuptake inhibitors (SSRIs) metabolized by
Cytochrome P450 2D6. Abnormal clinical response may
occur due to aberrant drug metabolism, and genetic test-
ing may yield useful information to aid in dosing para-
meters.12 A commercially available microarray has been
developed and FDA approved for use to assist in deter-
mining Cytochrome P450 polymorphisms, and other clin-
ical laboratory tests are used in a variety of settings for
consideration in drug dosing.13
Nonpolymorphic genetic modifications are increasingly
being applied to understand gene-environment interac-
tions in diseases and clinical conditions. Further expan-
sion of the capabilities of microarray technology has
enabled genomic analysis at additional levels by mea-
suring DNA methylation and histone modification.14 In
addition, analysis of copy number is providing insight
about genomic variation beyond nucleotide polymor-
phism, showing significance in the etiology of cancer,
atherosclerotic heart disease, and complex neurological
conditions such as Alzheimer’s disease and schizophre-
nia.15,16 Although not as commonly applied in the clinical
laboratory as expression profiling, these methods are
showing promise in therapeutic research and develop-
ment and translational research genomic analytical lab-
oratories. 
Clinically meaningful laboratory applications in the
future will need to overcome significant barriers.
Currently, there are not widely accepted methods and
standards for performing genomic analysis using array
platforms. There is also wide variation in the analytical
and computational methods used in comparative
genomic analysis. In addition, there is a paucity of stan-
dardized control biomaterials for use in analyses. Finally,
all of these quantitative measures are highly sensitive to
clinical specimen acquisition, preparation, and storage
methods. Little comparative work on standards for con-
trols and disease biospecimens has been done on estab-
lishing normal datasets for gene expression methods.
Recently, a summary of these issues was addressed
through a guidance document issued by the Centers for
Disease Control and Prevention (CDC).17 The lack of
highly annotated and fully characterized biospecimens
with longitudinal phenotypic and demographic infor-
mation remains a significant barrier for all of transla-
tional research in personalized medicine, but is most
notable in large-scale genomic analyses.18
The application of the various genomic technology plat-
forms has led to transformative research in population
genetics. Over the last several years, population-based
research studies, such as the Framingham Heart Study,
have enabled large-scale genomic analyses from clinical
resources. Collectively, these genome-wide association
studies (GWAS), have enabled cross-study analyses
from publicly available databases known as dbGAP
(database of genotype and phenotype).19 Over the past
several years, hundreds of new GWAS results have
yielded insights into multigene effects to a wide variety
of human diseases and conditions. Many of these new
mutations are identified in noncoding regions.
Collectively, the discovery of these new associations is
prompting more hypothesis generation about disease
pathways than generating platforms for new diagnostics
and therapeutics. These public resources are proving to
be useful discovery resources for various disease areas,
such as psychiatry, enabling consortia of investigators to
use statistical analytic methods to map genetic architec-
ture of common disorders.20
Information technologies in health care and impact on
personalized medicine
A key infrastructure needed to establish a medical prac-
tice environment for individualized decision making is a
robust and facile information technology capability. The
reasons for this are the dependency on key attributes
about the patient’s health status, detailed data needs for
phenotypic characteristics, and the complexity of the
types of analytical data and decision algorithms that will
be used to support more precise, preferred, and predic-
tive health outcomes for the patient. 
Much of the advances in genomic research have been
supported by computational studies that have enabled
large databases to be assembled with highly contextual-
ized data to develop associative information about the
relation of genes and biology. While technological
advances in capacity for sequencing analysis have
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exceeded the benchmark measure of computing power,
Moore’s Law, there is no doubt that this success has been
largely tied to computational advances. 
The transfer of this knowledge from the laboratory to
the health care setting faces a steep climb to establish
information management practices in the US. Improved
clinical knowledge from research is highly dependent on
recovering standardized, useful clinical information from
medical practice. The delivery of knowledge in clinically
useful formats to support decision-making processes is
similarly critical. The information management needs to
span these gaps is found in the electronic health infor-
mation technology (health IT). The major components
of a health IT system to support personalized medicine
includes widely used electronic medical record systems
and personal health records that consumers can use for
recording their own health care information. A second
component is a nationwide effort to enable health infor-
mation exchange among health care providers and insti-
tutions that will enable portability of information to suit
purposes on demand. A third element includes elec-
tronic decision support capabilities that engage medical
records systems to facilitate evidence-based health care
choices by the health care provider. Collectively, these
are dependent on data standards that enable semantic
and syntactic interoperability of data across health IT
systems. As a health care enterprise, the US has a dearth
of electronic information to support these needs, and it
will take many years to achieve all of these steps to ben-
efit all patients. The inability to connect information
sources is a major contributor to the high costs of clini-
cal research, particularly clinical trials. Despite escalat-
ing health care costs and substantial service inefficien-
cies in the US, there has been little incentive until
recently to make capital investments in information sys-
tems for the inpatient and ambulatory care setting. 
Today, less than 20% of all physicians use electronic
health record systems, and far fewer have systems that
provide decision support capabilities to aid personalized
medicine. Some progress is being made on the require-
ment for electronic transmission of prescriptions from
the health care provider to the pharmacy. Computerized
physician order entry (CPOE) for ordering laboratory
tests and other services has also been improving. As part
of the American Recovery and Reinvestment Act of
2009, nearly $20 billion will be invested in the next sev-
eral years to build health IT capacity through network
capabilities, support acquisition of electronic systems by
practice groups and health care institutions, and provide
fiscal incentives for adoption and use of health IT sys-
tems.21
The ability to harness clinical information and use it for
research applications will be crucial for personalized
medicine to benefit from these national investments.
Paramount for patients is the knowledge that their infor-
mation will be handled securely, that their privacy in
health matters will be protected, and that the confiden-
tiality of this information is respected. Altogether, for
personalized medical practice to flourish and provide
meaningful value, a health information exchange system
must be developed that enables information to be
mobile, standards-based, and support evidence-based
medical care practices. The yield from this will be greater
use of health care provider resources, more precision
and predictability in medical choices, and provision of
patients with more information and choices to address
their needs. 
Public databases and data access 
One of the key facets enabling the rapid entry of
genomic information into clinical application is the pol-
icy framework that underpinned the dissemination of
research information. The public aspects of federally
funded research did not stop with the completion of the
human genome project. While the early part of this
decade led to the birth of commercial entities that build
genomic databases, the avenues of public information
resources continued to evolve. A series of policies led
major science and medical journals to require submission
of newly discovered gene sequences into GenBank. This
process of openness continued with establishment of
additional databases requiring transparency of research,
enabling resources to be used for new discovery rather
than replication of results. One of the key building blocks
for establishing the base for personalized medicine and
the rapid advances of genomic research was built on fun-
damental public access policies initiated in the 1990s. In
1996, free Internet access to the National Library of
Medicine Medline holdings of scientific information
rapidly accelerated the dissemination of new science. The
National Center for Biological Information added
immense public databases of genomic information, imag-
ing repositories, and many other resources that support
the translation of research into medical applications.
Further advancing this is a policy implemented in 2008
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requiring all NIH-funded scientific publications to be
made publicly available within 12 months of publication.22
PubMed Central, an open-source digital information
resource, was established in February 2000 and has been
followed by additional open-source publication venues.
The net yield of these public policy efforts was to make
biological information more readily available and accel-
erate the application of discovery research into clinical
and translational research. While it is difficult to quantify
the impact of public policies on the openness of scientific
information, the effects have been widespread. Lowering
barriers to commercial sector technology development,
increasing the diversity of scientific collaborations, and
enabling global research collaborations through the open
language of science have been important steps to accel-
erate the arrival of personalized medicine. 
Taken together, the profound advances in informatics
platforms, allowing large and complex data to be moved
rapidly, coupled with computational capabilities for
gleaning meaningful associations of biological systems,
have been transformative. Policies promoting sharing
and dissemination of information have had a similar
impact on accelerating the pace of science. 
Vocabulary standards
The Human Genome Project brought with it a key
aspect of data standards guiding the vocabularies of
genetic information. The requirement to use interna-
tionally accepted common data elements for gene
nomenclature and reference sequence information has
provided specificity and avoided (to a large degree) con-
fusion about the meaning of scientific data. Structuring
digital biology to conform to unified modeling language
(UML) has enabled genomic information to be modeled
across all domains of scientific application through
genomic standards, which has aided in the translation to
clinical application. Standard clinical nomenclature is
now being widely accepted for genomic test information.
Health Level 7 (HL7), Online Mendelian Inheritance in
Man (OMIM), Logical Observation Identifiers Names
and Codes (LOINC), and Systematized Nomenclature
of Medicine (SNOMED) provide widely accepted stan-
dards for clinical definitions, including disease and con-
dition terminology, laboratory test information, and
other terms for health care practices. Highly annotated
clinical reference repositories for standards have been
developed including the National Cancer Institute
repository of data elements caDSR (cancer data stan-
dards registry and repository). The caDSR is a database
and a set of Application Programming Interfaces (APIs)
and tools used to create, edit, control, deploy, and find
common data elements (CDEs) for metadata consumers
and for UML model development.23
Protection of civil rights regarding genetic information
On May 21, 2008, the US framework of civil rights was
enhanced through the signing into law of the Genetic
Information Non-discrimination Act of 2008 (GINA).24
This legislation was long sought on behalf of public
interest, as the absence of federal regulations to prohibit
use of genetic test information in employment decisions
and provision of health insurance benefits on the basis
of inherited traits was a deterrent for individuals to par-
ticipate in research studies. Together with the Health
Insurance Portability and Accountability Act provisions
(HIPAA), GINA generally prohibits health insurers or
health plan administrators from requesting or requiring
genetic information of an individual or an individual’s
family for decisions regarding coverage, rates, or preex-
isting conditions. The law also prohibits employers from
using genetic information for hiring, firing, or promotion
decisions, and for any decision regarding terms of
employment. Importantly, the statute provides defini-
tions regarding the consideration of genetic test and its
application under GINA. 
Regulatory oversight of genetic testing
In the US, the proliferation of genetic tests has raised
awareness about a dichotomy in the regulatory frame-
work across technology platforms and the federal agen-
cies that oversee them. Molecular diagnostics that are
performed in a laboratory as a laboratory-developed test
are overseen by federal regulations issued under the
Clinical Laboratory Improvement Act of 1972 (CLIA)
that addresses the analytical validity of the testing pro-
cedures. Analytical validity of a genetic test defines its
ability to accurately and reliably measure the genotype
of interest. Examples of common tests of this type
include cytogenetic studies, immunohistochemical analy-
ses, and fluorescent in situ hybridization assays per-
formed by clinical reference laboratories. 
Molecular laboratory assays that are assembled and
marketed as “kits” are medical products reviewed by the
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FDA for analytical validity and clinical validity. Clinical
validity of a genetic test defines its ability to detect or
predict the associated disorder or phenotypic presenta-
tion. In this scenario, kits such as the polymerase chain
reaction assay can be used in a clinical setting that may
be outside of the clinical reference laboratory. The FDA
review of these assay kits is considered a medical prod-
uct under regulations of devices. In recent years, there
has been much discussion regarding the different path-
ways that genomic assays may be brought into the clin-
ical market based on the oversight of laboratory tests.
Much of this discussion has been centered on a subset of
clinical tests known as in vitro diagnostic multivariate
index assays (IVDMIA) that integrate the analysis of
multiple genes on technology platforms, providing an
index score as a result. The mathematical algorithms that
reflect the integration of these various gene expressions
or polymorphisms are based on clinical population stud-
ies that associate the interaction of various genes under
different clinical scenarios. Today, IVDMIA are used in
guiding treatment decisions in breast and colon cancer,
and providing clinical guidance regarding likelihood of
recurrence under various treatment regimens. These
tests are performed in clinical reference laboratories and
are not subject to FDA review. A draft guidance has
been issued that proposes that manufacturers of 
IVDMIA obtain premarket approval. Recognizing that
the potential for a large number of complex genetic tests
will be coming into the clinical marketplace in the near
future, the Secretary of Health and Human Services
requested a review of the federal oversight of genetic
tests. The Secretary’s Advisory Committee on Genetics,
Health, and Society issued a comprehensive report in
April 2008 that highlighted the impediments to data sup-
porting medical use of genetic tests and recommended
steps to improve the oversight process.25
Policy issues regarding clinical utility and medical 
benefit from the use of genetic tests
Beyond the regulatory review of medical products, the
integration of personalized medicine technologies into
clinical practice also requires coverage and reimburse-
ment of costs of the tests by health care insurance
providers and other organizations that pay for health
care services. A centerpiece of these considerations is the
evidence that supports genetic test information adding
value to the medical care experience. The clinical utility
of a genetic test defines the elements that need to be
considered when evaluating the risks and benefits asso-
ciated with its introduction into routine practice. Overall,
the framework for supporting coverage and reimburse-
ment decisions for genetic tests has been hampered by
the lack of substantive clinical data to demonstrate con-
firmed value for their use in health care. The lack of a
clinical trial infrastructure for diagnostic assays, similar
to that for drugs and biologics, has made demonstration
of clinical utility and medical effectiveness difficult to
demonstrate. For personalized medicine applications,
economic issues play some part in the inability of small
diagnostic companies or reference laboratories to per-
form randomized clinical trials to show benefit by the
determination of medical intervention on the basis of
treatment outcome. 
One suggested framework for considering the compos-
ite evidentiary needs for genomic tests identifies impor-
tant information needs for medical use.26,27 In 2004, the
Centers for Disease Control and Prevention (CDC) ini-
tiated a program to systematically review the clinical evi-
dence supporting applications of genetic tests. The pro-
gram, known as the Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) con-
ducts systematic, evidence-based process for assessing
genetic tests and other applications of genomic technol-
ogy in the transition from research to clinical and public
health practice.28 Through this program, CDC supports
evidence evaluations through literature reviews. One of
the first studies conducted involved the use of pharma-
cogenetic testing of Cytochrome P450 polymorphisms in
patients being prescribed SSRIs. The evidence review
concluded, as it has for a variety of other genetic tests,
that there was insufficient data to support routine use of
genetic testing.29 Multiple other studies have been con-
ducted to examine other genetic tests and similar find-
ings were noted. This pattern suggests that to fully inte-
grate genetic testing practices into health care,
substantially more clinical research is needed to demon-
strate clinical utility. 
Health care financing considerations about coverage
and reimbursement of genomic tests
The Centers for Medicare and Medicaid Services (CMS)
recently deliberated on the coverage and reimbursement
of pharmacogenomic testing. Coverage decisions regard-
ing new health technologies under Medicare can be han-
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dled in two ways: local coverage decisions that are made
by petitioning authorization by the sponsor to a regional
Medicare contractor, or a national coverage decision
that CMS itself coordinates through administrative
processes. The latter was employed by CMS recently
through the conduct of an evidence review for coverage
consideration of pharmacogenomic testing of genes
associated with the biotransformation of warfarin, a
powerful anticoagulant. In May 2009, after extensive
review, CMS made a decision that denied coverage for
routine warfarin pharmacogenomic testing as their find-
ings indicated that clinical utility had not been demon-
strated. CMS went further to outline parameters for
future studies that they would consider supporting under
a “coverage with evidence development” process. This
process allows for the reimbursement of tests if done as
part of a randomized clinical trial where utility can be
assessed. To date, the alignment of evidence needs for
pharmacogenomic tests to meet clinical validity and util-
ity have not been mapped sufficiently for clinical stud-
ies to meet the regulatory needs of FDA and CMS.
Further work in advancing the application of pharma-
cogenomics in medical practice could benefit from most
strategic alignment of evidence needs and resources to
support these studies. 
The perspective of personal utility of genomic informa-
tion has opened a door for new business opportunities
in consumer health services. In 2008, several new direct-
to-consumer services were launched, providing relatively
low-cost genomic analysis and interpretation capabili-
ties to the public, without a physician order. 23andMe,
Knome, deCODEme and Navigenics are among the
companies offer comprehensive genomic analysis and
interpretation to consumers via a Web-based linkage.
These services provide health information to patients
about various personal traits (including behavioral ten-
dencies) and risk assessment probabilities. The genomic
tests in these cases are performed in CLIA-certified lab-
oratories but not FDA approved. Some controversy has
arisen over the validity of these tests and the consistency
of analysis across platforms and databases. Furthermore,
there is concern that none of the genomic information
provided is directly medically actionable. Other genetic
testing services focused on specific genetic mutations
and their associations to neurologic and psychiatric con-
ditions using data developed from GWAS studies have
arisen, including those predicting likelihood of autism
spectrum disorders, and suicidal ideation related to
SSRIs. Due to the lack of substantive clinical trials show-
ing evidence to support these claims and the potential to
cause patient confusion about the interpretation of the
results, these tests have largely been controversial.30
Among the issues frequently mentioned about the con-
sumer genomics services are the variation in reference
data populations used by the different services account-
ing for different interpretations of risk for the same
patient, oversight of the clinical laboratory measure-
ments through CLIA, and transparency of the use of the
consumer information by the service providers. 
Federal Trade Commission authorities are also playing
a role in assessing unscrupulous marketing tactics by
some companies of tests with unsubstantiated claims of
benefit. Despite the uncertainty, these trends indicate
several factors. Some segments of the consumer base are
interested in potential genetic risks and may use this
information to guide lifestyle and behaviors in their own
health care. Moreover, the interest in consumer genomic
services demonstrates some level of consumer empow-
erment and self-determinism that now permeates other
segments of health care through social networking and
community engagement. How these early experiences in
commercial sector genomic services relate to future
applications is unclear. The likelihood is, however, that
armed with risk information, consumers will seek more
insights from health care providers to guide them in the
use of this information. Most health care providers, how-
ever, are poorly equipped at the present time and access
to medical genetic counselors is sparse, although pro-
vided by some of the current consumer services. 
Conclusions
Overall, the impact of genomic technologies on the
understanding of disease and environment interactions
has been substantial. To translate these advances into
health care as personalized medicine will require sub-
stantial innovation in a systems redesign yielding trans-
formative changes in the values, priorities, and roles of
all participants. Building on information policies in
research, we can anticipate that personalized medicine,
in the context of health care reform, will need to address
some key areas. Molecular diagnostics, for example, are
likely to be required to have higher levels of trans-
parency of supporting data, and confirmatory evidence
that meaningful therapeutic selection decisions can be
made on the basis of the information they provide. Some
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important decisions will need to be addressed in estab-
lishing a clinical research framework for evidence devel-
opment in testing the applications of molecular diag-
nostics. Achieving this will almost certainly require more
collaborative interactions between public and private
sectors. 
The attributes of potential cost savings through the
reduction of adverse events and avoidance of using ther-
apeutics when patients will experience no benefit will
need substantive clinical evidence to support coverage
and reimbursement policies. Application of genomic
analysis in risk determination and behavioral and pre-
ventive interventions requires substantially more
research to achieve the most beneficial applications of
scare resources. Furthermore, there will likely be a
greater role for government-sponsored or public-private
collaborations to support prospective and comparative
trials to evaluate the contributions of genomic-based
diagnostic tests. Improvements in cost accounting
throughout health care will be required to demonstrate
the evidence that supports early detection and preven-
tion strategies yield relevant health outcome benefits.
Efforts to identify key data needs to assess clinical util-
ity and cost-effectiveness of molecular diagnostics over-
all will help refine innovation goals for clinical applica-
tion of genomics, and provide innovators with more
specific targets for their research and development
investments. Finally, substantial needs exist for educa-
tion and training of health care providers across many
disciplines to understand the patient care objectives of
personalized medicine. If the course of these develop-
ments is focused on patient care and quality improve-
ment processes, the future contributions of personalized
medicine to patient care will be substantial. ❏
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Perspectivas estratégicas en los nacientes 
caminos de la medicina personalizada
Los notables avances en el conocimiento funda-
mental acerca de las bases biológicas de la enfer-
medad y los avances técnicos en los métodos para
evaluar la información genómica han conducido al
sistema de asistencia sanitaria a las puertas de la
medicina personalizada. Ahora es posible conside-
rar la aplicación estratégica de la información
genómica para que el manejo del paciente resulte
predecible, prioritario y preventivo, y se permita la
participación del paciente en las decisiones médi-
cas. La evidencia inicial de esta transición tiene
algunas características particulares en cuanto a que
las innovaciones alteran las prácticas de la asisten-
cia sanitaria existentes. Se presenta una evaluación
de las modificaciones que están en proceso para
permitir que este nuevo concepto de atención sani-
taria en los Estados Unidos aumente la precisión y
la calidad de la atención a través de innovaciones
dirigidas a propuestas individualizadas para la
toma de decisiones médicas. Será necesario consi-
derar una amplia gama de posturas de políticas
públicas para las empresas prestadoras de atención
sanitaria para que ajusten las promesas de esta
nueva ciencia y tecnología para el beneficio de los
pacientes.   
Perspectives stratégiques dans la voie de la
médecine personnalisée
Des avancées notables dans les connaissances fon-
damentales des bases biologiques des maladies et
des progrès techniques dans les méthodes d’éva-
luation de l’information génomique ont permis de
faire évoluer le système de santé au seuil de la
médecine personnalisée. Il est désormais possible
d’utiliser des applications stratégiques de l’infor-
mation génomique pour guider la prise en charge
du patient, afin qu’elle soit prédictive, préemptive,
et préventive, et qu’elle permette la participation
de celui-ci aux décisions médicales. Cette transition
s’est illustrée de manière précoce par des innova-
tions qui tranchaient avec les pratiques soignantes
existantes. Nous examinons ici les modifications
nécessaires à l’émergence de ce nouveau concept
de soins aux États-Unis afin d’améliorer la précision
et la qualité des soins par des innovations visant à
individualiser la prise de décision médicale. Adapter
cette nouvelle science prometteuse et la technolo-
gie pour le bien des patients nécessitera d’envisa-
ger une grande variété de positions dans l’élabora-
tion de la politique des pouvoirs publics au service
de la santé.
27. Haddow JE, Palomaki GE. ACCE: A model process for evaluating data on
emerging genetic tests. In: Khoury M, Little J, Burke W, eds. Human Genome
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and Prevent Disease. New York, NY: Oxford University Press; 2003:217-233.
28. Centers for Disease Control and Prevention. Evaluation of Genomic
Applications in Practice and Prevention. Available at: http://www.cdc.gov/
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Treated With Selective Serotonin Reuptake Inhibitors (SSRIs). Structured
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Background: structural and 
functional brain imaging
brain imaging method could be defined as any
experimental technique that allows human (or animal)
brain structure or function to be studied, preferably in
vivo in the current context. Such a method should ideally
produce accurate timing (in the case of functional imag-
ing) and spatial localization (for both structural and func-
tional imaging) of cerebral function, structure, or changes
in these properties of the brain. The method should be
minimally invasive and repeatable (to facilitate use in
treatment monitoring and development of therapeutic
strategies). Current structural magnetic resonance imag-
ing (MRI) has good spatial resolution, is noninvasive, and
meets the above criteria well for structural analysis. In
contrast, no single technique currently in existence would
meet all these criteria in the case of functional imaging,
but the most common widely used methods are elec-
troencephalography (EEG), positron emission tomogra-
phy (PET), and functional magnetic resonance imaging
(fMRI). Of these three methods, EEG has been available
for the longest time (but arguably not so as a viable map-
ping method). PET has been available for the second-
longest period (in the order of four decades), and fMRI
is the newest widely used technique. PET is arguably the
most invasive (involving radioisotope administration)
and EEG makes the closest approach to measuring neu-
ronal activity directly (but has rather poor spatial map-
ping properties). As the location of cerebral activity and
changes in activity associated with changes in brain state
(either experimentally or illness-determined) seems to
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have been the priority in most of the research to date,
fMRI has emerged as the most widely used functional
brain mapping method.
Structural MRI (sMRI) has been a common tool for the
investigation of trauma and disease-related brain
changes for some considerable time, but fMRI is a more
recent addition to the MRI armory of methods. It has
been available for a little less than two decades, since
Ogawa et al1 first coined the term BOLD (blood oxygen
level-dependent) contrast for what has become the most
widely used approach in use today. At first sight, BOLD
imaging has a number of shortcomings. At what is still
the most common field strength in MR scanners in clin-
ical use (1.5 Tesla), the signal changes following neural
activation are only a few percent. There are also a host
of artifacts that can interfere with the signal, most
notably head motion. The BOLD “signal” is also not a
direct readout of neuronal electrical activity, but rather
a downstream consequence of this activity, dependent
on the response of the circulatory system. Finally, there
is still a dispute about exactly what neural changes
underlie the BOLD response (for a recent viewpoint on
some of these issues, see Logothetis2). Despite all these
apparent problems, BOLD fMRI has revolutionized the
study of human brain activity. It is noninvasive (does not
require administration of radioisotopes), can be per-
formed repeatedly on the same individuals, and uses
equipment that is increasingly widely available. There
have been tens of thousands of papers published in
which fMRI has been used to investigate a vast array of
aspects of human brain function.
Brain imaging and psychiatry
When MRI technology first became available to psychia-
try and neurology, one of the primary aims was to use this
new technology to establish what have often been
described as the “neural correlates” of various mental dis-
orders, ie, to determine the location and magnitude of
changes in brain structure or function compared with sub-
jects from a suitable reference population. This would facil-
itate the identification of “biomarkers” (objective quan-
tifiable changes in brain function) of the mental disorder
in question. The longer-term aim was then to use these bio-
markers to test the effects of drug treatment or behavioral
therapy, ie, to use them as quantitative measures of the
effectiveness of treatment in restoring “normality.”
As a research enterprise, the application of neuroimag-
ing with the above aims has resulted in a very large num-
ber of studies and an impressive number of research
publications in many of the major psychiatric and neu-
roscience journals, particularly in the case of fMRI. In
2003, barely a decade after the appearance of fMRI as a
viable imaging tool, it was possible to list, in a book enti-
tled Neuroimaging in Psychiatry3 produced by a number
of my colleagues in London as well as eminent
researchers from other centers, hundreds of research
papers involving MR (as well as a large number from
longer established methodologies such as PET). Since
2003 the knowledge base in this area has continued to
expand at an impressive rate and, reading the literature
to date, one might well conclude that fMRI has had a
considerable impact on our understanding of abnor-
malities in brain function and structure. However, one
might ask a different but no less important question.
Standing as we do, almost two decades after the appear-
ance of fMRI and having (as we do) access to widely
available and reasonably reliable methods of analyzing
brain imaging data, has brain imaging started to make
an impact on the clinical issues of interest? Has brain
imaging materially altered the pressing issues of the
diagnosis and treatment of brain disorders? 
This issue was the subject of a recent editorial in the
British Journal of Psychiatry by Bullmore et al4: “Why
psychiatry can’t afford to be neurophobic.” One of the
issues raised in that article is “the reality of psychiatric
practice in the UK, where there is currently agreed to
be no clear role for neuroimaging, biomarkers or
genetic testing.” The main question in relation to imag-
ing is why the large number of research studies have not
been translated into clear beneficial effects in clinical
practice. This is clearly a complex and multifactorial
issue, but the aim of the present contribution is to exam-
ine the simple question of whether neuroimaging is ask-
ing the appropriate questions of the data to maximize
its relevance to psychiatry and drug discovery and
development. For an interesting discussion of the gen-
eral issue of using neuroimaging to understand brain
function, see ref 5.
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Selected abbreviations and acronyms
fMRI functional magnetic resonance imaging
ROI region of interest
sMRI structural magnetic resonance imaging
SPM statistical parametric mapping
SVM support vector machine
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Background to current 
approaches to MRI analysis
In order to understand how the current approaches to
MRI analysis have arisen, one needs to return to the
period before fMRI was widely available, and brain acti-
vation and analysis was mainly undertaken using PET. The
technique, known as region of interest (ROI) analysis, was
the earliest to be employed and consisted, as its name sug-
gests, of picking, a priori, a region or regions of the brain
which were proposed, on the basis of previous findings or
hypotheses to respond to the experimental task being
studied. Typically, data would be averaged over the
ROI(s) and the change in blood flow related to task per-
formance would be studied, preferably with reference to
a control (nonresponding) region or regions. This method
remains arguably the simplest and one of the most statis-
tically powerful approaches to studying changes in brain
function and structure when the areas involved are well
known or strongly predicted a priori. However, universal
application of this method would entail a complete knowl-
edge of all the brain regions involved in normal brain
functions of interest, and (in psychiatry) when brain func-
tion or structure is abnormal. Given that we are still far
from such a state of knowledge, more exploratory
approaches were, and still are, needed in many cases.
Ideally, these methods needed to be able to explore activ-
ity changes at the limit of resolution of the brain images
(ie, at voxel level). In the late 1980s and early 1990s, Karl
Friston and his colleagues at the Hammersmith hospital
in London began to develop methods for the analysis of
changes in brain activation over the whole brain, an
endeavor which led to the development of the package
known as statistical parametric mapping (SPM—for
details see http://www.fil.ion.ucl.ac.uk/spm/doc/#history).
This package, freely available to researchers since 1991,
has become the most widely used approach for whole-
brain analysis of functional imaging data. In order to
achieve a principled approach to the problem, SPM devel-
oped a sophisticated way of dealing with the obviously
severe multiple comparison problem inherent in per-
forming tens of thousands of statistical tests, one at each
voxel.6 This approach, using the statistical theory of
Gaussian random fields,7 has earned Karl Friston deserved
recognition for revolutionizing the analysis of brain imag-
ing data. With the appearance of fMRI, the SPM package
was rapidly adapted to deal with the rather different char-
acteristics of the new data sets. Somewhat later, the possi-
bility of similarly analyzing structural changes voxel by
voxel led to the development of what is now known as
voxel-based morphometry or VBM. SPM was rapidly
applied to large numbers of structural and functional brain
imaging projects. It is the method of choice when changes
need to be investigated over the whole brain, either
because there is no strong prior hypothesis about the
areas that need to be studied, or because the distributed
nature of the expected changes makes ROI-based analy-
sis very challenging. On a more prosaic note, it also
removes much of the tedium (and potential error) of man-
ually defining ROIs on large, high-resolution MRI data
sets. Anyone who attempted to analyze structural MRI
data prior to the appearance of VBM might speculate that
the automated nature of this technique might have led
many researchers to take this route, even when an ROI
analysis might have been possible.
Since the early 1990s, there have been a large number of
technical developments in understanding, and dealing
with, sources of error in analyzing MRI data, and many
excellent packages are now available, but the main
analysis approach remains a suitably corrected voxel-by-
voxel exploration of whole-brain activations (or struc-
tural changes) with inferences as to which brain loca-
tions are exhibiting significant effects or changes in
effect brought about by the nature of the experimental
task undertaken or the membership of a particular sub-
ject group (eg, patient/control). The main approach
might be termed locationist and nonconnectionist, in
that it seeks to locate areas of significant response
(change) but ignores, by its independent voxel-by-voxel
analyses, interactions between brain regions, at least at
the primary phase of analysis. Note, however, that post-
hoc connectivity analyses are often undertaken in the
case of fMRI. Ignoring intervoxel interactions greatly
simplifies the analysis, but ignores our current knowl-
edge, suggesting that almost all significant brain activity
involves network or system level behavior. 
It is interesting to consider the pros and cons of this
piecewise approach to the analysis of brain function on
the current position of brain imaging vis à vis its uses in
psychiatry and drug discovery and testing. The obviously
positive aspects of 15 or so years of brain imaging
research using (predominantly mass-univariate) fMRI
are as follows. Firstly, our knowledge of the functional
neuroanatomy of the brain has been expanded consid-
erably. Secondly, if the multiple comparison problem
inherent in mass univariate analysis has been tackled in
MRI analysis—impact on clinical applications - Brammer Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
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a conservative and principled fashion, the areas that we
have identified should be relatively robust, as the ten-
dency would have been to make type II rather than type
I errors. On the other hand, the lack of consideration of
inter-regional interactions during whole-brain activation
detection will mean that we have missed some activa-
tions that might be weak but highly correlated between
brain regions. In other words, we might have under-
reported and underdetected the distributed networks
involved in many brain functions and in pathological
changes in these functions. In simple terms, we have
been “throwing away” useful information in the data sets
during analysis. A more important consideration, central
to the main theme of this article, is that, in the mass uni-
variate analysis, there is no combination of information
over the whole brain to assemble some sort of “figure of
merit” indicating how well our analysis results allow us
to, say, separate controls from patients, or drug respon-
ders from nonresponders. In other words, there is no
indication of how well the whole-brain data would allow
us to be confident that the pattern of activation was
characteristic of a patient rather than a healthy subject.
Instead of being able to make a prediction about an indi-
vidual being healthy or not on a network-wide basis, we
would instead be confined to making statements about
the overall separation of groups at a particular voxel or
in a particular region of interest, on the basis (typically)
of a t statistic.
New developments in analyzing brain 
imaging data: machine learning methods
These observations on the mainstream fMRI analysis
status quo have been made by a number of statisticians
and neuroscientists in recent years.8,9 In response to the
issues described above, growing interest has now come
to be focused on a group of analysis techniques that
have been described as “brain-reading” or “brain-
decoding” methods10 that belong to a broad group of
techniques known collectively as machine learning.11
The basic idea of these methods is that, instead of ana-
lyzing the brain voxel by voxel, data from groups of
voxels (ROI) or indeed from the whole brain, are used
to train a computer program. In one set of classifica-
tion methods, the most common variant of which is
called the support vector machine (SVM), the program
will typically find a boundary (referred to as a hyper-
plane in the relevant literature because it exists in
high-dimensional space) between different classes of
data (eg, data from patients and data from controls
either from structural images of the same fMRI exper-
iment). Once this boundary has been located, predic-
tions can be made for data not in the training data set.
For example, having trained the program to distinguish
controls from depressed patients and define the opti-
mal hyperplane to achieve this distinction, a new sub-
ject could be classified as belonging to the “patient” or
the “control” class based on the relationship of their
data to the hyperplane. The specificity and sensitivity
of these predictions can be examined using standard-
ized statistical approaches. In the most common of
these, the so-called “leave one out” methods, the com-
puter program is training on all the subjects but one
and tested on the remaining individual. This is
repeated until all the subjects have been the “one left
out.” By averaging the results across all the tests it is
possible to compute the sensitivity and specificity,
where sensitivity here refers to the probability of cor-
rectly classifying a patient as a patient, and specificity
the probability of correctly classifying a control as a
control. If the data to be analyzed are obtained with a
continuous rating (depression scores) rather than a
classification variable (ill/not ill), then similar pro-
grams can operate on a data regression basis, learning
the association between the continuous rating and
brain structure or function. As well as providing infor-
mation that may clearly be of value in a clinical setting
in the form of classification accuracy, which communi-
cates the level of confidence we can have in the pre-
dictions made by this type of analysis, these “brain-
decoding” methods can also produce maps which
indicate the levels to which different brain regions are
involved in the classification accuracy that has been
achieved. However, here a note of caution is in order.
Unlike the maps produced by the more commonly
used mass-univariate methods which can be unequiv-
ocally interpreted in terms of the size of the effect (eg,
difference in response between groups) at each voxel,
the maps produced by the machine learning methods
explicitly contain the effects of interactions between
voxels or brain regions. In other words, a particular
voxel could be important in distinguishing two groups
either because there is a large difference in function or
structure at that point or because there is a small dif-
ference that is highly correlated with those in many
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other brain regions, gaining importance from these
correlations. There are two main consequences arising
from this. The first is that the maps may be inherently
more sensitive in depicting effects than those that we
may be accustomed to seeing (though this is debated
and is still undergoing detailed study). The second is
that, unlike univariate maps, that can be subjected to
statistical thresholding at a particular P value, thresh-
olding these multivariate maps is more challenging,
and the most effective way to accomplish this is an
active area of investigation.
To summarize the above discussion, both the mass-uni-
variate and multivariate “brain reading” methods of ana-
lyzing MRI data can give information about the location
of disease-related changes in structure or function. The
univariate methods are in fact easier to interpret, but
may be less sensitive in detecting small changes to dis-
tributed systems. Few would argue, however, that if
properly carried out, both approaches can potentially
produce useful maps.
It is valuable at this point, however, to consider the rela-
tionship between producing a reliable map and estab-
lishing a usable biomarker for a psychiatric illness. The
concept of a biomarker contains within it the idea of
classification. It associates a pattern of changes in brain
structure or function with a particular mental state. This
is in fact the core idea of the “brain-reading” method-
ologies, as stated above. However, without knowledge of
the classification accuracy associated with the map of
brain changes, the map itself has little value. In a dis-
tinction between two classes, a random allocation
process would produce a classification accuracy of 50%.
A useful biomarker would be a pattern of changes with
a classification accuracy of such a level that its proba-
bility of arising by chance would be very small. We can
carry out such a test very easily. Having determined the
classification accuracy as described earlier, we the ran-
domly allocate the data to the two classes of interest
(thus achieving the null hypothesis of no difference
between the classes) and repeat the “leave one out” test-
ing. If we do this a very large number of times, we can
establish how likely the classification process is to pro-
duce the original classification accuracy under the null
hypothesis of no difference between the classes. In sim-
ple terms, we can see how far away from chance the clas-
sification lies. The further this is, the “cleaner” the sep-
aration between the groups achieved by the imaging
“biomarker.”
Machine learning in current image 
analysis—a change of emphasis?
Although “brain reading” using machine learning meth-
ods (often also referred to as pattern classification meth-
ods) is currently arousing a good deal of interest, their
use in the investigation of brain imaging is not new. In
fact, they were used as long ago as the 1990s to investi-
gate PET data.12,13 However, functional and structural
brain imaging research has produced a host of new and
interesting analysis methods over the last two decades.
The reasons why some methods become widely used
whereas others do not is a topic of considerable interest.
O'Toole and colleagues8 devoted considerable space to
discussing this issue and raised issues of what will move
researchers out of their “comfort zone” to a new and
potentially useful way of using their data. Given the
availability of high-quality packages such as SPM, where
mass-univariate analysis is efficiently implemented, and
which are well-known and respected by neuroimagers,
new methods have to be easy to use and to offer con-
siderable added value to justify the investment in using
them.
Why then does the author of the current article believe
that machine learning methods may be widely taken up
when many other promising methods have not? In the
early 2000s considerable interest in questions of
face/object recognition in the visual cortex led to some
fascinating experiments. Notably, a very elegant study of
face and object processing in the visual cortex by Haxby
and his colleagues appeared.14 This paper did not use
machine learning methods, but introduced the idea of
associating brain states (recognition of different types of
object) with distributed patterns of brain activity. Shortly
afterwards, in 2002, Golland et al wrote a highly inter-
esting account of the use of classifiers in brain imaging,15
introducing the use of the SVM, and in 2003 Cox and
Savoy10 used an SVM (see above) in the same area of
research as Haxby.14 It was clear from these data that
information might be available in distributed patterns of
brain activity that were not accessible by considering
each voxel in isolation. Moreover, this information could
aid classification. This was a way, not simply of locating
functional or structural changes in the brain due to illness
or a change in an experimental paradigm, but of using
data from many voxels to explicitly classify brain data
according to the group to which they belonged. A num-
ber of groups then began to realize that these ideas were
MRI analysis—impact on clinical applications - Brammer Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
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much closer to the notion of a network-level biomarker
than a statistically unconnected set of results from inde-
pendently analyzed brain regions. Machine learning
methods were soon applied to analysis of fMRI data,16,17
demonstrating the power to achieve good classification
accuracies based on networks located in believable brain
regions. It is but a small step from this point to the idea
of automated diagnosis. In the area of structural MRI,
Alzheimer's disease has been one of the major targets for
this latest phase of applications of machine learning.18,19
This is perhaps understandable, given that it gives rise to
both distributed and major effects on gray matter den-
sity, making it an obvious target for a multivariate classi-
fication method. The use of fMRI for diagnostic purposes
has also been investigated using SVM.20,21 Machine-learn-
ing based classifiers are currently achieving accuracies of
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Figure 1. Data flow in a simple 2-task functional magnetic resonance imaging (fMRI) experiment (alternating blocks of each task) through traditional
univariate analysis with general linear modeling (GLM) and support vector machine (SVM) analysis. The univariate approach analyses indi-
vidual voxels using time points when task 1 is being performed and time points where task 2 is being performed, contrasting the two using
a simple statistical test (eg, a t test) with a correction for the number of voxels analyzed. The output is a map of regions where the responses
to the two tasks are significantly different. SVM-based analysis takes whole-brain volumes when task 1 is being performed and whole-brain
volumes when task 2 is being performed and “trains” a computer program to associate  patterns of fMRI response with each task. The out-
puts are a map of the regions which discriminate between the two tasks and a measure of how well the two tasks are discriminated on the
basis of the whole brain data. After training, the task being performed can be predicted purely from the fMRI data. For group separation,
tasks 1 and 2 can be replaced by groups 1 and 2 ( eg, patients/controls) performing a given task or structural MRI data from the two groups.
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75% to 95% using functional and structural imaging data
and active research in this area is extending the armory
of methods beyond categorical classification to proba-
bilistic output using techniques such as Gaussian Process
methods.22 Other techniques of interest include single-
class SVM in which the goal is outlier or novelty detec-
tion. This method has considerable promise for detection
of deviations from statistical homogeneity in clinical pop-
ulations.
In a recent demonstration of the possibilities for
machine learning, Sato and his colleagues carried out an
interesting experiment.23 They first trained a computer
program (using a technique called maximum entropy
linear discriminant analysis) to recognize the association
between age and brain activation changes during per-
formance of a motor (finger-tapping task). They were
then able to predict the ages of subjects not included in
the training purely from their brain activation data. If
one imagines the association computed in this experi-
ment as a biomarker for age, and then extends the logic
to other areas (eg, changes in depression) one can appre-
ciate the possibilities of the method. 
Some of the most exciting possibilities of machine learn-
ing methods in clinical practice stem from the ideas
raised in the two previous paragraphs. One is that we
may be able to locate individual patients on a continuum
of brain structural or functional abnormalities that are
correlated with illness severity. This would be a great
advance on simply categorizing an individual as belong-
ing to the group of “controls” or the group of “patients.”
We would also be able to identify patients who, on the
basis of their brain structure or function, appeared to be
atypical of their diagnostic group.  The second is that this
“continuum” or probabilistic rather than categorical
approach, could be extended from diagnosis to response
prediction—personalization of treatment. The probabil-
ity that a given patient might be a “responder” rather
than a “nonresponder” based on objective measurement
of brain structure or function would be a valuable
adjunct to the choice and direction of treatment.
In order to make these new methods available on a wide
basis, a number of groups are also actively developing
toolboxes with user-friendly interfaces. Also, in order to
avoid repetition of already time-consuming image pro-
cessing, these toolboxes are often being designed to
accept data from widely used preprocessing streams in
packages such as SPM.
Conclusion
Seventeen years ago, it was felt that fMRI might revo-
lutionize the study of human brain activity.1,24 Arguably,
this has proved to be the case. It was also felt by many
that fMRI might prove to be an invaluable clinical for
the investigation and treatment of mental illness. There
are many who would argue that has not proved to be the
case. Kosslyn in 19995 asked “If fMRI is the answer—
what is the question?” With machine learning, perhaps
fMRI may be able to answer more of the questions that
we wish to ask. ❏
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El papel de las neuroimágenes en el 
diagnóstico y en la medicina personalizada:
situación actual y probables proyecciones
futuras
El objetivo principal de este artículo es analizar la
situación actual de los métodos de neuroimágenes
in vivo en el contexto del diagnóstico y del trata-
miento de las enfermedades mentales. Se discute el
fundamento de la práctica actual y los nuevos
métodos introducidos, los que pueden tener la
capacidad de aumentar la importancia de las imá-
genes de resonancia magnética, en especial de la
resonancia funcional, para la aplicación clínica. El
foco principal estará en las imágenes de resonancia
magnética, pero muchos de los comentarios tienen
una relevancia general para las distintas modalida-
des de imágenes. 
Rôle de la neuro-imagerie dans le diagnostic
et la médecine personalisée: position
actuelle et perspectives éventuelles
Cet article vise principalement à examiner la place
actuelle des méthodes d’imagerie cérébrale in vivo
dans le contexte du diagnostic et du traitement des
maladies mentales : une discussion du  cadre des
pratiques actuelles est proposée, ainsi qu'une intro-
duction aux  nouvelles méthodes qui pourraient
augmenter la pertinence de l’imagerie par réso-
nance magnétique, plus particulièrement  l’IRM
fonctionnelle,en ce qui concerne ses  applications
cliniques. Le sujet principal en est l'IRM, mais un
grand nombre des commentaires sont également
valables pour d'autres méthodes d'imagerie. 
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egenerative medicine appears to be on the
brink of a bonanza in terms of new treatment options, ie,
stem cell-based therapy. Up to now, stem cell-based
interventions (SCBI) have still been in an immature
state. Only a few trials are currently under way, and are
so far mostly in a preclinical phase. Current focuses
include Duchenne’s disease, Parkinson`s disease, and
Alzheimer’s disease.1 The major concept of all these
experiments is to create a treatment scheme similar to
that in bone-marrow diseases where hematopoietic stem
cells are regularly used as a cure for certain types of
leukemia—in this case, the issue of the appropriate stem
cell type used has been solved. For SCBI in neurode-
generative disease there is an ongoing debate regarding
which cell type might be suitable for transplantation—
embryonic versus fetal versus adult stem cells.
Furthermore, the question of stem-cell homing needs to
be addressed, since one may not need to transplant the
cells by neurosurgical procedures. Instead, it could be
sufficient to inject these cells into the cubital vein only,2
since the plasticity of these cells enables them to find the
niche where they are needed—even within the central
nervous system (CNS). 
Apart from technical aspects, ethical problems arise.
Even without touching on the debate of using human
embryonic stem cells, there is plenty of groundwork for
bioethicists to do. 
When the ethical and technical issues have been resolved,
we may proceed from neurodegenerative to psychiatric
illnesses such as affective disorders and schizophrenia. 
We still face a substantial lack of proof as to whether
these psychoses are the cause or the correlate of dis-
turbed adult neurogenesis.3 If so, we may consider these
severe illnesses as being neurodegenerative, as there is
some compelling data for this, at least in the field of
397
T r a n s l a t i o n a l  r e s e a r c h
R
Copyright © 2009 LLS SAS.  All rights reserved www.dialogues-cns.org
Stem cell approaches in 
psychiatry—challenges and opportunities 
Jens Benninghoff, MD
Keywords: stem cell; neurogenesis; transplantation; depression; schizophrenia
Author affiliations: Department of Psychiatry, Ludwig-Maximilian University,
Munich, Germany   
Address for correspondence: Jens Benninghoff, MD, Molecular and Clinical
Neurobiology, Department of Psychiatry, Nussbaumstrasse 7, D-80336 Munich,
Germany
(e-mail: jens.benninghoff@med.uni-muenchen.de)
Exploring stem cells is a fascinating task, especially in a dis-
cipline where the use of stem cells seems far-fetched at first
glance, as is the case in psychiatry. In this article we would
like to provide a brief overview of the current situation in
relation to the treatment of mental diseases. For reasons
that we will explain, this review will focus on affective dis-
orders. The following section will give a more detailed
account of stem-cell biology, including current basic science
approaches presenting in-vivo and in-vitro techniques. The
final part will then look into future perspectives of using
these stem cells to cure mental illnesses, and discuss the
related challenges and opportunities. 
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depression. There may be some clinical trials of graft-
ing stem cells, in a long and cumbersome process, into
the brains of diseased patients. In our opinion, this will
only be the case for very severe cases of depression,
after having tried nearly all the available medication
options and unsuccessful electroconvulsive therapy
(ECT). 
Past and current status
In the past, psychiatric diseases have been treated phar-
macologically with broad-profile medication—the so-
called “shotgun method.” In the same way that a shotgun
fires many pellets at once, psychiatric medication can
impact on many different neurotransmitter systems. Due
to this profile, many of these drugs, such as tricyclic anti-
depressants (TCAs) or first-generation antipsychotics
(FGAs) caused severe undesirable side effects, which
were held responsible for poor compliance and discon-
tinuation of the prescribed medication.
During the last two decades, new drugs have surfaced
with fewer shotgun side effects because of their particu-
lar pharmacodynamic design targeted against one single
and very specific molecule. In this context, selective sero-
tonin reuptake inhibitors (SSRIs) should be mentioned
here as an example of an antidepressant agent acting
solely on one neurotransmitter system and within the
serotonergic system on one distinct transporter molecule.
The same holds true for second-generation antipsychotics
(SGAs) displaying only few side effects due to less rigid
inactivation of dopamine receptor type 2 (DR2) and
therefore fewer extrapyramidal motor symptoms recall-
ing parkinsonism.
Nevertheless, we are still struggling with inefficacious
medication, since only about one third of antidepres-
sant agents work in a given patient, meaning that one
has to try on average three different medications in
order to alleviate this patient`s symptoms. For schizo-
phrenia the same holds true. Sometimes, the individual
situation seems even worse than in the field of affective
disorders. 
Some stem cell basics
As mentioned above, this article emphasizes the link
between disturbed adult neurogenesis (AN) and affec-
tive disorder. The case seems to be much more evident
here than in schizophrenia, although decreased neural
stem cell proliferation in the dentate gyrus (DG) of the
hippocampus has been demonstrated in postmortem
human brain from schizophrenic patients.4
Stem cells can be characterized by two fundamental qual-
ities: first, they have the capacity for unlimited self-
renewal, and second, they can produce at least one type
of highly differentiated descendants.5 This particular cell
division is termed “asymmetrical”: in general, each stem
cell division gives rise to one stem and one committed
somatic daughter cell.6 Stem cells are single cells that,
once developed, self-renew for the lifetime of the organ-
ism. These stem cells should be distinguished from tran-
sient progenitor cells, which have a limited self-renewal
lifespan.7 Some steps earlier during the embryonic period,
cells become gradually restricted to distinct pathways of
differentiation. This process includes modification of their
developmental potential; they become pluripotent
(“many, several”). The major difference between totipo-
tency and pluripotency is that an embryonic stem cell (ES
cell) which is by definition “pluripotent,” can only form
cells which constitute the embryo itself but not the pla-
centa. Early ES cells can be taken from the embryo and
grown in vitro. When retransferred into the embryo, these
cells can still generate all tissues, including the germ line.8
ES cells also play a central role in the generation of trans-
genic animals such as knockout mice.
Pluripotency of stem cells becomes progressively
restricted and they become multipotent. Multipotent
stem cells in the brain ultimately give rise to all different
types of neuronal and non-neuronal cells in the central
nervous system. Presumably they have lost the ability to
produce cells of ento- and mesodermal origin. Because
they are capable of generating the entire progeny of a
given tissue, some investigators have termed these mul-
tipotent stem cells “progenitor cells.” Moreover, there is
controversy as to whether neural stem cells can actually
remain viable during the entire lifespan.9
Adult forebrain neural stem cells were discovered in
199210 in the adult remnant of the embryonic brain ger-
minal zone surrounding the lateral ventricle. Evidence for
their participation in repopulating the adult lateral ven-
tricular subependyma following irradiation11 led to the
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hypothesis that neural stem cells also exist after the
embryonic and fetal period, similarly to hematopoietic
stem cells. Hematopoietic stem cells in adult animals can
restore different blood cell types. For a long time it has
been thought that once a cell had been programmed to
produce a particular tissue, its fate was sealed and it could
not reprogram itself to form another tissue. Contrarily to
this view, reactivation of dormant genetic programs
appears to work under certain circumstances. Intriguingly,
stem cells from brains of adult mice have been shown to
possess the potential to become functional blood cells.12
Similar results for the inverse case were reported, ie, mul-
tipotential mesenchymal cells transformed into neural
cells—astrocytes in this case.13
According to Fred H. Gage, the term “neural stem cell”
should therefore be used with caution to describe cells
that “a) generate neural tissue, b) are capable of self-
renewal, and c) give rise to cells other than themselves
through asymmetric cell division.”14 In fact, when the
issue of lineage specificity of adult neural stem and prog-
enitor cells is considered, there is abundant reason for
caution regarding the term neural stem cell. The ability
of bone marrow stem cells to generate astrocytes,13 the
finding that astrocyte-like cells in the subependyma are
neural stem cells,15,16 and that oligodendrocyte-precursors
contribute neural stem cell-like cells17—all these findings
soften the theoretical distinction between stem and prog-
enitor cells. All this makes it really difficult to decide
which type of stem cells one should use for transplanta-
tion. Even during the process of grafting stem cells they
can still start to differentiate and become more restricted
progenitors due to cell-cell contacts or influence of adhe-
sion inside the syringe. 
Further, neural stem cell research suffers dearly from the
lack of an antibody specifically identifying neural stem
cells. Detecting stem cells ad hoc and not ex post remains
a problem. Putative stem cells need to differentiate into
their derivative neural cell subpopulations before one
can positively identify them as regular neural stem cells.
In the past, efforts to generate antibodies against adult
stem cells did not prove sustainability.18,19 There are cer-
tain advantages of adult over embryonic stem cells in that
the former may be easier to manage. ES cells tend to dif-
ferentiate spontaneously into all kinds of specified tissue.
For example, when injected subcutaneously into
immunocompromised mice they grow into teratomas,
tumors consisting of numerous cell types ranging from
gut to skin. Before applying these cells in humans, gen-
eration of the desired cell types should therefore be
ensured without undesired side effects or unwanted cell
populations, respectively. Here, it seems that adult stem
cells are better behaved, since they do not differentiate
spontaneously.
Instead this can be induced by applying appropriate
growth factors. However, adult stem cells have a differ-
ent drawback, in that they seem to lose their ability to
divide and differentiate after some time in culture.
Maybe in the end ethical considerations will also con-
vince the scientific community to follow the adult stem
cell rather than the ES cell track. Compared with embry-
onic or fetal stem cells, adult stem cells pose fewer ethi-
cal problems because they can be obtained from sources
other than embryos or aborted fetuses.20 Even post-
mortem human tissue can yield neural stem cells.21 In
consensus with Frank E. Young22 the public, as well as
governmental authorities, should enter the process of
unbiased dialogue, in order to establish the principles
according to which research needs to be conducted. 
As of now, we should consider the human species an appro-
priate source for SCBI. Having said this, we should take
into account possible chimerae of animals with human cells
in their brains, and above all with possible human behav-
ior.23 Another issue to be ruled out is to prevent striking
behavioral traits after SCBI. In Parkinson’s disease patients
it has been shown that after L-Dopa treatment some
patients responded with pathological gambling,24 since
dopamine sustains the reward system. One could easily
imagine a scenario like this in a patient after SCBI. In this
case, it might not be as easy to lower the dopamine pro-
duction as it is with cessation of the medication. 
As mentioned above, grafting hematopoietic stem cells
has already become a conventional clinical tool in the
treatment of certain types of leukemia. Currently it can
only be hypothesized that transplantation of neural stem
cells has potential for treating brain disease.25
Although all these obstacles do exist, the main target for
the research on neural stem cells must be to restore reg-
ular neural function in areas where cells have died or lost
their physiologic behavior. Clinicians are eager, for exam-
ple, to transplant NSCs into patients suffering from
Parkinson’s disease,26 multiple sclerosis, or spinal cord
injuries, although it is not clear so far which is the appro-
priate cell to transplant—the CNS neural stem cells, the
actual neurons, or intermediate progenitors between the
two. Thus, in neurodegenerative diseases it is important
to first determine the rules of transplantation of stem,
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progenitor, and mature cells, as well as to determine the
sites into which the transplants must be located. In
Parkinson’s disease we do not know whether cells should
be placed into the substantia nigra, or striatum, or both.
So we continue wondering which particular region of the
abovementioned brain areas should be chosen—eg, the
ventral part or the dorsal putamen in only one hemi-
sphere or both. The variability in surgical methods
between centers which perform stem cell transplantation
makes it very difficult to assess the results of this proce-
dure.26 Still, if we get to the point where all these issues
are resolved, we will have to find better ways to secure
the long-term survival of the grafted cells.
So far, the de novo generated dopaminergic neurons
have only a limited lifespan in animal studies.27 Finally,
the source of the cells should be clarified, since we need
huge amounts of human fetal tissue for transplantation.
Although there has been much progress achieved over
the last few years, especially in long-term proliferation
and dopaminergic differentiation of progenitor cells,28 we
still have to invest much effort in finding alternative
methods, such as in vivo mobilization of dormant neural
stem cells, which seems to be a more useful concept.
Pathophysiologic models of depression
In the light of recent findings such as loss of total cell vol-
ume in certain brain areas observed in depressed patients
(see below), we can heretically define depression as a
“neurodegenerative” disease. As we will discuss, this par-
ticular illness does not necessarily require stem cell trans-
plantation. Instead, it may be possible to replenish miss-
ing neurons by regulating the microenvironment
surrounding the putative sites of neural stem cells where
neurogenesis takes place. Lessons from recent findings
in pathophysiology might open up a broad research
avenue with the ultimate goal of treating depression.
In a WHO survey, depression and manic-depressive ill-
ness will still rank among the top 10 causes for death in
the year 2010. Certainly not all forms of depression even-
tually lead to death by suicide, but even milder courses
of this illness may lead to severe incapacitation of mil-
lions of people worldwide. In particular, it impairs rein-
tegration into their familiar social environment and into
the working process. Accumulating evidence from neu-
robiology suggests that distinct biochemical processes are
derailed in a large number of depressed subjects. Cellular
and molecular adjustments following stress seem to play
key roles in onset and propagation of mood disorders. To
most of us, stress is a beneficial response of our neuronal
systems to acute challenges of the exterior world. To put
it simply, it is more beneficial for a rabbit to become
stressed and flee when it sees a fox approaching.
However, severe or repeated stress can lead to detri-
mental effects on regular neural function.29
Neural plasticity is a term which involves interneuronal
communication and adaptation in order to give the
appropriate responses to stress or aversive stimuli. One
example of such a response could be changes in neuro-
genesis—the generation of new neurons. Dysfunction of
adequate regulatory processing due to severe or chronic
stress is capable of disturbing neural plasticity.
Medical treatment with antidepressant agents may bring
back regular function of neural systems by influencing
neural plasticity: antidepressants require long-term
administration, while blockade of the reuptake of sero-
tonin (5-HT) and/or norepinephrine as their most com-
mon and initial mode of action is fairly rapid. There is a
process whereby neurons can adapt to and regain plas-
ticity while the local biochemical environment is chang-
ing due to the application of antidepressants. Thus, the
long-term mode of action of antidepressant medication
seems much more dynamic and complex than just up- or
downregulation of synaptic levels of monoamines.
The role of the hippocampus
The hippocampus is a well-characterized brain structure.
In 1886 C. Golgi stained hippocampal neurons with his
novel silver impregnation technique, which became
known as the Golgi procedure. Since then a great num-
ber of neuropsychiatric phenomena have been studied in
the hippocampal formation.
The relatively simple organization—pyramidal neurons
in the hippocampus proper and the granule cells of the
dentate gyrus are arranged in single, densely packed cell
layers—is one of the major reasons why the hippocam-
pus has frequently been used as a cytoarchitectural
model of the cortex. Recent findings in volumetric neu-
roimaging studies make a strong case that biochemical
changes in the brain carry morphological sequels. So far
we have learned that gray matter volumes are diminished
in depressed patients and in post-traumatic stress disor-
der patients in the medial and orbital prefrontal cortex,
the mesiotemporal cortex, and the ventral striatum, and
are accompanied by an enlargement of the third and the
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lateral ventricles.30-33 Hippocampal gray matter volume is
reduced strikingly in depressed patients.34,35
Additional postmortem brain studies underpin the above-
mentioned results. According to Vincent et al36 there is a
layer-specific reduction of interneurons in the anterior cin-
gulate cortex. Significant reduction in numbers of non-
pyramidal neurons in the CA2 area of hippocampus was
reported in postmortem studies of bipolar disorder.37 Also
in regions other than hippocampus, there may be a decline
in brain region volume and total cell number.38,39
Elevation of cortisol levels in the elderly correlates with
reduced hippocampal volume, and is associated with
memory deficits.40
Patients with depression have a functional deficit of the
hypothalamic-pituitary-adrenal (HPA) axis.41 Hippocampal
neurons are reported to be damaged by exposure to stress
or activation of the HPA axis and elevation of glucocor-
ticoids. Taken together, this overview of morphologic evi-
dence strongly supports a functional link between changes
at the molecular levels and morphology. The task of future
research could be to develop strategies allowing the dis-
eased hippocampus or other affected brain structures to
regain regular morphology and function. Focusing on neu-
rogenesis—which is defined as a series of events including
proliferation of a neural precursor or stem cell that results
in appearance of a new neuron42—may be a systematic as
well as pragmatic way to proceed.
There is a growing body of evidence for the phenomenon
of neurogenesis in humans.15 Localization of pluripotent
progenitor cells and thus neurogenesis appears to be
restricted to certain brain regions, in particular, the sub-
ventricular zone (SVZ) and the subgranular layer of the
dentate gyrus of the hippocampus.42 Neurogenesis in the
adult mammalian brain is regulated by genetic and envi-
ronmental factors43-45—all leading to the exciting possi-
bility of pharmacological regulation of neurogenesis in
the adult brain, and eventually of the disease-related
pathophysiological changes.
One of the mainstay therapies in the treatment of recur-
rent mood disorders, lithium, ranks among such pharma-
cologic candidates. Lithium increases the levels of the
antiapoptotic protein bcl-2.46,47 We now know that besides
its role in cell cycle control, bcl-2 functions as a neu-
rotrophic factor, since bcl-2 promotes axon regeneration
as well as neurite and axonal outgrowth.48 In general,
neurotrophic factor signaling is mediated both by the
phosphatidyl-inositol-3-kinase pathway and activation of
the MAP (mitogen-activated kinase) cascade.49,50
Activation of MAP cascade augments bcl-2 expression.
This is very likely to involve the cAMP responsive ele-
ment binding protein (CREB).51
CREB is attractive to many researchers because it
appears in some way required for long-term memory.52
CREB may increase the integrity and functional plastic-
ity of granule cell neurons assuming that CREB is a crit-
ical determinant of neural plasticity as well as cell sur-
vival. One putative gene target of CREB—and thus of
chronic antidepressant treatment—is brain-derived neu-
rotrophic factor (BDNF). There is a functional cAMP
responsive element in the exon III promoter of the
BDNF gene.53 In the light of this, it is not surprising that
local infusion of BDNF in the hippocampus produces an
antidepressant effect.54
In vitro, activation of the cAMP system upregulates
BDNF expression in hippocampal cells.55,56 Additionally,
BDNF expression effects neuronal depolarization and
activation of voltage-dependent calcium channels. These
alterations at the synaptic level underlie the influence of
BDNF on long-term potentiation.57 This underscores the
central role of BDNF in neurogenesis considering the
pivotal role attributed to BDNF in lineage differentia-
tion of neural stem cells.
Another key player in the pathophysiology and treat-
ment of depression, the biogenic amine 5-HT, should not
be neglected, since 5-HT is one of the most extensively
studied neurotransmitters of the central nervous system.
Moreover, novel findings indicate that 5-HT is particu-
larly relevant to neurogenesis in the hippocampus
(Figure 1), because in adult rats it has been shown that
decreased 5-HT lowers the rate of neurogenesis in the
dentate gyrus of hippocampus.58 Historically, 5-HT was
first described as a serum component augmenting
Stem cell-based therapy in psychiatry - Benninghoff Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
401
Figure 1. A) Putative model of the serotonergic (5-HT) machinery in adult
neural stem cells. Tryptophan hydroxylases (TPH) produces 5-HT,
which controls its own metabolism mainly via 5-HT1A and 5-
HT2C receptors. B) TPH inactivation leads to less 5-HT produc-
tion—model proposed by the author based on own experi-
mental data (Benninghoff et al, unpublished data).
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smooth muscle contraction.59 In such non-neural systems,
5-HT has been a potent mitogen.60,61
In the brain, 5-HT is among the most widely distributed
neurotransmitters. All serotonergic fibers originate in the
brain stem raphe nuclei. By way of extensive synaptic
connections of the serotonergic fibers, 5-HT contributes
to many physiologic functions such as endocrine and cir-
cadian rhythms, food intake, sleep, reproductive activity,
and motor function, as well as cognition, mood, and anx-
iety.62 In the brain we currently know of 16 different
cloned receptor types and subtypes, but it can be
expected that their number will grow even further in the
near future. In contrast to the multitude of 5-HT recep-
tors, there is only a single 5-HT transporter (5-HTT)
responsible for the reuptake of 5-HT into serotonergic
neurons after its release into the synaptic cleft. As our
own studies have shown, 5-HTT does not have a large
impact on neurogenesis.63
A possible role for 5-HT as direct mediator of granule cell
generation is currently discussed, since elevated 5-HT lev-
els in the hippocampus increase the rate of proliferation
of granule cell precursors.64 Epidermal growth factor
(EGF) is believed to exert an essential function on the
generation and maintenance of neural stem cells. It is
therefore not surprising that in non-neural systems, EGF
and 5-HT can augment the rate of cell proliferation in a
synergistic manner.65 BDNF again seems involved in medi-
ating the effects of 5-HT. Thus, chronic administration of
5-HT-selective reuptake inhibitors, clinically used as anti-
depressants, leads to upregulation of BDNF mRNA.56
As already mentioned above, 5-HT exerts its action
through a large family of receptors in the periphery and
throughout the CNS.62 A possible role for the 5-HT1A
receptor in the modulation of anxiety and depression, as
well as in the mode of action of anxiolytic and antide-
pressant drugs, has been suspected for many years.66 5-
HT1A receptors operate both as somatodendritic autore-
ceptors and postsynaptic receptors. Research regarding
5-HT1A receptor has shown67 that the effect of antide-
pressants upregulating extracellular serotonin levels
worked via the 5-HT1A receptor subtype, thus opening
a link between our in vitro system, neurogenesis, and clin-
ical relevance in terms of affective disorders. 
Althogh the serotonin hypothesis of depression68 is very
attractive in this regard, it should not be omitted here
that there are additional compelling findings dealing with
other neurotransmitting systems, eg, supporting cholin-
ergic mechanisms.69 Riederer et al70 came to the conclu-
sion that a brain area-specific imbalance of neurotrans-
mitters leads to the clinically different manifestations of
depression. The loss of regional interneuronal home-
ostasis must not necessarily affect huge brain areas; it
might be only limited to certain small and circumscripted
regions in the brain. As a consequence, clinicians should
be able to choose the pharmacologically appropriate
medication for the affected brain region.71
Concluding remarks
Stem-cell maintenance and generation take place in a
distinct microenvironment where appropriate external
signals can best exert their regulatory function on these
cells. Signals provided by neural growth factors are
responsible for neural stem-cell growth. Since compo-
nents of regular stem-cell maintenance like BDNF are
also implicated in mechanistic models characteristic of
mood disorders, they thus offer new targets for pharma-
cologic intervention in neuropsychiatric disease. More
thorough knowledge about this complex connection may
help us render antidepressant treatment more efficient
and reduce the undesirable side effects that impair
patient compliance. So far there is no stem-cell-based
approach really on the horizon for treating depression or
any other psychosis.  ❏
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Acercamiento a las células madre en 
psiquiatría: desafíos y oportunidades
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y oportunidades relacionadas con ellas.  
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Background
chizophrenia (SCZ) is a disease with an esti-
mated lifetime morbid risk approaching 1% worldwide,1
and its public health consequences (mortality and mor-
bidity) are severe. SCZ is associated with an increase of
at least 50% in mortality rates compared with the gen-
eral population,2 including a suicide rate of approxi-
mately 5%,3 resulting in 10-year average lifespan reduc-
tion.4 SCZ accounts for nearly 3% of all years lived with
disability5; amongst individuals aged 15 to 44, SCZ is the
third-leading cause of disability.6
Despite the demonstrated efficacy of antipsychotic drugs
(APDs) in short-term placebo-controlled clinical trials,
long-term outcomes frequently remain unsatisfactory. The
largest NIH-supported clinical trial of antipsychotic agents
conducted to date revealed that both first-generation
antipsychotics (FGAs) and second-generation antipsy-
chotic (SGA) agents have limited long-term effectiveness,
largely due to high rates of discontinuation (~75% dis-
continuation within 18 months).7 Similar results were
obtained in two large-scale European effectiveness trials.8,9
In each of these trials, clinically significant side effects were
noted in the majority of patients, and tolerability was the
primary cause of at least 20% of all drug discontinuations.
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Currently available antipsychotic drugs (APDs) carry sig-
nificant, though highly variable, liability to neurologic and
metabolic side effects. Pharmacogenetics approaches offer
the possibility of identifying patient-specific biomarkers
for predicting risk of these side effects. To date, a few sin-
gle nucleotide polymorphisms (SNPs) in a handful of genes
have received convergent support across multiple studies.
The primary focus has been on SNPs in dopamine and
serotonin receptor genes: persuasive meta-analytic evi-
dence exists for an effect of the dopamine D2 and D3
receptor genes (DRD2 and DRD3) in risk for tardive dysk-
inesia (TD) and for an effect of variation at the 5-HT2C
receptor gene (HTR2C) for liability to APD-induced weight
gain. However, effect sizes appear to be modest, and
pharmacoeconomic considerations have not been suffi-
ciently studied, thereby limiting clinical applicability at this
time. Effects of these genes and others on risk for TD,
extrapyramidal side effects, hyperprolactinemia, and
weight gain are reviewed in this article. 
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:405-415.
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The high likelihood of medication discontinuation has
substantial clinical and economic implications, as treat-
ment nonadherence is perhaps the single strongest pre-
dictor of relapse and rehospitalization.10 Patients who
have discontinued APDs may be as much as five times
more likely to relapse as medicated patients.11 Moreover,
nearly half of rehospitalization costs in SCZ may be
accounted for by medication nonadherence.12 In addition
to the effectiveness trials cited above, many observa-
tional studies and controlled trials have presented evi-
dence that perceived side-effect burden frequently leads
to both poor attitudes towards medications and a ten-
dency towards discontinuation, nonadherence, and par-
tial adherence.13,14 Although side effects are highly preva-
lent, there is also substantial variability in liability to
clinically significant or intolerable adverse events.15
Consequently, understanding and predicting liability to
side effects may be an effective strategy to improve
prognosis in schizophrenia.
Antipsychotic-induced side effects
FGAs were most commonly associated with neuromus-
cular side effects, including the potentially irreversible
movement disorder, tardive dyskinesia (TD).16 In large
cohort studies, TD has been shown to affect at least one
in five, and perhaps as many as one in three, patients
treated chronically with FGAs.17 New onset (incidence)
of TD is approximately 3% to 5% per year of treatment,
and these rates are increased as much as fivefold in
elderly patients.18 In addition to physical discomfort and
social stigma, presence of TD has been associated with
reduced quality of life, increased psychopathology, and
increased mortality rates.19 Even at low doses and/or
intermittent treatment schedules, the high prevalence
and morbidity associated with TD was the primary
impetus for the promotion of SGAs as preferred first-
line treatment, at least in the United States.15,20 Although
use of SGAs is not entirely free from TD risk, incidence
and rates are as much as 80% lower for SGAs compared
with FGAs.21,22
Though treatable and reversible, extrapyramidal symp-
toms (EPS) including Parkinsonian motor difficulties as
well as akathisia, are highly prevalent with FGAs and are
also associated with patient discomfort, dissatisfaction, and
discontinuation of treatment.16 Despite the initial optimism
that SGAs would greatly reduce EPS burden, most SGAs
still demonstrate a clinically relevant tendency to induce
these symptoms.23,24 In a large-scale effectiveness trial in
chronic SCZ patients, SGAs were indistinguishable from
a low-dose FGA (perphenazine) in rates of new onset of
akathisia and EPS (5% to 10% each, irrespective of drug
assignment).25 However, meta-analytic reviews of the lit-
erature demonstrate that overall EPS burden may be
reduced by 30% to 50% with SGAs.26 Because the mech-
anism of action for all currently approved antipsychotic
medications remains blockade of dopamine receptors,27
motor and other side effects (eg, prolactin elevation)
remain a concern in the treatment of SCZ.
While SGAs have moderately reduced EPS and sub-
stantially reduced TD liability relative to FGAs, these
newer antipsychotics are most notable for their propen-
sity to induce weight gain,28 as well as related metabolic
disturbances such as hypertriglyceridemia and hyper-
glycemia.29 Clozapine and olanzapine are the APDs most
frequently associated with weight gain, but all APDs,
even first-generation agents, seem to share these effects
as a group to varying degrees.30 For example, a large-
scale effectiveness trial in antipsychotic naïve patients
demonstrated clinically significant weight gain (≥7% of
baseline) in more than half of patients treated with
haloperidol.9 Obesity has serious implications for over-
all health and survival due to an increased risk for car-
diovascular and malignant disorders31; these risks may be
of particular importance in patients with SZ who often
have limited access to health care and decreased moti-
vation for weight reduction secondary to negative symp-
tomatology.13 Unfortunately, APD-induced weight gain
is very difficult to reverse, even with sophisticated
behavioral, dietary, and pharmacological interventions.32
Pharmacogenetic studies of 
antipsychotic-induced side effects
While the side effect profile of APDs is extremely bur-
densome in the aggregate, there is substantial interindi-
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Selected abbreviations and acronyms
5-HT serotonin
APD antipsychotic drug
EPS extrapyramidal symptom
FGA first-generation antipsychotic
SCZ schizophrenia
SGA second-generation antipsychotic
SNP single-nucleotide polymorphism
TD tardive dyskinesia
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vidual variation in the degree of any particular motor
or metabolic effect for a given patient.15 Despite exten-
sive research over the last two decades, data on clini-
cal or biological predictors of antipsychotic side effects
are limited. A few generalizations can be made, but
these are not sufficient for individual-level prognosis:
i) both the very old and the very young appear to be
more susceptible to most APD-induced adverse
events18,32; ii) patients experiencing extrapyramidal
symptoms are twice as likely to develop TD as patients
who do not exhibit EPS33; iii) olanzapine and clozap-
ine have greater liability for metabolic effects and
reduced incidence of motoric side effects compared
with most other agents7,9,26,30; iv) APD dose may be cor-
related with some of these effects, but the relationship
is weak and even low doses may carry substantial
risk.16,17,32 A priori identification of the patients who will
be at a higher risk for development of adverse side
effects could help clinicians avoid lengthy ineffective
APD trials and limit patients’ exposure to drug side
effects. 
Since the mid-1990s, the field of pharmacogenetics has
offered the potential for providing readily accessible,
immutable biomarkers—DNA sequence variants—that
might be predictive of an individual’s propensity for
both positive and adverse effects of drugs. However, to
date, the promise of personalized medicine has
remained unfulfilled. Because academic pharmacoge-
netic research is often limited to small and clinically het-
erogeneous samples, individual studies have been
unable to provide compelling results. Additionally, the
modest effect sizes which are common in complex
genetics present an obstacle in the quest for valid bio-
markers, which require high sensitivity and specificity
for individual clinical prediction. Moreover, examina-
tion of disparate polymorphisms across a wide variety
of candidate genes has created an impression of scat-
tered, unreplicated findings. Recently, however, a series
of findings across multiple laboratories have begun to
converge for a few genes related to serotonin and
dopamine, the most prominent neurotransmitters tar-
geted by APDs. In the subsequent sections, we will focus
on the converging evidence implicating the most well-
studied candidates for pharmacogenetic predictors of
antipsychotic-induced side effects. Particular emphasis
will be placed on single nucleotide polymorphisms
(SNPs) that have a sufficient evidence base to have per-
mitted published meta-analytic studies.
Tardive dyskinesia 
Tardive dyskinesia is the most extensively studied APD-
induced side effect in the pharmacogenetics literature to
date. These studies have typically been cross-sectional in
nature, with ascertainment based on retrospective iden-
tification of cases with varying treatment histories and
duration. The ability to study prevalence, rather than
incidence in the context of a clinical trial, has permitted
cumulative sample sizes in the thousands. It is important
to note, however, that this ascertainment strategy may
suffer from false negatives (patients with mild or
reversible TD) and false positives (patients with acute
motoric abnormalities that do not persist). Within this
literature, variants within the genes encoding dopamine
D2 and D3 receptors have been the primary focus, as
detailed below.
Dopamine D2 receptor blockade is a property of all
known antipsychotics, as demonstrated in vitro and in
vivo,34 yet a predictive relationship between variation in
the DRD2 gene (located on chromosome 11q22) and
APD-induced side effects has only been examined in a
handful of studies. Most pharmacogenetic studies to
date have examined the 3’ Taq1A polymorphism
(rs1800497), which more recently has been determined
to be a nonsynonymous coding SNP in a neighboring
ankyrin repeat gene (ANKK1 Glu713Lys).35 Possibly
due to linkage disequilibrium with another site (or sites)
within DRD2 (Figure 1), the minor (T) allele (also
called the A1 allele) at rs1800497 has been associated
with a 40% reduction in striatal D2 receptor density
based on both in vitro assays36 and in vivo imaging stud-
ies.37 This allele appears to be protective against TD. As
shown in Table I, two recent meta-analyses (based on
overlapping sets of studies) have persuasively demon-
strated increased rates of TD in A2 (C) allele carri-
ers.38,39 The odds ratio (OR) of 1.30 indicates a 30%
increase in risk for TD per allele, so that A2/A2 homozy-
gotes are nearly 80% more likely to develop TD as
A1/A1 homozygotes. Alternately, it can be said that
A1/A1 homozygotes have nearly half the rate of TD
compared with A2/A2 homozygotes. However, it is
important to note that the A2 allele is the common
allele at this SNP, and A1/A1 homozygotes represent
<10% of the Caucasian population (A1 allele frequen-
cies are much higher in non-white populations).
Like the D2 receptor, the dopamine D3 receptor is also
selectively expressed in the basal ganglia and is consid-
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ered to be a target of antipsychotic action45; conse-
quently, several pharmacogenetic studies in schizophre-
nia have examined the DRD3 gene, located on chromo-
some 3q13.3. To date, only one functional SNP (rs6280),
a missense variant resulting in a Ser to Gly substitution
at amino acid position 9, has been validated for DRD3.46
The Gly variant has about a 35% allele frequency in
non-African populations, and is actually the ancestral
allele. The Gly variant has been associated with 4-fold
greater dopamine binding affinity in vitro,47 resulting in
increased dopamine-mediated cAMP response and pro-
longed mitogen-associated protein kinase (MAPK) sig-
nal.48 Several studies49-52 (but not all)53,54 have indicated
that subjects carrying the Gly variant exhibit enhanced
symptom response to treatment with clozapine or
risperidone.
Concordant with the finding of heightened dopaminer-
gic sensitivity for the Gly allele, multiple studies have
demonstrated a significant increase in risk for tardive
dyskinesia (TD) amongst Gly carriers. Despite several
P h a r m a c o l o g i c a l  a s p e c t s
408
Figure 1. Location of the Taq1A polymorphism in the context of ANKK1 and DRD2 at chromosome 11q22. Red triangles represent areas of high
linkage equilibrium (D’). 
Gene SNP Allele No of studies N patients (with /without TD) OR Reference
DRD2 Taq1A (rs1800497) A2 (C) 6 1256 (507/749) 1.30 Zai et al 200738
DRD2 Taq1A (rs1800497) A2 (C) 4 764 (297/467) 1.30 Bakker et al 200839
DRD3 Ser9Gly (rs6280) Gly(C) 8 780 (317/463) 1.33 Lerer et al 200240
DRD3 Ser9Gly (rs6280) Gly(C) 11 1610 (695/915) 1.17 Bakker et al 200641
DRD3 Ser9Gly (rs6280) Gly(C) 13 2026(928/1098) 1.16 Tsai et al 200942
COMT Val158Met (rs4680) Val(G) 5 1089 (382/707) 1.19 Bakker et al 200839
HTR2A T102C (rs6313) C 6 635 (256/379) 1.64 Lerer et al 200543
CYP2D6 Loss of function alleles 8 569 (220/349) 1.43 Patsopoulos 200544
SOD2 Ala9Val (rs4880) Ala(T) 4 680 (134/546) 2.04 Bakker et al 200839
Table I. List of meta-analytic studies of single nucleotide polymorphisms (SNPs) from candidate genes for tardive dyskinesia (TD), with the associ-
ated allele and odds ratio (OR) of the association.
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negative studies in the literature, three recent meta-ana-
lytic studies40-42 indicate that this effect is detectable
across a large pooled sample including patients of mul-
tiple ethnicities (Table I). Intriguingly, a recent study
indicates a strong association of the Gly allele with
familial essential tremor, the most common inherited
movement disorder.48 However, the effect size for TD
risk is modest (OR=1.16 in the largest meta-analysis),
with diminishing effects in the more recent studies of
this SNP. This pattern of diminishing effect size estimates
over time, termed “the winner’s curse,” is common in
genetics studies and can ultimately result in rejection of
the initial finding as a false positive.55 It is notable that
this phenomenon was observed in the context of 13 pub-
lished studies of DRD3 Ser9Gly. Moreover, a very recent
study in the large CATIE cohort (n=207 cases with TD
vs 503 cases without TD), which was not included in any
meta-analysis, demonstrated essentially no effects of
either DRD3 Ser9Gly or DRD2 Taq1A.56 Therefore, cau-
tion is warranted in the interpretation of other relation-
ships reported across much smaller study sets.
A third dopamine-related gene that has been investigated
in multiple pharmacogenetic studies of TD is Catechol O-
methyltransferase (COMT). While subcortical dopamine
activity is primarily terminated by reuptake mediated by
the dopamine transporter, a secondary mechanism for
dopamine clearance is metabolic degradation via COMT.57
Additionally, COMT is the predominant mechanism of
dopamine clearance in frontal cortex. The COMT gene
contains a functional polymorphism that codes for a sub-
stitution of methionine (met) for valine (val) at codon 158.
The met allele, which has 36% to 48% allele frequency
across various ethnicities, results in a thermolabile protein
that has one fourth the enzymatic activity of the val car-
rying protein.58 (In other words, the val allele results in
reduced synaptic dopamine due to more rapid clearance).
Across five studies meta-analyzed by Bakker and col-
leagues,39 the val allele was associated with modestly
increased risk for TD (OR=1.19; Table I). It is unknown
whether the protective effect of the met allele is a direct
result of subcortical COMT activity, or is secondary to
alterations (eg, upregulation) in frontostriatal circuitry. 
In addition to dopamine antagonism, one of the common
features of many antipsychotics is near-saturation bind-
ing of serotonin (5-HT)2 receptors, which has been con-
firmed in vivo using PET imaging.59,60 While 5-HT binding
is often considered a hallmark of SGAs, it is important to
note that serotonergic binding properties are observed for
several FGAs as well.61,62 The 5-HT2A receptor gene
(HTR2A) has been examined in several pharmacogenetic
studies of TD; in particular, a promoter region SNP
(rs6313), which has been previously associated with
response to antipsychotics (as well as antidepressants), has
been extensively studied in relation to TD. While these
studies generally converge to indicate a modestly reduced
effect of the C allele on symptom response,63 this same
allele has been associated with significantly increased risk
for tardive dyskinesia.43 As shown in Table I, a recent
meta-analysis reported an odds ratio of about 1.6 for C
allele carriers across 6 studies; effects were strongest in
older patients (age >47 years), and were specifically asso-
ciated with limb-truncal (but not orofacial) TD.43 Notably,
this SNP is a perfect proxy for another promoter region
SNP, rs6311 (also referred to as -1438G/A), which appears
to affect transcription of the receptor.64 Specifically, the G
allele (a perfect proxy for the C allele at rs6313) tends to
be associated with reduced expression of the receptor. It
can therefore be inferred that reduced availability of the
5-HT2A receptor is a risk factor for tardive dyskinesia.
Notably, 5-HT2A receptors are strongly expressed in the
caudate and putamen,65 and recent evidence obtained
from dopamine-depleted rodents suggests a complex
interplay of subcortical dopamine and 5-HT in the regu-
lation of motor behavior.66
Two genes outside of the dopamine and 5-HT systems
have received sufficient attention in the pharmacoge-
netics of TD to merit meta-analysis (Table I). Many com-
monly prescribed APDs, including FGAs (haloperidol,
perphenazine, thioridazine), as well as SGAs (risperidone
and aripiprazole), are metabolized in the liver by
CYP2D6 (debrisoquine hydroxylase).67 The CYP2D6
gene is highly polymorphic, with over 70 known variants
(for a current classification, view the allele nomenclature
at http://www.imm.ki.se/CYPalleles/). Homozygosity for
null alleles gives rise to the “poor metabolizer” pheno-
type characterized by no enzyme activity while null allele
heterozygosity gives rise to an intermediate debrisoquine
hydroxylase metabolic phenotype characterized by
impaired—but not absent—enzyme activity.68 Reduced
CYP2D6 activity can be expected to result in higher
effect dose as measured by blood levels of active drug,
with potential for increased dose-dependent side effects.
Consistent with this pharmacokinetic prediction, a meta-
analysis of 8 studies demonstrated a moderate effect of
(any) loss of function alleles on risk for TD (OR=1.43),
while homozygotes (poor metabolizers) had 1.64-fold
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greater odds of suffering tardive dyskinesia.44 A recent
small study further confirms these results.69 A similar
effect has been studied for SOD2, the gene encoding
manganese superoxide dismutase, a mitochondrial
enzyme involved in oxidative metabolism. A functional
SNP (Ala9Val), affecting efficiency of MnSOD transport,
has been associated with TD risk; counterintuitively, the
less efficient val allele is protective.39 Homozygotes for
the Ala (T) allele are about twice as likely to develop TD
compared with val carriers (Table I).
Extrapyramidal symptoms
Compared with the relative plethora of studies on tar-
dive dyskinesia, pharmacogenetic studies of EPS are
lacking. However, a few studies have reported allelic
effects on acute side effects that are consistent with
those reported for TD. For example, Eichammer et al70
reported increased incidence of akathisia amongst
DRD3 Gly carriers; however, two studies of extrapyra-
midal symptoms have been negative.71,72 One additional
study identified another DRD3 SNP (rs167771) which
was associated with EPS in a study of 270 risperidone-
treated patients,73 but this result awaits replication. One
small study has demonstrated an effect on EPS risk for
the C allele of rs6313 in HTR2A that parallels its effect
on TD.71 Although not previously examined in TD stud-
ies, a SNP in RGS2 (rs4606) has been associated with
extrapyramidal symptoms in two studies.74,75 Although
a third study was negative, this regulator of intracellular
dopamine signaling merits additional research.76
Prolactin elevation 
While prolactin elevation has also not been widely studied
across most of the genes listed in Table I, there have been
seven published studies examining DRD2 Taq1A.77-83 As
displayed in Table II, these studies have yielded mixed
results across a variety of APDs. Notably, the three pos-
itive studies all reported that the A1 allele was associ-
ated with increased risk for hyperprolactinemia, and a
fourth study demonstrated the same effect in females
only. This is the opposite allele that was associated with
TD, which may reflect the fact that prolactin response is
mediated via the tuberoinfundibular pathway (hypo-
thalamus and pituitary).84
Weight gain
It has been suggested that increased 5-HT binding pro-
files may account for the increased liability to weight
gain observed in the second-generation antipsychotics.85
A survey of the literature of the regulation of feeding
behavior points to a major role for 5-HT, with both ani-
mal and human investigations showing, in general, that
increasing 5-HT results in decreased feeding, with the
reverse also true.86 Pharmacologic agonists of 5-HT2C
lead to decreased feeding in animals87 it is logical to spec-
ulate that 5-HT2C antagonists, including most second-
generation antipsychotics, might lead to increased food
intake. 
Perhaps the best evidence for a specific role of sero-
tonin-related genetic factors in antipsychotic–induced
weight gain is provided by studies of the promoter
region polymorphism, -759 T/C (rs3813929), in the
HTR2C gene (on the X chromosome). Reynolds and
colleagues88 studied 123 adult drug-naïve Han Chinese
SCZ patients treated primarily with risperidone or
chlorpromazine. Subjects with the T allele at this locus
gained significantly less weight than subjects with the
C allele in short-term (6- and 10-week) treatment; none
of the 27 subjects with the T allele met criteria for
severe (>7%) weight gain after 6 weeks, as compared
with 28% of the 96 subjects without the T allele. Two
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Reference Drug N patients Allele Significant?
Calarge et al 200977 Risperidone 107 A1 (T) Yes
Kwon et al 200878 Aripiprazole 90 No
Yasui-Furukori et al 200879 Risperidone 174 No
Aklillu et al 200780 Perphenazine 22 A1 (T) Yes
Anderson et al 200781 Risperidone 101 No
Young et al 200482 Various 144 A1 (T) Yes
Mihara et al 200083 Nemonapride 25 A1 (T) Females only
Table II. List of studies of the Taq1A polymorphism (rs1800497) from the ANKK1/DRD2 locus in association with antipsychotic drug-related prolactin
levels. 
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studies89,90 also reported an association of the T allele to
reduced weight gain in a small samples of clozapine-
treated patients, although this effect was only signifi-
cant in males in one of these. Ellingrod and colleagues91
reported that the T allele is associated with less weight
gain in Caucasian patients treated with olanzapine, and
Templeman et al92 reported the same for weight gain
associated with a mixed group of antipsychotics in a
small Spanish first-episode cohort. Recently, Lane et
al93 extended these findings to include risperidone (in
123 Han Chinese inpatients), and Ryu et al94 demon-
strated the same effect for the T allele in 84 Korean
inpatients treated on various antipsychotic monother-
apies. A few studies, however, have not detected sig-
nificant associations between–759 T/C and clozapine-
induced weight gain95-97 which may reflect the winner’s
curse, but it should be noted that these studies were
restricted to chronic patients with extensive prior treat-
ment. A meta-analysis of 8 studies demonstrated a
greater than 2-fold increase in risk for clinically signif-
icant (7% to 10% or greater) weight gain from baseline
associated with the C allele at this SNP.98
Analogous to the aforementioned role of RGS2 in EPS,
one gene involved in intracellular signaling has been
repeatedly with respect to APD-induced weight gain.
GNB3 encodes a subunit of a heterotrimeric guanine
nucleotide-binding protein (G protein), which integrates
signals between receptors and effector proteins.99 An SNP
polymorphism (C825T) in this gene has been associated
with essential hypertension and obesity; this SNP is also
associated with relative prevalence of a high-activity splice
variant of GNB3.100 According to a recent meta-analysis,
five studies have examined effects of this SNP on APD-
induced weight gain; the T allele was marginally associated
with increased weight gain.101 However, this effect was con-
sistent with its effect on BMI and other metabolic vari-
ables in the general population, so the mechanism in the
context of APD treatment remains unclear.
Conclusions and future directions
As summarized in the preceding sections, pharmacoge-
netic studies have begun to converge on a few genetic
variants that are replicably associated with the common
APD-induced motor and metabolic side effects.
However, three factors limit the ability of the field to
deliver on the promise of personalized medicine at this
time, and point to critical issues for the next generation
of pharmacogenetic studies. First, a treating psychiatrist
would be unable to use this information to offer a vali-
dated alternative, due to the lack of pharmacogenetic
head-to-head comparisons of treatment with differing
mechanisms. Second, even fairly consistent single-gene
results, such as those observed for DRD3 and TD, fail to
provide large enough effect sizes to make confident clin-
ical decisions. In order to provide a clinically useful test,
with sufficient sensitivity and specificity to make confi-
dent individual predictions, a combination of SNPs
across different loci will be required. Third, the eco-
nomics of conducting pharmacogenetic tests on a large
clinical scale will need to be justified to payers, includ-
ing the insurance companies and the federal govern-
ment. In order to do so, pharmacogenetics researchers
will need to quantify the beneficial economic impact of
tailored prescription practices.102
Of course, any personalized clinical decision-making
process will optimally include validated predictors of
symptom response as well as adverse effects. The vari-
ability in symptom response ranges from patients who
experience rapid symptom remission to a subset of
patients often described as “treatment-refractory.”15
Even when fully adherent with medication, as many as
40% of patients fail to demonstrate adequate response
on the hallmark positive symptoms of hallucinations and
delusions.103 Unfortunately, the literature on pharmaco-
genetics of response is more difficult to summarize than
for side effects; due to wide differences in trial method-
ology and definition of dependent measures, no meta-
analytic studies have been published in the last decade.
(One early meta-analysis of clozapine response identi-
fied an effect of HTR2C T102C, as described earlier.61) 
Finally, it should be noted that candidate gene
approaches to pharmacogenetics run a dual risk of either
an overly restrictive search space, or a potentially over-
whelming number of candidates. While initial pharma-
cogenetic studies have primarily focused on dopamine
and serotonin genes, the slow pace of individual candi-
date gene investigations has resulted in many additional
scattered and isolated studies across investigators. On
the other hand, the advent of genome-wide association
studies (GWAS) provides a hypothesis-free method of
generating candidate genes for novel complex pheno-
types. Unfortunately, this method carries its own statis-
tical concerns, most notably limitations in statistical
power (due to correction for multiple comparisons) in
necessarily limited clinical trial samples. 
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One way to enhance sample size and statistical power in
the short run is to utilize a strategy that permits cross-
sectionally defined phenotypes. In a proof of principle
study, we have recently utilized the Affymetrix 500K
microarray in a sample of our retrospectively-charac-
terized patients with schizophrenia. (Initial case-control
analyses were SCZ diagnosis were published for data
obtained from the first 322 Caucasian subjects.104 All sub-
jects self-identified as Caucasian non-Hispanic; testing
of 210 ancestry informative markers (AIMs) revealed no
evidence of population stratification). In this same sam-
ple, we have performed a preliminary analysis examin-
ing treatment responsiveness, using clozapine assign-
ment as a proxy for poor response. Detailed chart
reviews permitted classification of 97% of the sample.
Approximately 35% of patients were assigned clozapine
due to treatment nonresponsiveness, and groups were
matched on key demographic variables including age,
duration of illness, sex, and family history. Despite the
small sample for this interim analysis, one SNP nearly
obtained genome-wide significance (P=4.3*10-7). This
SNP neighbors CNTN4 (contactin-4), a neuronal mem-
brane protein that functions as a cell adhesion molecule,
and is thought to be critical for the formation of axon
connections in the developing nervous system105; CNTN4
has also recently been implicated in autism.106
In the longer term, much larger prospective studies will
be required to achieve to: i) obtain clear estimates for
risk parameters; and ii) determine whether application
of a pharmacogenetic risk profile is clinically and eco-
nomically advantageous. Optimally, such studies may
focus on the first episode of SCZ, which typically occurs
in late adolescence or early adulthood107 and may be the
most critical period in the life of an individual with SCZ.
Successful treatment of the initial psychotic episode is
crucial for minimizing the cascading effects of social and
vocational deterioration.108,109 From a methodological per-
spective, studies of first-episode patients minimize poten-
tial confounds associated with chronic illness and vari-
able history of prior treatment; first-episode cohorts are
also marked by reduced duration of psychotic symptoms,
substance abuse, and functional/social disabilities.110 By
contrast, studies of chronic SCZ may systematically over-
represent patients who are not fully responsive to treat-
ment or are nonadherent to treatment (or both), and
underestimate APD response. First-episode samples may
be less biased on these factors and therefore may be
more informative about the spectrum of outcomes with
APD treatments. While large-scale prospective trials
involving first-episode cohorts are logistically challeng-
ing, such studies would hold substantial promise for
advancing the field in the next decade. ❏
P h a r m a c o l o g i c a l  a s p e c t s
412
REFERENCES
1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the preva-
lence of schizophrenia. PLoS Med. 2005;2:e141.
2. Goff DC, Cather C, Evins AE, Henderson DC, et al. Medical morbidity and mor-
tality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194. 
3. Palmer BW, Heaton RK, Gladsjo JA, et al. Heterogeneity in functional sta-
tus among older outpatients with schizophrenia: employment history, living
situation, and driving. Schizophr Res. 2002;55:205-215. 
4. World Health Organization. World Health Report 2001: new understand-
ing, new hope. Geneva: World Health Organization, 2001.
5. Murray CJL, Lopez AD. The Global Burden of Disease: a Comprehensive
Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in
1990 and projected to 2020. Cambridge, MA: Harvard University Press; 1996.
6. World Health Organization. International Classification of Functioning,
Disability and Health- ICF. Geneva, Switzerland: World Health Organization, 2001.
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic
drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
8. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the
effect on Quality of Life of second- vs first-generation antipsychotic drugs
in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in
Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
9. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group.
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schiz-
ophreniform disorder: an open randomised clinical trial. Lancet.
2008;371:1085-1097.
10. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr.
2007;12(10 suppl 17):21-26.
11. Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse fol-
lowing response from a first episode of schizophrenia or schizoaffective dis-
order. Arch Gen Psychiatry. 1999;56:241-247.
12. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull.
1995;21:419-429.
13. Correll CU. Balancing efficacy and safety in treatment with antipsy-
chotics. CNS Spectr. 2007;12(10 suppl 17):12-20.
14. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA,
Lieberman JA. Predictors of medication discontinuation by patients with
first-episode schizophrenia and schizoaffective disorder. Schizophr Res.
2002;57:209-219.
15. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association
Pharmacopsychiatry Section statement on comparative effectiveness of antipsy-
chotics in the treatment of schizophrenia. Schizophr Res. 2008;100:20-38.
16. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tar-
dive dyskinesia. Schizophr Res. 1991;4:109-120.
17. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, inci-
dence, and risk factors. J Clin Psychopharmacol. 1988;8(4 suppl):52S-56S.
18. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull. 1993;19:303-315.
19. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive
dyskinesia and the 3-year course of schizophrenia: results from a large,
prospective, naturalistic study. J Clin Psychiatry. 2008;69:1580-1588.
20. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric
Association; Steering Committee on Practice Guidelines. Practice guideline for
the treatment of patients with schizophrenia, second edition. Am J Psychiatry.
2004;161(2 suppl):1-56.
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 412
Pharmacogenetics of antipsychotic side effects - Lencz and Malhotra Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
413
Farmacogenética de los efectos secundarios
inducidos por los antipsicóticos
Actualmente los fármacos antipsicóticos (FAP) dis-
ponibles conllevan, con una alta y significativa aun-
que  variable probabilidad, efectos secundarios neu-
rológicos y metabólicos. Las aproximaciones
farmacogenéticas ofrecen la posibilidad de identi-
ficar biomarcadores específicos para el paciente
para predecir el riesgo de estos efectos secundarios.
A la fecha, múltiples estudios han convergido en
dar sustento a unos pocos polimorfismos de nucle-
ótidos simples (SNPs) de un pequeño grupo de
genes. El foco primario ha estado en los SNPs de los
genes de los receptores de dopamina y serotonina;
estudios de meta-análisis han demostrado una evi-
dencia convincente para el efecto de los genes de
los receptores de dopamina D2 y D3 (RDD2 y RDD3)
en el riesgo de disquinesia tardía (DT) y para un
efecto de variación del gen del receptor 5HT2C
(R5HT2C) en la probabilidad de aumento de peso
inducido por los FAP. Sin embargo, la magnitud del
efecto parece ser modesta y las consideraciones far-
macoeconómicas no se han estudiado suficiente-
mente, por lo que la aplicación clínica en este
momento es limitada. En este artículo se revisan los
efectos de estos y otros genes en los riesgos de DT,
efectos secundarios extrapiramidales, hiperprolac-
tinemia y aumento de peso.
Pharmacogénétique des effets secondaires
induits par les antipsychotiques 
Les médicaments antipsychotiques disponibles
actuellement sont significativement responsables,
bien que de façon très variable, d’effets secondaires
métaboliques et neurologiques. La pharmacogéné-
tique permet d’identifier des biomarqueurs spéci-
fiques des patients permettant de  prédire le risque
de survenue de ces effets indésirables. À ce jour, un
petit nombre de polymorphismes de nucléotide
simple (single nucleotide polymorphism ou SNP)
issus d'une poignée de gènes, a été identifié au
cours de  plusieurs études. Les SNP des gènes du
récepteur à la dopamine et à la sérotonine ont été
les premiers à être étudiés : des métaanalyses
convaincantes ont montré une implication des
gènes DRD2 et DRD3 (récepteur à la dopamine D2
et D3) dans le risque de dyskinésies tardives (DT) et
celle d'une  variation du gène du récepteur HT2C
(5-HTR2C)  dans la prise de poids due aux antipsy-
chotiques. L’importance de ces effets semble néan-
moins modeste et, les considérations pharmaco-
économiques étant insuffisamment étudiées,  les
applications cliniques restent aujourd’hui limitées.
Cet article analyse les effets de ces gènes ainsi que
d'autres  sur le risque de DT, d’effets extrapyrami-
daux, d’hyperprolactinémie et de prise de poids.
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ajor Depressive Disorder (MDD) is common,
costly,1-3 and notably heterogeneous. Unfortunately, the
accurate prediction and subsequent prevention of MDD
episodes (MDEs) has been challenging. There is evi-
dence that MDEs are variously associated with elevated
psychosocial stress, the postpartum period, hypothy-
roidism, circadian changes, cerebrovascular disease,
administration of inflammatory cytokines such as inter-
feron-α (IFN−α), etc. Therefore, one approach for pre-
venting a MDE could be to avoid stressful circum-
stances, pregnancy, cerebrovascular disease, and/or
IFN−α therapy. However, this is often impractical.
Thankfully, most people who are exposed to these vari-
ous“triggers” do not develop MDD. 
Identifying modifiable markers of risk in specifically
vulnerable people, and then mitigating these before
MDD occurs, could be a better approach for prevent-
ing MDD. However, identifying causal risk factors that
pre-exist in nondepressed people requires prospective
studies, and the incidence of an MDE over 1 year is less
than 2%.4-6 The necessarily large epidemiologic studies
have successfully identified predictive risk markers
such as gender, age, cohort, family history, marital sta-
tus, socioeconomic status, and stressful life events6,7—
but each of these is difficult or impossible to mitigate.
Another strategy is needed for prospectively assessing
nondepressed people for modifiable risk factors, and a
related strategy is needed for examining whether
specifically alleviating these vulnerabilities prevents
MDE.
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Major Depressive Disorder (MDD) during interferon-α
(IFN−α) treatment can occur within a few months of ther-
apy, and shares many homologies with other forms of
MDD. Most patients are resilient to the side effect of inter-
feron-induced depression (IFN-MDD), but 15% to 40% are
vulnerable. Several studies have employed antidepressants
to prevent the incidence of an IFN-MDD episode, and the
results suggest that prophylactic antidepressants may be
specifically useful in those with pre-existing subthreshold
depressive symptoms and/or a history of prior MDD
episodes. Several other potential markers of vulnerability
for IFN-MDD have been implicated in assessments of non-
depressed patients before they start IFN−α. These include
poor sleep quality, premorbid elevations in inflammatory
cytokines, genetic polymorphisms in the serotonin system,
personality, and social support. The interplay of these fac-
tors strongly predicts who is at risk for IFN-MDD, and indi-
cates several potentially modifiable targets for the per-
sonalized prevention of IFN-MDD. 
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:417-425.
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MDD during IFN-α therapy
One approach for delineating modifiable risk factors is to
examine homogeneous groups of people who are defini-
tively known to soon be exposed to a specific MDD-evok-
ing situation. Towards this end, patients receiving IFN−α
may be ideal candidates for examining MDD vulnerabil-
ity.8-12 MDD during IFN−α treatment (IFN-MDD) typi-
cally develops within the first 2 or 3 months of adminis-
tration,13-17 and occurs in about 15% to 40% of patients.18
Thus, prospectively assessing IFN-MDD onset is feasi-
ble—and consequently it may be possible to determine
predictive modifiable vulnerabilities in the 15% to 40%
who subsequently develop IFN-MDD. 
Of course, it is conceivable that IFN-MDD is unique, and
that other forms of MDD are completely distinct from it.
However, several lines of evidence indicate that IFN-
MDD may successfully inform us about MDD in general.
First, a variety of studies have found a robust relationship
between IFN−α and MDE, including those demonstrat-
ing a dose-response relationship,19,20 studies with control
groups,16,19-21 and prospective documentations of worsen-
ing depression during IFN−α treatment with a return to
baseline mood after discontinuation.23-25 Thus, IFN-MDD
is a replicable finding in prospective studies. Second, IFN-
MDD has phenomenological resemblance to MDD diag-
nosed in other situations.21-24 That is, IFN-MDD is not sim-
ply fatigue and malaise but—similarly to
MDD—involves anhedonia, depressed mood, irritability,
anxiety, social withdrawal, poor concentration, altered
sleep, personality changes, and suicidal ideation (Table I). 
Third, MDD and IFN-MDD may share similar patho-
physiologic mechanisms, as indicated by various inde-
pendent lines of investigation:
• Many inflammatory cytokines are elevated during
MDD.51-53
• Psychosocial stress can increase the levels of inflam-
matory cytokines.54,55
• IFN−α and other cytokines can affect central
monoaminergic systems plausibly involved in MDD.56-63
• Peripheral cytokines and IFN−α have access to the
CNS through a variety of routes in addition to being
synthesized in the brain.64-66
• Endogenous IFN−α mRNA can be induced in the cor-
tex, hippocampus, and hypothalamus, with correlated
changes in behavior in animal models of depression.64,67
• Systemic administration of IFN−α and other cytokines
can affect amotivation and anhedonia behaviors in
rodent models of depression.68-75
• Once IFN-MDD is diagnosed, it responds to treat-
ments that are effective for idiopathic MDD, ranging
from selective serotonin reuptake inhibitors (SSRIs)
and tricyclic antidepressants to electroconvulsive ther-
apy,15,76-85 with about 79% to 85% of patients respond-
ing to antidepressants.86,87
• IFN−α administration can influence frontal lobe and
anterior cingulate function,88,89 dopaminergic activity,60
and serotonergic function,90-93—all of which may con-
tribute to the development of depression in a manner
homologous to other types of MDD. 
Of further public health significance, the use of IFN−α is
not rare. Almost 2% of the U.S. currently has chronic
hepatitis C (HCV).94 IFN−α is the only FDA-approved
treatment for HCV,95,96 whereas about 170 million people
worldwide have been infected with HCV.97 Supporting
IFN−α’s widespread use, untreated chronic HCV can
lead to cirrhosis, hepatocellular cancer, and liver failure,
Selected abbreviations and acronyms
IFN- interferon-alpha
IL interleukin
MDD major depressive disorder
SSRI selective serotinin reuptake inhibitor
Signs and symptoms MDD IFN-MDD
Anhedonia Yes Yes24-29
Depressed mood Yes Yes26-30
Sleep problems Yes Yes26,27,29-32
Amotivation Yes Yes27
Decreased appetite Yes Yes27,28,30
Concentration changes Yes Yes27-29,33-36
Tearfulness Yes Yes27
Social withdrawal Yes Yes27
Guilt Yes Yes26
Interpersonal sensitivity Yes Yes37
Suicidal ideation Yes Yes27,29,38
Associated symptoms
Irritability Yes Yes26,27,29,30,39
Increased neuroticism Yes40,41 Not known
Care-seeking behaviors Yes42 Seen in illness behavior43
Dependency/acting out 
regression/somatization Yes44,45 Seen in illness behavior46-50
Table I. Comparison of Major Depressive Disorder  (MDD) and inter-
feron-α depressive disorder (IFN-MDD) during interferon-α treat-
ment.
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resulting in about 10 000 deaths per year in the US,98 a
rate which exceeds that from acquired immunodeficiency
syndrome.99 Unfortunately, IFN-MDD can potentially
result in suicide,38 dose reduction with risk for viral
relapse,16 discontinuation of treatment,100,101 and lower
quality of life.102,103 Therefore, the two rationales for pre-
venting IFN-MDD are that (i) this is a common and dis-
abling syndrome; and (ii) it may be and ideal strategy for
informing us about ways to prevent MDD in general.
Prevention studies of IFN-MDD
A few prophylactic trials using selective serotonin reup-
take inhibitors (SSRIs) have transpired. These preven-
tion studies initiated SSRIs in patients who were not cur-
rently experiencing any MDE prior to beginning the
IFN−α therapy (Table II).80,83,85,104-107 The first randomized
placebo-controlled trial (RCT) was done in patients with
metastatic melanoma, using very high doses of intra-
venous IFN−α. This initial study found strong evidence
for prevention of IFN-MDD, with only 2/18 paroxetine-
treated patients (11%) developing IFN-MDD, as com-
pared with 45% of the placebo-treated group.80 Similarly,
in three open-label trials of prophylactic SSRIs given to
nondepressed HCV patients, only 3/32 patients (9%)
developed IFN-MDD, despite all 32 patients having a
prior history of affective disorder. These open-label stud-
ies are thus consistent with this RCT study, supporting
the conclusion that preventative treatment with SSRIs
may be useful. 
However, two small RCT studies have now been com-
pleted in patients with HCV (Table II). Neither study
found IFN-MDD prevention.85,106 Prophylactic SSRIs may
therefore not be universally effective. Despite these two
negative findings, one of these studies did report that
24/29 patients in the placebo group developed elevated
depression symptoms compared with 10/23 in the parox-
etine group.106 Additionally, further exploratory analyses
indicated that prevention may have been most success-
ful for those subjects who already had high pretreatment
baseline levels of depressive symptoms.106 This would be
an example of “indicated prevention” whereby treating
“subthreshold” depression symptoms may prevent sub-
sequent worsening to full categorical MDD.108-111 It has
been well-replicated that higher levels of pretreatment
depression symptoms are associated with the develop-
ment of IFN-MDD,18,112-115 and these subthreshold symp-
toms may be an appropriate target for using preventive
SSRIs. Another open possibility is that prophylactic
SSRIs specifically prevented IFN-MDD in those with
past histories of MDD in remission. This type of preven-
tion would be consistent with the use of antidepressants
to prevent recurrence of remitted MDD.116-119
To explore this latter possibility, we prospectively fol-
lowed 31 patients who were not depressed at the onset
of IFN−α therapy (as determined using a Structured
Clinical Interview of DSM-IV Axis I diagnoses). All of
these patients had no MDEs within 6 months prior to
starting IFN−α, but they did have a history of past
MDD. Ten of these patients were stably taking SSRIs.
Only 20% (2/10) of the patients on SSRIs developed
IFN-MDD, while 47.6% (10/21) not on antidepressants
did. These results are numerically similar to the RCTs
reviewed above. This very limited analysis suggests a
SSRI Trial type (N) Baseline characteristics Diagnosis Comments
Paroxetine80 RCT 18 vs 20 Melanoma patients; average HAM-D>5 DSM-IV Prevented IFN-MDD. 2/18 vs 9/20
Paroxetine85 RCT 14 vs 19 Average HAM-D<3 DSM-IV Did not prevent IFN-MDD. 5/14 vs 6/19
Paroxetine106 RCT 23 vs 29 Median MADRS = 3 DSM-IV or Did not prevent IFN-MDD overall 3/23 vs 6/29
MADRS>15 Benefit for patients with baseline MADRS >3
Citalopram104 Open label 10 vs 0 MDD history in remission HAM-D =17 1/10 had recurrence of IFN-MDD
Paroxetine or Open label 8 vs 0 History of previous IFN-MDD HADS>8 0/8 had recurrence of IFN-MDD
Citalopram120 (Comparison with prior IFN−α trial) Small average increase in HADS scores
Citalopram107 Open label 14 vs 11 Average MADRS >10; DSM-IV 2/14 developed IFN-MDD vs 7/11
History of affective disorder in the comparison group
Various Open label 10 vs 21 History of any DSM-IV affective disorder DSM-IV 2/10 developed IFN-MDD vs 10/21
in the comparison group
Table II. Studies examining prevention of IFN-MDD using antidepressants. Three randomized placebo-controlled trials (RCT), and four open-label stud-
ies examining the prevention of major depressive disorder (MDD), diagnosed using criteria from the Diagnostic and Statistical Manual  of
Mental Disorders-IV (DMS-IV), the Hamilton Depression rating scale (HAM-D), or the Montgomery-Asberg Depression Rating Scale (MADRS). 
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more targeted use of SSRIs to prevent recurrence, lim-
iting prophylactic SSRI to those patients who are known
to have past MDD histories. 
However, all of these studies have been very limited in
size, and therefore power. Assessing all of the six pub-
lished prevention studies and our open-label data com-
bined—in a very exploratory type of meta-analysis—
15/97 (15%) patients receiving SSRIs prior to starting
IFN−α developed IFN-MDD, compared with 36/99
(36%). This is a significant difference, χ2=8.2; P<0.001.
However, limiting the meta-analysis to the three RCTs,
10/55 (18%) subjects randomized to pretreatment
paroxetine developed IFN-MDD while 21/68 (31%) ran-
domized to placebo did. The trend is numerically similar
to the larger meta-analysis, but does not have the power
to be significant in a chi-square test (χ2=1.98). 
At this point, only tentative conclusions are possible: (i)
Prophylactic SSRIs may plausibly cut in half the inci-
dence of IFN-MDD. To conclusively determine this,
however, will require a larger-size trial than those per-
formed to date; (ii) SSRIs may specifically benefit sub-
jects with either pre-existing depressive symptoms (ie,
subthreshold depression) and/or a history of prior MDD.
This is consistent either with studies of “indicated pre-
vention” in which patients with subthreshold depression
are prevented from worsening to full categorical MDD
by about 30%,108-110 or with studies preventing recurrence
of MDD.116-119 A more targeted prevention RCT would
be valuable to examine these two possibilities; (iii) Even
if SSRIs are found to be effective prophylactics for some
people, about 15% to 20% of patients still developed
IFN-MDD even when prescribed SSRIs, therefore anti-
depressants may not be universally effective. Other tar-
gets and approaches for prevention are needed; (iv)
Most importantly, about half of the patients with a his-
tory of MDD remain resilient even during IFN−α treat-
ment. Identifying the source of this resilience for poten-
tial replication in other patients would be beneficial. 
Modifiable risk factors for IFN-MDD
The goal for this work is preventative treatments that
can be targeted towards specifically mitigating those
mechanisms underlying vulnerability. Poor sleep quality
prior to IFN−α treatment may be one such risk fac-
tor.121,122 Patients with scores greater than 10 on the
Pittsburgh Sleep Quality Index, a validated self-report
assessment of sleep quality,123 were ten times more like
to subsequently develop IFN-MDD than patients sleep-
ing better than this.122 This large effect size was evident
even when controlling for other depression symptoms.
It is also consistent with large epidemiological studies
wherein insomnia predicted the subsequent develop-
ment of MDD over follow-up intervals of 1 to 35
years.124-127 As many treatments for sleep exist, this may
be a potentially modifiable risk factor for preventing
IFN-MDD. This has previously been suggested for
MDD,128 but may now be readily testable in patients
about to be treated with IFN−α.
There is also evidence that increased age may be another
risk factor for IFN-MDD,129 although this is certainly not
a consistent finding.130,131 Despite the fact that age itself is
not modifiable, this could indicate the presence of age-
related modifiable risk factors. Related to this, elevated
levels of inflammatory cytokines, such as interleukin-6
(IL-6), prior to IFN−α therapy have been associated with
subsequent IFN-MDD.132,133 Additionally, a polymorphism
in IL-6 that has been associated with increased IL-6 lev-
els is predictive of IFN-MDD.134 In the subset of people
with increased IL-6 during IFN−α administration, the IL-
6 levels temporally predicted next month’s depression
symptoms.133 This is consistent with cross-sectional stud-
ies in which elevated IL-6 levels are associated with
MDD.54,132,135-140 Thus, increased IL-6 may be another plau-
sibly modifiable target for preventive intervention in
depressed individuals. Interestingly, IL-6 increases with
age but can be modified by diet141 and/or exercise.142,143
Potential premorbid risk factors for IFN-MDD that may
be modifiable through psychosocial interventions could
include social isolation144 and neuroticism.115,145 However,
when controlling for other premorbid risk factors, the effect
size for these is fairly small.146 Another risk factor may be a
hyperactive stress response in the hypothalamic-pituitary-
adrenal (HPA) axis.147 Given the common association
between abnormalities in the HPA axis and MDD,148-150 this
may also be a potentially useful predictive marker.
Interestingly, HPA axis responsiveness can be therapeuti-
cally modifiable by antidepressants.151-154 It is therefore plau-
sible that patients with overactive HPA responses may be
the subjects who benefit most from antidepressant pro-
phylaxis. Consistent with this, stress-reactivity did correlate
with depressive symptoms prior to IFN−α therapy147—and
thus elevated stress-reactivity may be a potential predictor
of the need for “indicated” SSRI prevention.
Genetic polymorphisms within the serotonergic system
have also been associated with vulnerability to IFN-
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MDD.134,146,155 Two studies have replicated the finding that
a short allele in the serotonin transporter robustly
increases risk for IFN-MDD.134,146 Vulnerability to tryp-
tophan depletion has also been associated with poly-
morphisms in the 5-HT reuptake transporter.59 Because
IFN-MDD has been associated with lowered tryptophan
levels during treatment,57,91,93,156 this suggests that differ-
ences in serotonergic tone may leave some people vul-
nerable to IFN-MDD. It is also plausible that these are
the same subjects who may benefit from SSRI prophy-
laxis, a possibility that requires testing. 
Interestingly, gender has not been a consistent predictor
of IFN-MDD,37,157,158 which suggests that IFN-MDD may
be partially distinct from some forms of MDD that are
unique to females. Also, as long as patients remain absti-
nent, a past history of drug and alcohol abuse is not pre-
dictive of increased risk.15,37,131 This suggests that risks for
drug and alcohol abuse are distinct from risk for IFN-
MDD. One critical implication is that a past history of
drug use, in remission, is not a contraindication to pre-
scribing IFN−α. Nonetheless, several leads are now sug-
gested by these various predictive risk factors, several of
which may be amenable to modification. The IFN-MDD
paradigm has now been used in several studies to exam-
ine whether SSRIs can prevent depression. It may now
be useful to determine whether other preventive treat-
ments are effective.
Other populations at selective risk for MDD
In summary, encouraging results indicate that: (i) specific
patients may be at elevated risk for IFN-MDD; (ii) this
vulnerability may be identifiable prior to IFN−α treat-
ment; (iii) some sources of this vulnerability (such as
poor sleep) may be modifiable; and (iv) therefore per-
sonalized prevention is testable and could become a real-
ity. Because of the high incidence of IFN-MDD in the
first few months of treatment, and the ability to recruit
nondepressed patients prior to IFN−α treatment, exam-
ining these possibilities appears to be practical and fea-
sible in this population. Several studies with prophylac-
tic SSRIs have already occurred. Furthermore, because
of the homologies between IFN-MDD and MDD in gen-
eral, any lessons learned from IFN-MDD may be trans-
latable to other types of MDD. As examples, MDD
occurs at higher rates in populations with multiple
chronic illnesses,159 during bereavement,160 in caregivers
of demented patients,161 in stroke survivors,162-164 in post-
partum mothers,110,165,166 and there is preliminary evidence
that MDD incidence could potentially be reduced in
these settings.161,167 Similar to IFN-MDD, most people in
these settings are resilient to developing MDD, with only
a subset who are vulnerable.168
Conclusion
It remains an intriguing possibility that modifiable risk
factors identified for IFN-MDD may also be modifiable
risk factors in these other settings. Thus, targeting the
appropriate prevention to the appropriate patient may
be possible, and this may soon lead to the personalized
prevention of MDD. ❏
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Depresión mayor durante el tratamiento 
con -interferón: vulnerabilidad y 
prevención
El trastorno depresivo mayor (TDM) durante el tra-
tamiento con -interferón (IFN) puede presentarse
a los pocos meses de terapia y comparte muchas
características con otras formas de TDM. La mayo-
ría de los pacientes son resilientes al efecto lateral
de la depresión inducida por interferón (TDM-IFN),
pero el 15% a 40% es vulnerable. Varios estudios
han utilizado antidepresivos para prevenir la inci-
dencia de un episodio de TDM-INF y los resultados
sugieren que los antidepresivos profilácticos pue-
den ser empleados específicamente en quienes tie-
nen síntomas subumbrales pre-existentes y/o una
historia de episodios previos de TDM. Se han pro-
puesto varios potenciales marcadores de vulnera-
bilidad para el TDM-INF en la evaluación de pacien-
tes no depresivos antes de iniciar el αINF. Estos
incluyen una mala calidad del sueño, aumento pre-
mórbido de las citoquinas inflamatorias, polimor-
fismo genético en el sistema serotoninérgico, per-
sonalidad y apoyo social. El interjuego de estos
factores predice en forma importante quién está en
riesgo de un TDM-INF y señala varios blancos poten-
cialmente modificables para una prevención perso-
nalizada del TDM-INF.  
Dépression majeure au cours d’un 
traitement par interféron- : 
vulnérabilité et prévention
Un épisode dépressif majeur (EDM) peut survenir
au cours des premiers mois d’un traitement par
interféron- (IFN-), montrant  des similitudes avec
les autres formes de dépression caractérisées. La
plupart des patients présentent une résilience  à
cette dépression induite par l'interféron mais 15 à
40 % y sont vulnérables. Plusieurs études ayant uti-
lisé des antidépresseurs pour prévenir la survenue
d’un EDM lié à l’IFN (IFN-EDM) ont montré qu’une
prophylaxie antidépressive peut être utilisée spé-
cifiquement chez les patients ayant une sympto-
matologie dépressive infraclinique et/ou des anté-
cédents d' EDM. Des patients non dépressifs ont été
testés avec des marqueurs potentiels de susceptibi-
lité aux IFN-EDM avant de débuter un traitement
par IFN-α. Ils incluent un sommeil de mauvaise qua-
lité, une augmentation prémorbide des cytokines
inflammatoires, des polymorphismes génétiques du
système sérotoninergique, des éléments de la per-
sonnalité et de l’environnement social. L’interaction
de ces facteurs prédit fortement qui est à risque
d’IFN-EDM et constitue certaines cibles potentielle-
ment modifiables dans le cadre de la prévention
personnalisée de l’IFN-EDM.
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harmacological developments in the 20th cen-
tury have produced a wide range of drugs that have
greatly improved the treatment of many serious diseases.
In psychopharmacology, the discoveries of antipsychotic,
tranquillizing, or antidepressant agents, such as selective
serotonin reuptake inhibitors (SSRIs), were milestones
in the treatment of mental illness. However, compared
with the general pharmacological progress, the psy-
chopharmacological development, whilst noteworthy,
has been somewhat less spectacular. Despite heavy
investments in mental health-related research,1 there
have been few important discoveries since the 1950s,
when a number of psychopharmacological agents were
discovered that are still in use. For example, clozapine
was synthesized over 50 years ago but continues to be
described as the “most effective antipsychotic drug” for
the treatment of schizophrenia,2 and is recommended in
the UK National Institute of Health and Clinical
Excellence (NICE) 2009 update to its schizophrenia
guidance.3
Traditionally, the drugs developed have been “one size
fits all,” ie, standardized drugs targeting symptoms or
syndromes that can be shared by various diseases, rather
than being disease-specific, let alone patient-specific.
Even though health care is by definition personalized in
the sense that the patient’s needs broadly determine the
nature of recommended treatment, eg, type and dosage
of medication, traditional medication leaves little room
for individual variations in responses to treatment,
notably through the randomized double-blind procedure
used in clinical trials that is incompatible with individu-
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alized assessment. This can be regarded both as a
strength, because the structure of the trials ensures that
known or unknown confounding factors are evenly dis-
tributed between the treatment groups, thus yielding
accurate results; or as a weakness because individuality
is not taken into account. For better or for worse, drugs
are not individually developed; they do not target the
individual biological system.
However, human individuals are, biologically as well as
socially, highly varied, and a common medical problem
is that people with similar symptoms, or the same illness,
may react quite differently to a prescribed drug. Even
if available data justify the prescription of a given drug,
the effects of this drug can vary extensively between dis-
tinct individuals. Whereas one individual may be greatly
helped by the drug, another may be more or less non-
responsive to it; and whilst one patient will suffer severe
side effects, another will not. From the point of view of
the patient, it is clearly of interest to know if one
belongs to the group (normally, the majority) that is
helped by the drug, or to the minority that is not,
whether one will suffer side effects, and, if so, of what
type and degree. For society, adverse drug responses
(ADRs) are a major medical and economic problem.
ADRs cause thousands of deaths and serious injuries
yearly, and have even been suggested to constitute
between the fourth and the sixth leading cause of death
in the US, which would rank ADRs ahead of pneumo-
nia and diabetes.4 Thus the concern felt by many people
regarding what side effects they are likely to experience
is very valid: even a brief glance at the most common or
important side effects may be rather alarming. The side
effects of psychopharmacological drugs can be very seri-
ous, including loss of muscular coordination, slowing of
reactions, addiction, and psychiatric conditions other
than the one targeted by the drug (eg, depression or
anxiety).
The prescription of drugs that may have serious side
effects is not a satisfactory area for a trial-and-error
strategy, by which one might prescribe or take a drug
with reasonable hope for good results but without know-
ing in advance what will happen. Even if side-effect pro-
files are admittedly dynamic, the risk:benefit ratio pos-
itive, serious side effects statistically uncommon, and
prescription of the drug in agreement with the gold stan-
dard of psychiatric treatment in a given context, a physi-
cian or a patient might still hesitate to prescribe or take
it, and wish to know if her/his individual biological struc-
ture is compatible with the drug or not. Will the drug
help? If so, at what price? What can be done to optimize
its therapeutic effects?
Until recently, there were no options available other
than a probability calculus based on data collected from
previous and ongoing experience. There were scant pos-
sibilities to determine in advance how the patient as an
individual would react to the drug. Unsatisfactory, per-
haps, but unavoidable: he or she had to take it to find
out, a fact that we have “generally accepted with a cer-
tain fatalism.”5
The door to making such informed individual predic-
tions was opened when, in the mid 1950s, the link
between genetic makeup and drug metabolism was iden-
tified6; ie, when it was discovered that the causes for indi-
vidual variation in drug response could be genetic.7
More precisely, when the extent to which the causes of
diverse drug response could be genetic was realized, for
the genetic determination of the capacity of an organism
to respond to its environment has long been accepted in
biology,8 including the implication of enzymes in the
detoxification of foreign substances.9 In addition to non-
genetic and environmental causes and lifestyle factors,
eg, age, gender, family support, good diet, care in fol-
lowing prescriptions, etc, variations in DNA sequence
among individuals (genetic polymorphisms) were also
found to be involved in the response to drug therapies.10
Accordingly, knowledge of the individual genome
became strongly relevant to drug prescription.11
Increasing knowledge of the human genome has given
rise to the development of genomic medicine, genetic
testing, and also helped in diagnosing some unusual dis-
orders; still, the impact of genetics in medicine during the
20th century was relatively modest.12 The recent devel-
opment of new technologies for genetic testing has pro-
moted new studies in how drugs and genes interact with
potentials for much larger impact.13 Pharmacogenetics (a
term coined in the 1950s14) is the study of individual vari-
ations in drug response due to heredity. It can be distin-
guished from pharmacogenomics, a broader term denot-
ing all genes in the genome that may influence drug
response, but the terms are often used interchangeably.15
There is considerable hope that new and more effective
treatments for numerous mental disorders can result if
drugs are developed that specifically target the responsi-
ble genes, eg, schizophrenia susceptibility genes.16
If drug prescription can be personalized, ie, tailored to
suit the individual’s genetic makeup,17 this holds promise
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of enormous benefits in terms of, notably, personalized
medication with adjusted therapeutic doses, predictable
drug responses, reduced ADRs, and personal health
planning.18 It should be noted that personalization and
individualization, depending on how the concepts are
interpreted, need not mean the same thing, and that they
are in this context a matter of degree. Here, “personal-
ized medication” can logically, but not realistically, be
interpreted as medication developed to suit the singular
individual. The realistic interpretation is that personal-
ized medication is “relatively individualized” in the sense
of drugs having a more limited group specificity than the
earlier “one size fits all” drugs.
Other suggested benefits are considerable time and cost
reductions in the pharmaceutical development,19 and the
possibility of pharmacogenomics to simplify the clinical
trial process.20 The prospects are exciting, but at the same
time, these new techniques stand faced with important
ethical, legal, and social challenges that need to be met
in order for the scientific advances to be responsibly
applied. Below, the ethical balance between challenges
and opportunities of personalized medicine in psychia-
try from the points of view of adequacy, cost, and thera-
peutic equity, are reviewed.
Sound promotion versus hype
The sequencing of the human genome and the tentative
identification of genes' underlying susceptibility to men-
tal disorders suggest the possibility of developing novel
and more effective treatments for these disorders.
Increased knowledge of the pathways for the patho-
physiology of major mental illnesses can, it is hoped, lead
to major therapeutic breakthroughs, the assumption
being that understanding of the pathophysiological basis
of these illnesses will enable the development of tar-
geted drugs and new curative therapies.21
On the basis of genetic knowledge about patients’ drug
metabolic status, several studies recommend adjustment
of therapeutic doses of antidepressants22 or antipsy-
chotics23 in relation to CYP2D6, CYP2C9, and CYP2C19
phenotypes. The implementation of these techniques in
clinical practice—which is the ultimate goal of pharma-
cogenomics research in this field—can significantly
improve psychiatric treatment in terms of adequate dos-
ing, reduced side effects, averted toxic events, and
improved treatment adherence and efficacy.24 On the
other hand, looking at the development in pharmacoge-
nomics from the perspective of earlier hopes for gene
transfer-based therapies, there is a non-negligible risk
that scientists and their funding agencies, as well as the
pharmaceutical industry, play up or hype the possibili-
ties.25
The primary concern is with scientific adequacy. Are the
scientific underpinnings of the pharmacogenomic
promises sound? Do the players sufficiently acknowl-
edge the scientific uncertainties that are connected to
pharmacogenomics research; for example, the complex
interactions between genes/brain/environment that
underlie the development of mental disorders? In order
to appreciate the significance of genetic explanations of
complex and heterogeneous disorders, such as schizo-
phrenia, eg, in terms of the genetic susceptibility for its
development, it is necessary also to understand the role
of epigenetic factors (heritable genomic functions that
are not contained in the DNA sequence code) and fac-
tors related to the psychosocial environment.26 Likewise,
in order to properly assess genotype-specific psy-
chopharmacological products, complex epigenetic inter-
actions must be taken into account. The human brain is
fundamentally a biosocial structure, and mental health
throughout life depends on social as well as biological
conditions.27 The brain develops within a “genetic enve-
lope,” but the evolution of its architecture is subject to
important social impact, notably, through the gigantic
weight of the cultural imprints epigenetically stored in
our brains.28 The formation of synapses is both prenatal
and postnatal; it is far from complete at birth. The post-
natal development of the human brain lasts considerably
longer than in any other animal. The most intense devel-
opment occurs during the first 2 years, but it continues
to puberty and after, and the highest executive functions
that are determined by the frontal lobe are not fully
mature until the age of around 20.29 The environment is
important for this process to be efficient. If neural net-
works are not active, they vanish30: “Use it or lose it!,” as
the mantra goes. In the absence of adequate stimulation,
the cerebral network suffers irreversible injury,31 and
serious mental disorders might develop.
Genetic, epigenetic, neurophysiologic, and psychosocial
explanations of mental illness are complementary; they
do not stand opposed in modern psychiatry. However, a
correct understanding of the interactions between these
distinct perspectives in the complex causal structures
underlying mental disorders and their curative therapies
is hard to achieve. This is not a new challenge, specific to
Ethical challenges of personalized medicine in psychiatry - Evers Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
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pharmacogenomics, but a classical one that is reactual-
ized in this new context. More effective treatments for
mental disorders can indeed result if drugs are devel-
oped that specifically target the genes responsible. Yet
the role of genes in causing mental disorders is
extremely complex, as is the connection between geno-
type and phenotype in drug metabolism.32 It is, for exam-
ple, not possible to base high-probability predictions of
drug responses on single genetic variations.33 Whilst the
possible contributions of molecular biology to psy-
chopharmacological drug discovery are important,34 they
must not be overemphasized or oversimplified.35
It is important and legitimate for science, health care,
and the pharmaceutical industry to try to promote new
ideas and new types of drugs; however, if the expecta-
tions are exaggerated this may undermine public trust36
and reduce financial support in the longer perspective.
This is what happened to gene therapy: “When legiti-
mate promotion became hype, followed by very public
failures of clinical trials, venture capital and government
sponsors withdrew from the field. The result was that sci-
entific research suffered, and the public and other stake-
holders were left holding an empty bag of promises.”37
It has been claimed that enthusiasts within the academic
and business fields of pharmacogenomics are guilty of
too much speculation and unsubstantiated claims.38
Skeptics point not only to the scientific uncertainty con-
cerning the promises held out, but also to exaggerations
in the promised reductions in ADRs,39 and to the
cost:benefit ratio suggested. There are signs of hype
being created, when, in 2006, the pharmaceutical indus-
try predicted that by 2010, “the discovery and develop-
ment process will take half as long as it does now, and
costs per drug will fall to a quarter of the current aver-
age.”40 It is not impossible that their prediction will come
true in due course, but we are not there yet, and at the
time of writing that prediction seems, at least timewise,
overly optimistic.
The sociological analyses of these expectations have
focused on how key actors communicate visions about
future prospects of the new technology.41 These key
actors represent different interests, eg, industry, govern-
ment, health care providers, or patient groups. Their
visions are seen as coconstructions where each actor is
actively helping to shape the trajectory of an emerging
promising technology.42 Even bioethics is suggested as a
helpmate, actively recruited by pharmaceutical compa-
nies and the biotech scientific community in order to
serve as a ”political brooker.”43 A basic message in these
sociological analyses is that industry, the medical pro-
fession, and patient groups are coresponsible for pro-
ducing hype, and they call for a more social-science
based analysis of the science behind pharmacogenomics
to obtain a more realistic view of what can actually be
achieved, to unravel the interests pressing for early
implementation, and to deconstruct the hype.44 In that
context, it must not be ignored that social scientists, eg,
ethicists, themselves may feed on the hype and be guilty
of producing it. In other words, the methods of social sci-
ence should be used without, however, excluding social
science as an object for scrutiny.
Cost versus benefit
The first-generation antipsychotic drug clozapine is still
recommended in the UK National Institute of Health
and Clinical Excellence (NICE) 2009 update to its schiz-
ophrenia guidance, but in a 2002 Press Release, NICE
“recommends newer antipsychotic drugs as one of the
first-line options for schizophrenia.”45 The choice
between newer and first-generation drugs depends in
part on the relative benefits of the drugs and their side
effects, and in part on the health care budget. 
An important reason to recommend newer rather than
first-generation psychopharmacological drugs is that the
latter tend to have more severe side effects (eg, heart
disorders such as myocarditis and cardiomyopathy, the
blood disorder agranulocytosis, or tardive dyskinesia, a
movement disorder that is potentially irreversible). On
the other hand, the newer drugs tend to be more expen-
sive, sometimes considerably so. Often the incremental
efficacy is not very spectacular, but the tolerance is
improved at a cost that is unbearable for the health care
system. Hence, there is a clear health care budget issue
involved in the selection of drugs.
Developing new drugs is an increasingly costly proce-
dure.46 The development phase can take many years and
is very expensive. The testing phase needed to deter-
mine, eg, if the drug is effective, safe, and by what
method and dosage it is best delivered to the organ sys-
tem, can also take many years and is likewise very
expensive. More and more requirements are raised by
the regulatory agencies, and, of potential new medicines,
few will ever reach the stage of marketing and selling—
a phase that can cost even more than the preceding two
combined. These factors jointly make pharmaceutical
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development extremely costly, and consequently, phar-
maceutical companies do what they can to recoup their
outlays.
In recent years, the balance of power has shifted, and the
market has become more difficult for the pharmaceuti-
cal companies, due to, for example, expiring patents,
attrition in the pipelines, and the fact that governments,
insurance companies, and patients increasingly dictate
what kind of drugs they want, and how much they are
willing to pay for them. This means that it is not just the
drug makers who define the threshold of innovation, but
also the health care demanders. In this situation, where
the pharmaceutical industry has seen its value dwindle
compared with the glory days of the 1990s, the contri-
butions of molecular biology to drug discovery hold
promise of increased profit for the pharmaceutical com-
panies.
Concerning the cost:benefit ratio of pharmacogenomic
drug development, there are profoundly different visions
of the future. According to the optimistic vision, a better
understanding of how different diseases function both at
a molecular level and as part of a biological system
might enable the industry to define diseases far more
precisely, and to develop drugs that are targeted towards
specific disease types, rather than making one-size-fits-
all drugs focusing on symptoms shared by a range of dif-
ferent diseases.47 Many new drugs will then be based on
biology rather than chemistry because biologic entities
are typically more predictable and less toxic than chem-
ical entities. In the aim to “get the right drug into the
right patient,”48 human research subjects will be geno-
typed in clinical trials to find out likely drug responses,
a development also predicted importantly to reduce the
time and cost of making new drugs.
If that prediction is correct, then the cost of drug devel-
opment might pose less of a problem in the case of tar-
geted medication than in the case of one-size-fits-all
drugs. Pharmacogenomic developments could thus lead
to better health care without increasing the customer
prices, and perhaps even reducing them. This can then
be a win-win situation, where patients receive better
health care whilst industry boosts its revenues.
Skeptics (amongst whom we also find some sectors of
the pharmaceutical industry)49 recommend a more cau-
tious view, arguing that the niche products that pharma-
cogenomics would produce risk segmenting the market,
increasing the development costs, and reducing profits.
The research, argue the skeptics, will take longer than
predicted to produce clinical applications, and that the
alleged cost-saving will therefore not be provided.50
Of course, the cost:benefit ratio of new therapeutic cures
may be difficult to determine in advance; yet the argu-
ment of pharmacogenomic cost-efficiency can be ques-
tioned on a general basis. The market for a genotype-
specific drug is perforce smaller than that of the one type
fits all variety. Even if the development process becomes
more efficient, the development of highly specialized
drugs that target small rather than large populations can
also lead to very expensive drugs. The need for pharma-
ceutical companies to recoup their investments is an eco-
nomic reality that can clash with the interests of health
care, and it is not self-evident that the latter’s concerns
will outweigh the former.
Therapeutic winners versus losers
The screening of participants in clinical trials by geno-
type raises several ethical problems. Such stratification
might lead to the unfair representation of specific groups
in these trials, as well as a reduction in the number of
subjects included, which could affect the study’s exter-
nal validity and clinical applicability.51 Even with more
cost- and time-efficient clinical trials, if researchers can
recruit only people with a certain genotype for the test-
ing of a specific drug,52 there is a risk connected to the
fact that the prospective drug is tested only on a small
and genetically homogenous group. Side effects might
go undetected in the case of people who do not have this
genotype, which means that a drug could be marketed
with less premarketing exposure and less information
about adverse effects. This may not be a problem if only
patients with the tested genotype use it, but if (eg,
through prescription error, or nonprescribed uses) some-
one with a different genotype takes it, the knowledge of
possible additional side effects for these people is want-
ing. This is different from drug errors with the random-
ized tested traditional drugs. In the case of the latter, if
a person unjustifiably takes a nonprescribed drug, or if
a psychiatrist erroneously prescribes a drug, eg, an anti-
depressant, the possible risks and side effects are rea-
sonably well foreseeable, and can probably be treated if
the person seeks medical assistance. If the same person
erroneously takes a genotype-specific drug, there is no
tested knowledge about what might happen.
This is not an argument against the development of geno-
type-specific drugs, but an argument for the development
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of a social infrastructure to handle their distribution. The
problem highlights many challenges involved in inte-
grating pharmacogenomic drugs into psychiatric care, eg,
the need for simple and accessible pharmacogenetic tests
with clinical guidelines that allow psychiatrists and health
care personnel to use these tests adequately, and to pre-
scribe or recommend pharmacogenetic drugs,53 as well as
the need for effective measures to prevent nonprescribed
use. The genetic information obtained must also be
legally safeguarded to protect privacy and confidential-
ity,54 and calls for caution have been made to “regulate
the use of genetic tests.”55
A further problem remains, from the point of view of the
patient, that is connected to the costs involved in tar-
geted drug development. This concerns the fact that
some people may belong to less profitable patient
groups.
In order to regain the investment in a drug that is tar-
geted towards a small population, the price must be
higher than if the drug were able to be distributed to a
large population. This economic principle poses a prob-
lem for so-called “orphan diseases,” ie, medical condi-
tions that are either too rare, or that touch populations
too poor for drug development in that area to be prof-
itable. Less profitable patient groups stand a smaller
chance of having remedies developed than profitable
patient groups with diseases that are also prevalent in
developed countries. To remedy the situation, public
policies in many countries fund or facilitate research
aiming to produce “orphan drugs” specifically targeted
to treat these rare conditions, or these diseases that pri-
marily haunt poor populations. Now pharmacogenomics
introduces a new way of belonging to a less profitable
patient group. To the traditional criteria of having a rare
disease, or being burdened by poverty, we may now add
having a rare genotype.
When new pharmacogenomic drugs are developed they
need to be tested in specific patient groups targeted by
specific drugs. However, it might be difficult to find a suf-
ficient number of patients for a trial of rare variants of
individual biomarker profiles.56 It can also be expensive
to develop a new drug for such small groups. Patients
with less profitable genotypes are therefore at risk of
becoming “therapeutic orphans,” and governments may
need to extend their orphan drug policies to remedy this
additional form of inequity.57
If pharmacogenomic drug development enables preci-
sion in the inclusion of patients that can be helped by a
drug, it ipso facto entails the equally targeted exclusion
of those that cannot. The limit between pharmacological
inclusions versus exclusions can in some cases be a ques-
tion of race, or ethnicity. For example, drugs to treat high
blood pressure, or hypertension, have different effects
on black versus Caucasian populations, as the high num-
ber of clinical trials investigating this listed on the US
National Institute of Health’s Web site on clinical trials
illustrates.58 The concept “race” is scientifically contro-
versial; some claim that “race is biologically meaning-
less,”59 whereas others argue that this depends on how
the concept is defined.60 In pharmacology, it seems well
established that different ethnic groups, at least, respond
in different manners to drugs, which is one reason why
the International Conference on Harmonization (ICH)
was created to harmonize the technical requirements for
registration of pharmaceuticals for human use in the
three main regions: Europe, the US, and Asia. Japan has
insisted that due to their ethnic pharmacological speci-
ficity, phase 1 studies must always also be done in Asian
populations.61
If therapeutic (in)equity can be connected to race, or
ethnicity, this is something that the social assessment of
pharmacogenomic drug development needs to take into
account. As the problem of orphan drugs and diseases
illustrates, pharmaceutical companies have no obligation
to develop drugs in an equitable manner, eg, with racial
or ethnic nonbias. If a racial or ethnic group is very small,
for example, the cost:benefit ratio for developing drugs
to treat that group may not be economically rewarding.
This is a further form of possible discrimination that gov-
ernments may need to deal with in their health care and
health research policies in order to ensure the protection
of genetic or ethnic minorities.
Conclusion
Personalized medicine in psychiatry, eg, in the form of
tailored antidepressant or antipsychotic treatment, has
already made important progress, notably in terms of
adjusted therapeutic doses, and predictable drug
responses or drug-induced side effects. Although promis-
ing, these opportunities also give rise to numerous sci-
entific, ethical, legal, and social challenges. An adequate
assessment of personalized medicine in psychiatry must
within all these perspectives be based both on analyses
of the science behind pharmacogenomics research to get
a realistic view of what can actually be achieved, and on
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analyses of the relevant sociopolitical structures sur-
rounding this research. Justified hopes must not be
inflated to become hypes of exaggerated promises that
would serve no legitimate purpose. Signs of hype, for
instance in the form of pressures for rash implementa-
tion, should be forestalled and a realistic view presented.
Realistic cost:benefit analyses are needed to produce
reasonable health care budgets; pharmacogenetic tests
must be developed together with guidelines for their use,
so that the new techniques can be responsibly imple-
mented in clinical practice; public policies on orphan dis-
eases and drugs may need to be extended to avoid cre-
ating a new group of “genetic orphans”; whilst legal
regulations are needed to ensure that the genetic infor-
mation obtained is safely protected from misuse, and
that genetic or ethnic minorities are protected from dis-
crimination.
The ethical considerations that have here been consid-
ered in terms of adequacy, cost, and therapeutic equity
raise no objections to the development of personalized
medicine per se in this domain. Rather, they point to the
necessity of developing a social infrastructure with ade-
quate guidelines to ensure the responsible implementa-
tion of these promising new techniques. ❏
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La medicina personalizada en psiquiatría:
oportunidades y desafíos éticos
Los progresos farmacogenómicos generan espe-
ranzas para la medicina personalizada dentro de la
psiquiatría en cuanto a ajuste de dosis terapéuticas,
respuestas predecibles, reducción de las reacciones
adversas a los fármacos, diagnóstico precoz y pro-
gramas personales de salud. Las posibilidades son
apasionantes, pero al mismo tiempo estas nuevas
técnicas se enfrentan con importantes desafíos cien-
tíficos, éticos, legales y sociales, los que requieren
estar de acuerdo con los avances científicos para
que ellas se puedan aplicar responsablemente. Esta
revisión discute el balance ético entre los desafíos y
oportunidades de la medicina personalizada en psi-
quiatría en relación con aspectos de adecuación,
relación costo beneficio y equidad terapéutica. Se
argumenta que el carácter prometedor de estas
alternativas terapéuticas hace aun más importante
evitar la exageración de las expectativas y que se
necesita desarrollar una sofisticada infraestructura
social para asegurar la aplicación realista y respon-
sable de la medicina personalizada en psiquiatría. 
Médecine personnalisée en psychiatrie :
opportunités et défis éthiques 
Les développements de la pharmacogénomique ont
tenu leurs promesses pour la médecine personnali-
sée en psychiatrie en permettant d’ajuster les doses
thérapeutiques, de prévoir les réponses, de dimi-
nuer les effets indésirables, d'établir des diagnos-
tics précoces et des calendriers personnels de santé.
Les perspectives sont prometteuses mais en même
temps, ces nouvelles techniques doivent faire face
à des défis scientifiques, éthiques, légaux et sociaux
importants  afin de permettre aux avancées scien-
tifiques de s’appliquer de manière responsable.
L’équilibre éthique entre défi et opportunité de la
médecine personnalisée en psychiatrie fait l’objet
ici d’une discussion au sujet de sa pertinence, de son
rapport coût/bénéfice, et de son équité thérapeu-
tique. La nature prometteuse de ces possibilités thé-
rapeutiques prend le pas sur le risque d’attentes
exagérées ; la mise en application réaliste et res-
ponsable de la médecine personnalisée en psychia-
trie demande de développer une infrastructure
sociale sophistiquée.
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The current treatment paradigm for 
Major Depressive Disorder
ajor Depressive Disorder (MDD) is a signifi-
cant public health problem. The annual costs of depres-
sion are estimated at 83.1 billion US dollars.1 Nearly two
thirds of this cost comes from impaired productivity and
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Current treatment of Major Depressive Disorder utilizes a trial-and-error sequential treatment strategy that results in
delays in achieving response and remission for a majority of patients. Protracted ineffective treatment prolongs patient
suffering and increases health care costs. In addition, long and unsuccessful antidepressant trials may diminish patient
expectations, reinforce negative cognitions, and condition patients not to respond during subsequent antidepressant tri-
als, thus contributing to further treatment resistance. For these reasons, it is critical to identify reliable predictors of anti-
depressant treatment response that can be used to shorten or eliminate lengthy and ineffective trials. Research on pos-
sible endophenotypic as well as genomic predictors has not yet yielded reliable predictors. The most reliable predictors
identified thus far are symptomatic and physiologic characteristics of patients that emerge early in the course of treat-
ment. We propose here the term “response endophenotypes” (REs) to describe this class of predictors, defined as latent
measurable symptomatic or neurobiologic responses of individual patients that emerge early in the course of treatment,
and which carry strong predictive power for individual patient outcomes. Use of REs constitutes a new paradigm in which
medication treatment trials that are likely to be ineffective could be stopped within 1 to 2 weeks and other medication
more likely to be effective could be started. Data presented here suggest that early changes in symptoms, quantitative
electroencephalography, and gene expression could be used to construct effective REs. We posit that this new paradigm
could lead to earlier recovery from depressive illness and ultimately produce profound health and economic benefits.   
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absenteeism from work. Approximately 14.8 million
American adults2 (6.7% of the population) suffer from
MDD, and cost employers more than $44 billion per
year in lost productive time and 387 million days per
year of disability.1 While the economic costs are sub-
stantial, the personal costs of prolonged suffering are
incalculable. 
The costs of MDD are high, in part because it takes so
long for patients with MDD to recover from the illness.
Even after 1 year of treatment with enhanced resources
under a structured algorithm, only 11% of patients
achieved remission.3 This low recovery rate is not simply
a matter of needing more or better medications. There
are more than 20 treatments for MDD approved as
effective by the Food and Drug Administration (FDA).
The challenge is choosing the best treatment for each
patient. The current treatment guidelines for MDD of
the American Psychiatric Association4 support a “watch-
ful waiting” approach to determine if a particular med-
ication will be useful for an individual patient. In order
to determine whether a medication will lead to response
(≥50% reduction in depressive symptoms) or remission
(nearly complete resolution of symptoms), it is recom-
mended that a physician wait to see if it will be effective.4
On average, at least 4 weeks are needed to attain
response and 6 weeks to attain remission during treat-
ment with an initial selective serotonin reuptake
inhibitor (SSRI) antidepressant; in a number of cases,
however, remission can take 12 weeks or longer to
attain.5 In practice, physicians commonly wait 6 to 8
weeks to determine if a patient will recover with
whichever medication is chosen.6,7
It is not surprising that, under the current treatment par-
adigm, most patients face a long and frustrating course of
treatment. The Sequenced Treatment Alternatives to
Relieve Depression (STAR*D) study, the largest study of
MDD conducted in the United States, showed that even
with enriched resources devoted to treatment, recovery
with the first selected SSRI occurred only about 30% of
the time.8 More than 20% of those who failed to improve
with the first treatment simply stopped taking medication,
primarily within the first 2 weeks.9 Although medication
may take up to 12 weeks to be effective, 42% of patients
discontinue medication within the first 30 days.10 A high
proportion of the patients who prematurely stop treat-
ment are from ethnic minority groups,10 and this may con-
tribute to the significantly poorer clinical outcomes
observed among ethnic minority patients.11
Failure to respond to treatment at any one step is com-
monly followed by “sequential treatment” in which a
subsequent treatment is utilized either alone in combi-
nation,12-14 followed by another period of watchful wait-
ing. In most studies, only about 15% of patients will ulti-
mately fail to benefit from sequential medication
treatment, but it may take 1 to 2 years to identify the
treatment that will get a patient well—and many dis-
continue treatment before they can recover.15 For those
individuals who leave treatment prematurely, suffering,
disability, impaired productivity, and absenteeism from
work may continue indefinitely. For those who remain
in treatment, the delay in recovery from MDD increases
health care costs. While they are depressed, patients with
MDD have at least a 50% increase in total health care
costs for general medical conditions.16
The current paradigm of watchful waiting is seriously
flawed. Lengthy medication trials determine with a high
degree of certainty whether a particular medication will
be effective. Because only a minority of patients will
recover with any one medication, however, this para-
digm prolongs the length of depressive episodes for most
patients, increases health care costs, and increases the
likelihood that many patients will drop out and never
receive adequate treatment. The approach of lengthy
medication trials essentially sacrifices the health of the
majority of patients for the certainty of knowing
whether a particular antidepressant will be effective. 
Limitations of the current 
treatment paradigm
In sequential treatment, subsequent antidepressant med-
ications commonly are selected based upon their puta-
tive mechanism of action (MOA), with medications that
have a different MOA usually given preference.17 It has
never been shown, however, that MOA is related to
effectiveness in switching or combining medications.18
The results from level II treatment in STAR*D sug-
gested that patients respond or remit to different anti-
depressants at similar rates, regardless of the MOA.19,20
The sole reliable predictor of improvement in sequen-
tial treatment is that improvement at one step is asso-
ciated with further improvement at the next step,
whereas failure to improve indicates a poor prognosis
for improvement during future treatments.19,21 The
STAR*D study demonstrated that each subsequent
medication trial was less and less likely to be effective
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for patients with unsatisfactory response at the previous
level.13,19,21-23
The development of increasing resistance over the
course of antidepressant treatment is well established
but not well understood. It largely has been interpreted
as representing the fact that those who fail to benefit
from adequate trials of earlier treatments are simply pre-
disposed not to respond to multiple treatments, some-
times because of comorbid conditions.24 This hypothe-
sized process through which successive treatment
failures identify and isolate an increasingly treatment-
resistant population may account, at least in part, for the
escalation in failure rates with successive trials. This “dis-
tillation” hypothesis, however, is unlikely to account fully
for increasing treatment resistance with multiple anti-
depressant trials. Even within a trial of a single antide-
pressant medication, there is a great deal of hetero-
geneity in onset of improvement that is not easily
explained by commonly measured clinical features. Half
of patients require more than 6 weeks to enter remission
and a significant number of patients still enter remission
up to 12 weeks, yet these later remitters eventually may
attain a degree of improvement comparable to those
who enter remission rapidly.5
A number of factors are likely to affect speed and com-
pleteness of medication responsiveness. Whereas some
of these factors may reflect heritable or constant bio-
logical factors, others may be more dynamic and repre-
sent the state of the individual at the specific time that
he or she enters treatment.25-27 Many such intraindivid-
ual factors are psychological, including patient expec-
tations, cognitions, or conditioned responses. Data from
subjects enrolled in clinical trials has shown that
patients with high expectations of the effectiveness of
their treatment are more likely to benefit from their
treatment,28,29 and to respond more rapidly.29 Patients
who are uncertain about the benefit of their antide-
pressant treatment may even discontinue medication
before it has had time to work.30 These findings are con-
sistent with the fact that in the setting of a placebo con-
trolled trial, patients’ certainty that they will be receiv-
ing the active medication as compared with placebo is
directly related to their likelihood of response. Patients
who are informed that they have a 50% likelihood of
receiving active medication are significantly more likely
to respond than those who are informed that their prob-
ability of receiving medication is only 20%.31 It is rea-
sonable to postulate that anything in the treatment set-
ting that alters patients’ expectations of improvement
is likely to alter their likelihood of benefiting from a
medication. Insofar as prolonged prior administration
of an ineffective antidepressant may diminish expecta-
tions of improvement, this practice may contribute to
the failure of subsequent trials. 
Cognitive theories of depression suggest that, in the con-
text of dysfunctional attitudes that subserve depression,
failed treatment attempts would perpetuate negative
thoughts and contribute to future failures. Beck’s cogni-
tive theory postulates that dysfunctional attitudes
develop in response to specific stressors in the midst of
an episode of depression.32 The poorer treatment out-
comes of some depressive subtypes is partly explained
by the patients’ level of negative or dysfunctional cog-
nitions.33 Depressed patients’ interpretation of negative
events also may increase the likelihood of maintaining
depression and of poor response to medication.34,35 In the
midst of an episode of MDD, ineffective treatment trials
may constitute a specific stressor that, interpreted in a
negative context, could combine with dysfunctional atti-
tudes to result in increasingly resistant depression in
some patients. 
Classical conditioning also may play a role in antide-
pressant resistance during successive trials. Animal mod-
els have shown that pharmacologic responses to a num-
ber of different therapeutic agents can be classically
conditioned,36,37 including responses to antidepressant
agents.38 Similarly, pharmacologic nonresponse can also
be conditioned to a reuptake inhibitor drug.39 A related
concept in the classical conditioning paradigm is the
process of latent inhibition, in which frequent adminis-
tration of a cue (in this case, antidepressant pill-taking)
that is not associated with a significant outcome prevents
future conditioning to that cue.40 There is evidence to
suggest that patients’ physiologic responses to antide-
pressant medications are in part conditioned responses.
A number of brain imaging studies have shown that
effective antidepressant treatment is associated with
decreases in metabolism or brain electrical activity in the
prefrontal cortex.41,42 While these changes in function
appear to be associated with antidepressant treatment,
brain imaging during a placebo lead-in showed that the
changes thought to be associated with successful anti-
depressant treatment actually preceded administration
of the medication.25 These findings suggest that a psy-
chological process such as conditioning plays a role in
eliciting brain functional changes. Whether nonresponse
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to pharmacotherapeutic agents can be conditioned in
the clinical setting by prolonged nonresponse to antide-
pressants has not been established. 
It is difficult to demonstrate the role of expectations,
cognitions, or conditioned responses in the failure to
respond to successive antidepressant medication trials
in humans. It is known that administration of an antide-
pressant is less effective after the patient has received no
benefit from either a first antidepressant21 or a placebo,43
but multiple crossover trials would be necessary to
determine the mechanism for this loss of effectiveness.
There is clearer evidence from human pain studies, how-
ever, that ineffective medication trials directly contribute
to decreases in the effectiveness of subsequent analgesic
medications. The effectiveness of an analgesic medica-
tion is degraded when administered after an ineffective
dose of medication or placebo; furthermore, the more
doses of the ineffective compound that are given, the
less likely that the analgesic will have a therapeutic
effect.44,45 Blinded administration of effective analgesics
also diminishes their effectiveness.46 Expectations, con-
ditioning, and cognitive factors all have been shown to
be involved in mediating these effects.46,47
In summary, unsuccessful antidepressant trials may
diminish patient expectations, reinforce negative cogni-
tions, and condition patients not to respond during sub-
sequent antidepressant trials. Regardless of the psycho-
logical mechanism, the above theories and data suggest
that ineffective medication trials may, in and of them-
selves, predispose patients to experience diminished
medication effectiveness in future trials. 
The state of endophenotypic 
and genomic predictors
There are several strategies that could be employed to
overcome the shortcomings of the current paradigm for
prescribing antidepressant medications. One of these
would be to identify, prior to treatment, the medication
that has the highest likelihood of benefitting the patient.
Research has sought to indentify “endophenotypes” that
could predict response or remission to specific antide-
pressants for individual patients. As defined by
Gottesman and Gould,48 an endophenotype must meet
five criteria:
1. The endophenotype is associated with illness in the
population. 
2. The endophenotype is heritable. 
3. The endophenotype is primarily state-independent
(manifests in an individual whether or not illness
is active). 
4. Within families, endophenotype and illness coseg-
regate. 
5. The endophenotype found in affected family mem-
bers is found in nonaffected family members at a
higher rate than in the general population. 
Endophenotypes thus are measureable characteristics
or physiologic indices that fill “the gap between avail-
able descriptors and between the gene and the elusive
disease process.”49 Exhaustive studies of clinical features,
family history, as well as sleep patterns and neuroen-
docrine correlates, have identified general prognostic
indicators for treatment outcome for depression.50,51 In
some cases, the predictors may be useful for groups of
patients with certain subtypes of depression (ie, psy-
chotic depression).52 While some symptomatic and phys-
iologic features in MDD patients demonstrate promise
as putative endophenotypes, many do not fulfill the
actual criteria for an endophenotype or meet the goal of
providing greater prognostic specificity than the defini-
tion of the illness itself.53 Some brain imaging findings
also have demonstrated prognostic significance54-57 and
may fulfill the criteria for an endophenotype.58 Part of
the challenge in identifying true endophenotypes in
MDD is that the physiologic and genetic underpinnings
of MDD are complex and poorly understood. As a
result, imaging findings may reflect confounds such as
interindividual heterogeneity in brain structure or func-
tion unrelated to illness, or the effects of previous or con-
comitant medication treatment.58 No clinically meaning-
ful endophenotypes predictive of response to specific
medications in individual patients prior to the start of
treatment yet have been identified.59,60
An alternative to the endophenotypic approach has
been to examine genetic polymorphisms as possible out-
come predictors. Recent studies have suggested that
common genetic variations may be associated with
response to specific antidepressant medications.61-63 For
example, some common polymorphisms in serotonin
system genes have been shown to influence the outcome
of SSRI treatment.62,64 Many of these results have not
consistently replicated or do not allow the estimation of
prediction accuracy in a clinical population.65 The rela-
tive lack of reproducibility in pharmacogenetic studies
may reflect the fact that the contributions of individual
polymorphisms may be small and, therefore, large pop-
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ulations may be needed to detect the effect.66 Given the
complexity of influences “downstream” from genotype,64
genotype alone may be insufficient to capture the state
of those systems that subserve antidepressant action in
an individual patient. To date, research on possible
genomic factors has not yet yielded reliable predictors. 
Response endophenotypes
The most reliable treatment response predictors iden-
tified thus far are symptomatic and physiologic charac-
teristics of patients that emerge early in the course of
treatment. We propose here the term “response
endophenotypes” to describe this class of predictors.
Specifically, we define response endophenotypes (REs)
as latent measurable symptomatic or neurobiologic
responses of individual patients that emerge early in a
course of treatment and which carry strong predictive
power for individual patient outcomes. In some diseases,
endophenotypic characteristics are elicited by a physio-
logic challenge (ie, glucose tolerance tests, stress elec-
trocardiography).53,67 The distinction of the term response
endophenotype is that it describes a class of markers
that are exclusively observed in response to specific treat-
ment challenges. Although there is evidence that
response to medication is at least in part genetically
mediated, it is not firmly established that the REs pre-
sented below necessarily are heritable. It is therefore
appropriate to consider REs as putative endopheno-
types, pending research to establish heritability and ful-
fillment of the other characteristics of an endopheno-
type.48
In the prediction of treatment response in MDD, there
are significant advantages to composing endopheno-
types exclusively from measureable changes in an indi-
vidual in response to a specific treatment. First, the fact
that these characteristics are measured “within subjects”
likely enhances stability, statistical reliability, and there-
fore predictive accuracy of the measures. Preliminary
data presented below suggest that use of REs may facil-
itate prompt and accurate matching of patients with the
medication most likely to benefit them. Second, the fact
that RE components are measured in response to newly
administered treatments may overcome some of the
confounding factors inherent in the development of con-
ventional endophenotypes in MDD. It is problematic to
derive prognostic significance from static, cross-sectional
measures in MDD patients; such measurements are
inevitably affected by the number and severity of prior
episodes, the current phase of illness, and the extent and
types of prior and current treatment.58 Examination of
dynamic measures specific to the current treatment may
detect features that are common across individuals who
will respond to the treatment, irrespective of confound-
ing factors. There are three broad classes of measures
that may change within the first 48 hours to 2 weeks of
treatment that have been identified thus far as potential
predictors of treatment response or remission, and
therefore may be useful as components of an RE. Each
of these is discussed separately below.
Early changes in depressive symptoms
The average time to response in treatment with a pro-
totypical SSRI is 1 month, and to remission is 6 weeks.5
While some patients continue to enter remission up to
12 weeks or even longer after the initiation of treatment,
the time to symptomatic improvement is much shorter.
Many patients, particularly those with milder symptoms,
show improvement (defined by at least a 20% decrease
in depressive symptoms) within the first 2 weeks of
treatment.68-71 Although some have suggested that early
response is likely to represent a placebo response,72,73
early response is in fact twice as likely with medication
as with placebo.71
The largest meta-analytic study of this topic was per-
formed by Szegedi and colleagues,74 who examined 6562
subjects treated primarily with mirtazepine, but also with
SSRIs, tricyclic antidepressants (TCAs), and venlafax-
ine. These investigators found that more than 50% of
patients had at least a 20% improvement in depression
rating scores by the end of 2 weeks of treatment. Of
those who did not show early improvement, only 11%
and 4.1% showed eventual response and remission,
respectively. Early improvement was a highly sensitive
predictor of stable response (81% to 98%) or stable
remission (87% to 100%), and so was a positive prog-
nostic sign. However, the usefulness of early symptom
improvement was limited by the poor specificity for sta-
ble response (43% to 60%) or remission (19% to 28%). 
The results of all of these studies are difficult to evalu-
ate because they come from placebo-controlled treat-
ment trials of selected study populations. It is clear that
early symptom improvement is a positive prognostic
sign, and the absence of early improvement is a negative
prognostic sign. The poor specificity of the finding, how-
Predicting treatment response in major depression - Leuchter et al Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
439
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 439
ever, makes it difficult to make treatment decisions
based solely upon early symptom improvement; absence
of early improvement by itself is insufficiently powerful
evidence to prompt a change in treatment. It is possible
that early symptom changes could form part of the basis
for REs to reliably predict response and remission to the
specific medication that the patient receives within the
first 2 weeks of treatment. 
Early changes in brain electrical activity
One biomarker that has shown promise as a predictor of
treatment response is quantitative electroencephalog-
raphy (QEEG). Prefrontal QEEG power75-77 may iden-
tify patients who are most likely to respond to all major
antidepressant medication classes. Research has shown
that QEEG changes in the prefrontal region may reli-
ably identify antidepressant medication responders
within the first 48 hours to 1 week of treatment.42,78 These
findings are consistent with the fact that rhythmic mid-
line prefrontal EEG activity has been shown to reflect
the activity of anterior cingulate and midline prefrontal
cortex,79 brain areas implicated in mood regulation and
the pathogenesis of depression. 
Based upon these previous results, a multisite study was
designed to test the usefulness of QEEG as a predictor.
The BRITE-MD study (“Biomarkers for Rapid
Identification of Treatment Effectiveness in Major
Depression,” NCT00289523), examined for the first time
the usefulness of a new putative neurophysiologic bio-
marker for medication response and remission, the
Antidepressant Treatment Response (ATR) index.80
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Figure 1. Study flow chart. Ham-D, Hamilton Depression Rating Scale; SSRI, selective serotonin reuptake inhibitor; EEG, electroencephalography
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ATR is based upon QEEG data collected on two occa-
sions, at pretreatment baseline (immediately before med-
ication is started) and at the end of 1 week of treatment
with medication. ATR is based upon alpha and theta
band features of frontal brain electrical activity inte-
grated and scaled from 0 (low probability of response or
remission to the medication) to 100 (high probability).
BRITE-MD is the largest single study of any type of neu-
rophysiologic biomarker in MDD undertaken to date (N
=375). All subjects were treated with an initial 1 week of
escitalopram 10 mg, during which time ATR was calcu-
lated. Subjects then were randomized either to continue
escitalopram, switch to bupropion, or receive a combi-
nation of the two medications (Figure 1). 
The outcome measure was the Hamilton Depression
Rating Scale (Ham-D17) score at week 7, with response
defined as a 50% decrease from the baseline score and
remission defined as a final score ≤7. Other putative pre-
dictors examined in BRITE included other biomarkers
(serum drug levels, as well as serotonin transporter [5-
HTTLPR] and postsynaptic serotonin receptor [5-HT2a]
genetic polymorphisms), early changes in symptoms
(measured with the Ham-D17 at 1 week), and clinician
prediction of the likelihood of response (using a clinical
global impression measure at 1 week). 
The Receiver Operating Characteristic (ROC) curve for
predictive accuracy of ATR with escitalopram is shown
in Figure 2. An optimal threshold was chosen on this
curve (58.6) to maximize accuracy in predicting
response, with values above this threshold designated as
a “positive” ATR and those below the threshold as “neg-
ative.” 
A positive ATR biomarker predicted response and remis-
sion to treatment in the escitalopram arm with high accu-
racy. ATR values predicted response with 74% overall
accuracy, 58% sensitivity, 91% specificity, 88% positive
predictive accuracy, and 67% negative predictive accuracy.
ATR also predicted remission with 74% overall accuracy,
61% sensitivity, 82% specificity, 68% positive predictive
accuracy, and 77% negative predictive accuracy. Neither
serum drug level not genetic polymorphisms were signif-
icant predictors of response or remission with escitalo-
pram. Responders at week 7 had significantly larger
decreases than nonresponders in Ham-D17 scores at day
7 (P=0.005), although remitters did not. Clinician predic-
tion based upon global impression of improvement at day
7 did not predict final outcome. Logistic regression
showed that ATR and early Ham-D17 changes were addi-
tive predictors of response, but ATR was the sole signifi-
cant predictor of remission.80
Another goal of BRITE was to examine the prognostic
significance of a negative biomarker. The overall
response rate to escitalopram in the study was 52%, but
in those with a positive ATR biomarker, the response
rate was 61%. Conversely, in those with a negative ATR
biomarker, the response rate to escitalopram was only
28%. Analyses showed that a low ATR value predicted
not only nonresponse to escitalopram, but also subse-
quent response to treatment among those subjects who
were randomly assigned to receive the antidepressant
bupropion. Subjects with ATR values above the thresh-
old were more than 2.4 times as likely to respond to esc-
italopram as those with low ATR values (68% vs 28%,
P=.001). Subjects with ATR values below the threshold
who were switched to bupropion treatment were 1.9
times as likely to respond to bupropion alone than those
who remained on escitalopram treatment (53% vs 28%,
P=.034, Figures 3 and 4).81
These differences were statistically significant. One mea-
sure of the potential impact of the use of the ATR bio-
marker is the “number needed to treat” (NNT), namely
the number of patients to whom such a test would need
to be applied in order to realize one improved patient
outcome.82,83 These results equate to a NNT of 10 to 11,
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Figure 2. Receiver Operating Characteristic curve for ATR prediction of
response to escitalopram treatment. ATR, Antidepressant
Treatment Response index
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which is in the range that has been considered to be clin-
ically significant.84 These results must be interpreted with
the caveat that treatment was not assigned prospectively
on the basis of ATR values. 
These results are encouraging, and suggest that ATR
may be useful as a component of a RE for predicting
early in the course of treatment which medication will
be most helpful to an individual patient with MDD. The
fact that ATR data appear to be complementary to early
changes in depression rating scores suggests that a RE
model that integrates symptom and neurophysiologic
measures may be the most useful. 
Gene expression markers
Some of the more intriguing putative biomarkers for
antidepressant treatment response are early changes in
gene expression. Animal and cell culture research, as well
as study of postmortem human brains, indicates that reg-
ulation of gene expression represents a major component
of the mechanism of action of available antidepressants.
The expression of a host of gene families are altered by
antidepressant treatment, including those for trophic fac-
tors that promote cell proliferation, growth, and
resiliency (BDNF, FGF, and VEGF), cell signaling path-
ways, and pathways for neurotransmitter transport and
metabolism, among others.85,86
Because direct examination of gene expression in
patients’ brains is impractical, recent research has exam-
ined gene expression in peripheral leukocytes, which
share identical genetic material and may exhibit similarly
altered expression in response to antidepressant med-
ications. There have been limited small previous studies
of gene expression through leukocyte mRNA in response
to antidepressant or lithium treatment in patients with
MDD or bipolar disorder.87-93 These studies have con-
firmed and extended research from animals, showing sig-
nificant differences prior to treatment between bipolar
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Figure 4. Logistic regression models of escitalopram and bupropion
remitters stratified by ATR values. ATR values of subjects ran-
domly assigned to each treatment and who remitted with esc-
italopram or bupropion treatment. Subjects who remitted with
escitalopram (blue) tended to have higher ATR values, and
those who remitted with bupropion (red) tended to have lower
ATR values. Markers represent observed values and lines rep-
resent modeled values. ATR, Antidepressant Treatment
Response index
Adapted from ref 81: Leuchter AF, Cook IA, Gilmer WS, et al.
Effectiveness of a quantitative electroencephalographic biomarker for
predicting differential response or remission with escitalopram and
bupropion in Major Depressive Disorder. Psychiatry Res. 2009;169:124-
131. Copyright © Elsevier, 2009
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Figure 3. Logistic regression models of escitalopram and bupropion
responders stratified by ATR values. ATR values of subjects ran-
domly assigned to each treatment and who responded to esc-
italopram or bupropion treatment. Subjects who responded
to escitalopram (blue) tended to have higher ATR values, and
those who responded to bupropion (red) tended to have lower
ATR values. Markers represent observed values and lines rep-
resent modeled values. ATR, Antidepressant Treatment
Response index
Adapted from ref 81: Leuchter AF, Cook IA, Gilmer WS, et al.
Effectiveness of a quantitative electroencephalographic biomarker for
predicting differential response or remission with escitalopram and
bupropion in Major Depressive Disorder. Psychiatry Res. 2009;169:124-
131. Copyright © Elsevier, 2009
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or MDD subjects and normal controls in expression of
trophic and transcriptional factors, as well as cell signal-
ing proteins. In some small studies, antidepressant treat-
ment tended to normalize gene expression patterns and
the degree of normalization was proportional to the
degree of symptom improvement.90,92 No study has uti-
lized microarray-based screening of large numbers of
expressed genes to predict treatment response in MDD,
but one study has performed such screening in a small
number of subjects with juvenile epilepsy and identified
patterns of change in expression that accurately differ-
entiated subjects who were seizure-free on valproate
from those who were not.94
Because of limited research in this area, the gene expres-
sion approach is highly speculative. Furthermore, the bio-
logical basis through which gene expression changes
measured in peripheral blood reflect the central effec-
tiveness of medications admittedly is not fully clear.
There are several possible mechanisms including: i) par-
allel expression changes in the brain and peripheral
blood; ii) leukocyte responses to change in the brain; iii)
responses of the leukocytes to a change in the physio-
logical state of the subject; and/or iv) changes in the com-
position of the leukocyte population. Regardless of the
mechanism, sufficient data exist to support the plausibil-
ity of testing the use of gene expression in peripheral
leukocytes to predict clinical responsiveness to antide-
pressants. Expression profiles could potentially be
applied in the clinic to aid in the treatment of MDD, and
because the fundamental measure is the change in gene
expression within a patient between two time points, each
patient acts as his or her own control, greatly reducing
the artifacts that could arise from directly comparing
gene expression across unmatched subjects, such as sub-
ject-to-subject expression differences due to extraneous
factors such as ethnicity, gender, age, or environment fac-
tors. 
Conclusion
The use of REs for predicting antidepressant treatment
response and remission has the potential to overturn a
flawed biomedical paradigm that forms the basis for clin-
ical research and treatment in MDD, namely, the long
empiric medication trial. Fewer than half of patients
respond to treatment under this paradigm, and fewer
than one third recover. This paradigm leads to prolonged
suffering and increased health care costs. If we were suc-
cessful in identifying response endophenotypes for
patients with MDD, medications would be prescribed
under an entirely new paradigm that relied upon an early
response profile of each patient. The concept of the
response endophenotype shifts from the examination of
endophenotypes and genotypes, which have not proved
highly productive, to the study of dynamic treatment-
emergent characteristics. In this paper we have suggested
early changes in symptoms, brain neurophysiology, and
patterns of changes in gene expression as potential REs.
The RE concept need not be limited, however, to these
few measures. Any early treatment-emergent measures
that could be examined within the individual patient
could be incorporated in this paradigm. We posit that this
paradigm could optimize response and remission rates
with medication and prove superior to the current
approach, leading to earlier symptom improvement,
recovery from the illness, and ultimately profound health
and economic benefits in terms.  ❏
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Un nuevo paradigma para predecir la 
respuesta al tratamiento antidepresivo
El tratamiento actual del trastorno depresivo
mayor emplea una estrategia terapéutica secuen-
cial de ensayo-error que se traduce en demoras
para alcanzar la respuesta y remisión para la mayo-
ría de los pacientes. El tratamiento ineficaz pro-
longado alarga el sufrimiento del paciente y
aumenta los costos de salud. Además, los ensayos
prolongados e ineficaces con antidepresivos pue-
den disminuir las expectativas del paciente, refor-
zar las cogniciones negativas y condicionar a los
pacientes a no responder durante los siguientes
ensayos con antidepresivos, contribuyendo así a
una resistencia a posteriores tratamientos. Por
estas razones, es fundamental identificar predic-
tores confiables de la respuesta al tratamiento anti-
depresivo que puedan utilizarse para abreviar o eli-
minar los ensayos prolongados e ineficaces. La
investigación tanto de posibles endofenotipos
como de predictores genómicos aun no ha entre-
gado predictores confiables. Los predictores más
confiables que se han identificado hasta ahora son
ciertas características sintomáticas y fisiológicas de
los pacientes, las que aparecen precozmente
durante el curso del tratamiento. Aquí se propone
el término «respuesta endofenotípica (RE)» para
describir esta clase de predictores, definidos como
respuestas precoces y latentes tanto sintomáticas
como neurobiológicas que se pueden medir en
cada paciente y que tienen un alto poder predictor
para la evolución clínica individual. El empleo de la
RE constituye un nuevo paradigma para los ensa-
yos de tratamientos medicamentosos que tengan
una alta probabilidad de ser inefectivos, ya que
éstos podrían ser suspendidos dentro de una o dos
semanas para dar inicio a otra medicación con
mayor probabilidad de ser eficaz. Los datos aquí
presentados sugieren que los cambios precoces en
los síntomas, en la electroencefalografía cuantita-
tiva y en la expresión génica podrían ser utilizados
para construir REs efectivas. Se postula que este
nuevo paradigma podría llevar a recuperaciones
más precoces de la enfermedad depresiva y a la
larga producir marcados beneficios de salud y eco-
nómicos.    
Un nouveau paradigme de prédiction de la
réponse au traitement antidépresseur
Une stratégie thérapeutique séquentielle par
essais/erreurs est actuellement utilisée dans le trai-
tement du trouble dépressif majeur entraînant  une
réponse et une rémission retardées pour la majorité
des patients. Un traitement inefficace prolongé
allonge la souffrance du patient et augmente les
coûts des soins de santé. De plus, des séquences thé-
rapeutiques longues et infructueuses par antidé-
presseurs contribuent à diminuer les attentes des
patients, à renforcer les opinions négatives et
conditionnent les patients à ne pas répondre au
cours des traitements ultérieurs, contribuant ainsi à
une résistance. Il est donc crucial pour ces raisons
d’identifier des prédicteurs fiables de la réponse au
traitement antidépresseur, pour raccourcir ou éli-
miner les séquences thérapeutiques très longues et
inefficaces. La recherche sur des facteurs prédictifs
endophénotypiques ou génomiques possibles n’est
pas encore fiable. Les facteurs prédictifs les plus
fiables identifiés jusqu’à maintenant sont des carac-
téristiques symptomatiques et physiologiques des
patients apparaissant précocement au cours du trai-
tement. Nous proposons ici le terme « d’endophé-
notypes de la réponse » (ER) pour décrire cette
classe de prédicteurs, définis comme des réponses
précoces latentes symptomatiques ou neurobiolo-
giques mesurables pour chaque patient, avec un
pouvoir prédictif de l'évolution clinique de chacun.
L’utilisation des ER constitue un nouveau para-
digme dans lequel les séquences thérapeutiques de
traitements risquant d’être inefficaces pourraient
être arrêtées dans les 1 à 2 semaines, laissant place
à d’autres antidépresseurs probablement plus effi-
caces. Les données présentées suggèrent que les
modifications précoces des symptômes, l’électroen-
céphalographie quantitative et l’expression des
gènes pourraient être utilisés pour bâtir des ER effi-
caces. Nous postulons que ce nouveau paradigme
pourrait conduire à une guérison précoce de la
maladie dépressive et finalement apporter des
bénéfices économiques et de santé profonds.
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t has long been thought that it is not possible
to prevent the onset of mental disorders, because the
processes involved in the etiology are too complex and
not yet sufficiently understood. In the past 15 years, how-
ever, the knowledge about identifying target groups for
prevention and about the effects of preventive inter-
ventions has increased considerably. A growing number
of randomized controlled trials has shown that it is pos-
sible in some cases to actually prevent or at least delay
the onset of mental disorders, including depressive dis-
orders and anxiety disorders, and some studies indicate
that it may even be possible to prevent the onset of psy-
chotic disorders in high-risk groups (see review below). 
Research on effective prevention programs is very
important for several reasons. First, effective prevention
programs may potentially contribute to the reduction of
the enormous burden of mental disorders.1 Mental dis-
orders account for 22% of the total burden of disease in
established market economies, as measured in disability-
adjusted life years lost,2 with the common mental disor-
ders (depression, anxiety, and substance use disorders)
accounting for three quarters of the burden of all mental
disorders. At any given moment, 150 million people suf-
fer from a depressive disorder, 90 million suffer from a
substance-related disorder, and each year a million peo-
ple commit suicide. Mental disorders are associated with
huge losses in quality of life in patients and their relatives,
with increased mortality and morbidity, with high levels
of service use, and with enormous economic costs.3,4
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In the past 15 years a considerable number of studies
have found evidence that it may be possible to prevent
the onset of some mental disorders. Most evidence is
available for depressive disorders, but a growing num-
ber of studies have focused on anxiety disorders and
psychotic disorders. This paper reviews the studies which
have examined the effects of preventive interventions
on the incidence of mental disorders in people who do
not meet criteria for a mental disorder at baseline. More
than 20 studies have examined prevention of depressive
disorders, and they have found an overall reduction in
the incidence of about 25% compared with control
groups. The problem of identifying the most optimal
target groups for preventive interventions is also illus-
trated. This is a problem because most risk indicators
have a low specificity, and most people with a risk indi-
cator do not develop a mental disorder. Finally, this
paper will show how other statistics, such as the expo-
sure rate, the attributable fraction, and the number
needed to treat can help in identifying the most opti-
mal target groups for preventive interventions. 
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It is estimated that only half of the burden of the com-
mon mental disorders can be averted with existing treat-
ment methods (both psychological and pharmacologi-
cal) given maximized coverage (the number of people
seeking treatment), clinician competence, and patient
compliance with treatment.5 If we want to reduce the
burden of mental disorders further, we can either
develop new treatment methods that are considerably
better than existing ones, or we can develop preventive
interventions that result in reductions of new cases. The
option for preventive interventions has not been exam-
ined very thoroughly, although it can be regarded as a
promising way to reduce the burden of psychiatric dis-
eases.5 Another reason why this research is so important
is that it may increase our knowledge of the etiology of
mental disorders. Until now, most mental disorders have
been thought to be caused by multiple factors on differ-
ent levels (physical, social, psychological), and it is not
possible to predict which individual is going to develop
the disorder and who is not. If it proves to be possible to
prevent new cases of mental disorders, the interventions
must somehow change the basic mechanisms that lead
to the occurrence of the disorder. 
This review will first define exactly what prevention is.
Then, the research on the effects of interventions on the
prevention of the incidence of new cases of mental dis-
orders will be summarized. Finally, the possibilities of
developing personalized preventive interventions, using
new epidemiological methods to identify the most
important high-risk groups for prevention, will be
described.
What is prevention?
In the definition of depression which is currently used
by most researchers and practitioners, depression com-
prises all interventions which are conducted before sub-
jects meet the formal criteria for a mental disorder
(according to the Diagnostic and Statistical Manual of
Mental Disorders. 4th ed, DSM-IV).6 Curative interven-
tions are given to persons who suffer from acute disor-
ders, and maintenance treatments are given to patients
with chronic disorders. In this spectrum of interventions,
three types of prevention can be distinguished:
• Universal prevention is aimed at the general popula-
tion or parts of the general population, regardless of
whether they have a higher-than-average risk of devel-
oping a disorder. The best-known examples of univer-
sal prevention include school programs aimed at all
students, whether they have an increased risk of devel-
oping a mental disorder or not, and mass-media cam-
paigns, aimed at the general population. 
• Selective prevention is aimed at high-risk groups, who
have not yet developed a mental disorder. High-risk
groups include people who have recently experienced
a stressful life event or who experience a chronic stres-
sor, such as divorce, losing a family member through
death, caring for an ill family member, and unemploy-
ment.
• Indicated prevention is aimed at individuals who have
some symptoms of a mental disorder but do not meet
diagnostic criteria. Indicated prevention is aimed at
people who already suffer from some (depressive)
symptoms.
Is prevention of mental disorders effective?
In the past few decades, several hundred controlled stud-
ies have examined the effects of mental health programs
aimed at preventing mental health problems at school,7,8
substance use and abuse at school,9 work-related stress,10
distress among caregivers for the elderly,11,12 child
abuse,13–15 and many other conditions. This considerable
body of research has shown that some prevention pro-
grams in mental health are capable of strengthening pro-
tective factors, such as social skills, problem-solving skills,
stress-management skills, prosocial behavior, and social
support; that these programs can reduce the conse-
quences of risk factors, psychiatric symptoms, and sub-
stance use; and that they may have positive economic
effects. 
However, only a small proportion of these studies have
focused on possibilities for actually preventing the onset
of new cases of mental disorders.6 In recent years, a
growing number of studies have examined whether pre-
vention programs are actually capable of reducing the
incidence of cases of mental disorders as defined by
diagnostic criteria. In these studies a standardized diag-
nostic interview at baseline is used to exclude the pretest
presence of a full-blown depressive disorder and to
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examine the incidence of depressive disorders at follow-
up (again with a diagnostic interview). In the following,
we will review these studies.
Prevention of depressive disorders
Most research has focused on the prevention of depres-
sive disorders. Following the first studies conducted in
the 1990s,16-18 the number of studies has increased
rapidly since 2000. We recently conducted a meta-analy-
sis of these studies,19 and found a total of nineteen stud-
ies in which subjects with a depressive disorder accord-
ing to DSM criteria at baseline were excluded, and only
subjects with no formal depressive disorder were
included. All these studies examined whether the inci-
dence rate of mental disorders was reduced in the recip-
ients of preventive interventions compared with sub-
jects who did not participate in such an intervention. We
found that the overall incidence rate ratio was 0.78
(95% CI: 0.65~0.93). The incidence rate ratio is the inci-
dence rate of developing a depressive disorder in exper-
imental subjects relative to the incidence rate in control
subjects. An incidence rate ratio of 0.78 indicates a
reduction of the risk of developing a depressive disor-
der in the next year of about 22% compared with peo-
ple in the control groups. This study indicates that pre-
vention of new cases of depressive disorders is indeed
possible, and could be a realistic strategy to reduce the
enormous burden of these disorders, next to treatment
of existing depressive disorders. Preventive interven-
tions have been developed in several settings, including
the school setting, prevention of postpartum depression
in pregnant women, and prevention of depression in
general medical disorders. 
A considerable number of studies has examined the pos-
sibilities of prevention in the school setting.20,21 However,
most of these have only examined whether school pro-
grams are capable of reducing the overall level of
depressive symptoms in students. Although this is inter-
esting in its own right, and positive effects may be indica-
tive of effects on depressive disorders, the results of
these studies do not result in clear evidence of a pre-
ventive effect of these interventions on depressive dis-
orders. Until now, only four studies have examined pre-
ventive interventions aimed at the reduction of the
incidence of depressive disorders at school.17,22-24 Two
studies used a universal intervention aimed at all stu-
dents, regardless of whether they had an increased risk
of developing a depressive disorder.25,26 In both studies,
no significant effect on the onset of depressive disorders
was found. In three studies, the effects of an indicated
intervention were used examined,17,22,24 and these had
mixed results, with one study finding strong and signifi-
cant effects on the incidence of new depressive disorders
at 1-year follow-up.17 Most interventions in the school
setting, both universal and indicated, have used cogni-
tive behavioral group interventions. 
There is also a considerable number of studies that have
examined the possibilities of preventing postpartum
depression (PPD),27,28 but again most of these studies did
not use diagnostic criteria at pretest and post-test, to
exclude women who already had a depressive disorder
at pretest, and to examine the effects of prevention on
the incidence. Most studies have used self-report mea-
sures, and have only examined whether the level of
depressive symptoms have decreased in the prevention
groups compared with control groups. Many of these
studies used cognitive behavioral interventions,29-30
although other studies used psychoeducational inter-
ventions,31 debriefing,32 and interpersonal psychother-
apy.33,34 A recent meta-analysis of studies on prevention
of PPD did not find clear evidence that preventive inter-
ventions during pregnancy may reduce the incidence of
postpartum depression.27 This meta-analysis did not,
however, focus on studies in which women who met
diagnostic criteria for a depressive disorder were
excluded at pretest, and in which the incidence of
depression in treatment and control groups were estab-
lished according to diagnostic criteria. In the earlier
described meta-analysis, seven randomized controlled in
which diagnostic instruments were used, could be
included. These resulted in an incidence rate ratio of 0.65
(95% CI: 0.41~1.05; P<0.1).
Another group of studies has focused on the prevention
of depression in general medical disorders. Several
groups of general medical patients have been examined
in prevention studies, including adolescents with newly
diagnosed epilepsy and subthreshold depression (but no
major depressive disorder),35 older patients with neo-
vascular macular degeneration,36 and stroke patients.37
Three studies have examined the possibility of prevent-
ing depressive disorders in primary care.16,38,39 Most stud-
ies in this field used cognitive behavior therapy16,35,38 or
problem-solving therapy as intervention.36,37
One of the studies in primary care used a stepped-care
intervention. Such stepped-care interventions are inter-
Prevention and personalized medicine - Cuijpers Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
449
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 449
esting because they seem to have larger effects than sin-
gle interventions (with a reduction of the incidence of
50%),39 and because they devote most intervention time
to those who need it most. In such a stepped-care
approach, the first step is watchful waiting. This means
that no specific intervention is conducted for 6 to 8
weeks, because many subclinical depressive symptoms
recover spontaneously without intervention. In the sec-
ond step, a guided self-help intervention is provided to
patients. Guided self-help has been proven to be effec-
tive in the reduction of depressive symptoms,40 and may
be sufficient for some patients. If the guided self-help is
not sufficient and patients continue to have depressive
symptoms, a brief psychological intervention is provided,
such as problem-solving therapy, or a brief cognitive-
behavioral intervention. When this is not enough,
patients are referred to specialized mental health care
where they receive intensive treatment with antidepres-
sant medication.
Prevention of other mental disorders
Although most research has examined the effect of pre-
vention on the incidence of depressive disorders, a grow-
ing number of studies has examined the possibilities of
preventing the onset of anxiety disorders and psychotic
disorders in high-risk populations.
A considerable number of studies has examined the pos-
sibility of preventing the onset of post-traumatic stress
disorder (PTSD) with debriefing interventions.41
Unfortunately, many of these studies did not use diag-
nostic instruments to establish the presence of PTSD at
follow-up. However, the studies that have been con-
ducted seem to indicate that debriefing increases the risk
of developing PTSD, instead of decreasing this risk.41,42
Several other studies have examined the possibilities of
prevention of other anxiety disorders. In an early study
among patients with panic attacks who visited the emer-
gency room of a hospital, it was found that exposure
therapy had better outcomes than reassuring them that
there was no physical illness.43 In a more recent study
among persons with high levels of anxiety sensitivity, it
was found that preventive training consisting of psy-
choeducation and behavioral exercises significantly
reduced the risk of developing an anxiety disorder in the
following 2 years.44 In another study, it was found that
the incidence of panic disorder in people with sub-
threshold panic attacks is lower at 6 months' follow-up
in those who attended a 1-day preventive workshop
compared with those on a waiting list.45
In recent years, several studies have examined the effects
of preventive interventions on the onset of psychotic dis-
orders.46-49 In these studies, patients with subthreshold
symptoms of psychotic disorders (without meeting full
diagnostic criteria) are randomized to cognitive behav-
ior therapy or a control condition. These studies show
significant reductions of transition to psychotic episodes
in those who have received the preventive interventions,
compared with those in the control groups, although the
longer-term effects are not so clear.47,48
Problems in identifying target groups for pre-
ventive interventions
In the preceding paragraphs it was shown that a consid-
erable number of recent studies have examined the
effects of preventive interventions on the incidence of
mental disorders, and, when taken together, with con-
siderable success. However, the success of these inter-
ventions depends very much on the selection of the right
target populations. The first step in every intervention is
to select a target population which has an increased risk
of developing a mental disorder within the coming
months or year. In the following paragraphs, we will
explain why this selection of high-risk groups is very
complicated, and present some recently developed
methods in epidemiology to solve the problems in the
selection of target groups.
In the past few decades, an enormous body of research
has shown that many biological, psychological, and psy-
chosocial risk indicators are associated with the onset of
mental disorders. These include genetic factors, charac-
teristics of personality, social economic status, stress and
burden, urbanization, loneliness, life events, and somatic
factors, such as complications during pregnancy, devel-
opmental disorders, neuroendocrinological factors, and
general medical disorders. Note that we define these vari-
ables as risk indicators, and not as risk factors, as risk fac-
tors suggest that these are causally associated with the
onset of depressive disorders. Risk indicators only indi-
cate that there is an association between the variable and
the onset, while no causal association is assumed. In prin-
ciple, these risk indicators can be used to identify target
groups for preventive interventions. In the next part of
this paper, we will show that several groups of interven-
tions actually have focused on such high-risk groups.
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Although many risk indicators are known to be associ-
ated with the onset of mental disorders, most of them
have a low specificity. This low specificity implies that
most subjects who are exposed to the risk factor do not
develop the disorder, and that one such risk factor by
itself is not sufficient to bring the disorder into being.50,51
Furthermore, most risk indicators are related to lifetime
risk, while target populations for preventive interven-
tions must have an increased risk at the shorter term.
Suppose, for example, that the risk of developing a major
depressive disorder in the general population is 2.5% in
1 year.52,53 If a high-risk group has a relative risk of devel-
oping a depressive disorder of 4.00, this will be highly
significant (if the research population is large enough).
However, this means that still only about 10% of the
high-risk group will actually develop a depressive disor-
der, and about 90% will not. 
Many epidemiological researchers are satisfied after
finding a highly significant relative risk of 4.00, but from
the point of view of prevention this is clearly not
enough. A high-risk group will probably be difficult to
motivate for participation in a preventive program if
only 10% eventually will develop the disorder, apart
from the question of whether it is ethically acceptable to
identify such a population as being “at risk” when most
are in fact not at risk, or to intervene in such a popula-
tion when for the vast majority of participants the inter-
vention is not needed, and thus the time they spend on
it is, in a sense, wasted. Furthermore, such an interven-
tion is probably not very efficient or cost-effective,
because the majority will never develop a disorder and
the intervention has no preventive effect in this major-
ity. 
From the perspective of preventive intervention
research, this low specificity is also problematic because
very large numbers of subjects are needed to provide
sufficient statistical power for these intervention stud-
ies.51 Suppose, for example, that we would be able to
motivate people from the high-risk group (10% of
whom will develop a mental disorder in the following
year) to participate in a preventive intervention. In order
to show that such an intervention is capable of reducing
the incidence from 10% to 5% (a risk reduction of
50%), we would need about 950 persons in a controlled
trial (assuming a statistical power of 0.80; alpha level
0.05; calculations in STATA/SE 8.2). Trials of this size are
logistically complex, expensive, and have a high risk of
failure.
Towards an improved method of identifying
target groups for prevention
As previously stated, traditional indicators of the
strength between a risk indicator and the incidence of a
mental disorder are not sufficient when we want to iden-
tify the best target populations for preventive interven-
tions and to develop personalized interventions.
Improvements can be made by selecting target groups
while using indices other than odds ratios (ORs), rela-
tive risks (RRs) or incidence rate ratios (IRRs) alone,
and in particular by studying the cumulative effect of
joint exposures to several risk indicators rather than the
effect of a single risk indicator. The proposed method
can be carried out in several steps.
First, a set of significant risk indicators is identified such
that each of them has a statistically significant impact on
the likelihood that the disorder will develop. To do this
any of the available measures of association for binary
outcomes (OR, RR or IRR) can be used.
Second, if an OR can be calculated, then it is also possi-
ble to say how many people are exposed to that risk
indicator. Call this measure “exposure rate” (ER). For
prevention the ER is important, because it tells us how
many people have to be targeted by the preventive
intervention. Clearly, smaller groups (smaller ER) are
associated with less effort and hence lower costs of deliv-
ering the intervention.
Third, with the OR and ER in hand one can calculate
the population attributable fraction (AF). The AF indi-
cates by how many percent points the current incidence
rate of the mental disorder in the population could be
reduced when the adverse effect of the risk indicator is
completely blocked.54-56 This equals the maximum possi-
ble health gain of a completely successful preventive
intervention.
Fourth, if the OR can be calculated, then it is also possi-
ble to obtain the risk difference (eg, under a linear prob-
ability model) and its inverse: the number needed to
treat (NNT). In the context of these analyses the NNT
can be interpreted as the number of people who should
be the recipients of a preventive intervention to avoid
the onset of the disorder in one person. Again we have
to assume that the preventive intervention is completely
successful in containing the adverse effect of the risk fac-
tor. This assumption is not realistic, but the NNT may
still help to create a hierarchy of risk indicators to be tar-
geted in prevention.
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Now comes the most important part of the method. We
want to maximize the health gain (large AF) and mini-
mize the effort to generate this health gain by targeting
the smallest possible group (small ER) in the most effi-
cient way (small NNT). Best values overall can be found
by looking at combinations of risk indicators. That is, we
can see what combinations of exposures (joint expo-
sures) help to minimize and maximize the indices, such
that a target group is selected where prevention is most
likely to become cost-effective. 
There are several ways of finding specific combinations
of risk indicators, whether genetic or environmental, that
meet the above criteria, including sophisticated statisti-
cal techniques, such as classification and regression trees
(CART) analysis, and bootstrap aggregation (bag-
ging).57,58 The most straightforward method, which we use
here for illustrative purposes, is to select significant pre-
dictors of incidence (with standard techniques such as
logistic regression) after which all possible combinations
of these significant risk indicators are explored in terms
of maximizing the OR and AF, and minimizing ER and
NNT associated with each of the joint exposures. We
used this approach in a population-based sample of
older adults,54 and found that subjects with (subclinical)
depressive symptoms, functional limitations, a small
social network, and female gender comprised only 8%
of the total population (ER) while 24.2% of the new
incident cases could be attributed to this group (AF).
The number of subjects from this population that would
have to receive a preventive intervention in order to pre-
vent one incident case (NNT) was 4 (assuming that the
intervention is 100% successful). 
There is little doubt that these methods will help to iden-
tify the best target groups for preventive interventions
in the near future and to develop personalized inter-
ventions. However, at this moment these methods have
not yet been applied in intervention studies. 
Conclusion
This paper is intended to illustrate why prevention of
mental disorders is important. Reasons for its impor-
tance include its very high prevalence, incidence, disease
burden, and its huge economic costs of depression. It is
also important because current treatments can reduce
the disease burden only to a limited extent, even when
only evidence-based treatments are given and all
patients receive such an intervention. 
In the past 15 years a growing number of studies has
shown that interventions to prevent the onset of depres-
sive disorders are probably effective, and can reduce the
incidence by about one quarter. Prevention of anxiety
disorders and psychotic disorders may also be effective,
although the number of studies in these areas are lower.
It is not clear whether these preventive interventions
have actually prevented the onset of mental disorders
altogether, or only delayed the onset. In both cases, how-
ever, the health benefits of preventive interventions are
considerable.
In the next few years, the internet will probably provide
new opportunities for the broad implementation of pre-
ventive interventions, because access is easy, cheap, and
effective. Another important development is stepped-
care interventions, which are interesting because they
may have stronger effects than individual interventions
and spend most resources on those who need it most.
It has also been shown that traditional epidemiological
research can not identify the best target populations for
prevention. Relatively simple statistics, such as the expo-
sure rate, the population attributable fraction, and the
number needed to treat can be used to select those high-
risk groups which are as small as possible, but explain as
many of the new incident cases as possible. These meth-
ods will probably help in the further development of
personalized preventive interventions. ❏
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La prevención: un objetivo alcanzable en la
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he current complexity of treatments and out-
comes in modern medicine presents a fundamental
dilemma. Few medical treatment decisions involve a clear
best choice; the typical medical decision involves trade-
offs among multiple partially effective interventions with
different risks. Consider the case of surgical interventions.
Placing a pin in a fractured hip represents a rare case of
a consensual best treatment for almost every patient. In
many other common surgical situations, the evidence is
considerably more complicated. For example, surgery for
benign prostatic hypertrophy produces better urine flow
at the risk of incontinence and impotence. When men
understand the tradeoffs accurately, many prefer med-
ications or watchful waiting.1 Similarly, for early breast
cancer, spinal disk injury, prostate cancer, rotator cuff
injuries, uterine fibroids, coronary artery disease, and
many other surgical conditions, choice among different
interventions with complex outcomes and adverse effects
is the rule.2 This fundamental dilemma gives rise to the
belief that patients should be involved in making medical
decisions generally, and to the paradigm of shared deci-
sion making more specifically.
Shared decision making assumes that two experts (or
teams of experts) should collaborate in making complex
medical decisions.3 The health care provider (often a team
of professionals) brings expertise in understanding the
medical problem, the possible interventions, and the
potential benefits and risks of alternatives. The patient
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This paper describes the shared decision-making model,
reviews its current status in the mental health field, and
discusses its potential impact on personalized medicine.
Shared decision making denotes a structured process
that encourages full participation by patient and
provider. Current research shows that shared decision
making can improve the participation of mental health
patients and the quality of decisions in terms of knowl-
edge and values. The impact of shared decision making
on adherence, illness self-management, and health out-
comes remains to be studied. Implementing shared deci-
sion making broadly will require re-engineering the flow
of clinical care in routine practice settings and much
greater use of information technology. Similar changes
will be needed to combine genomic and other biologi-
cal data with patients’ values and preferences and with
clinicians’ expertise. The future of personalized medicine
is clearly linked with our ability to create the infrastruc-
ture and cultural receptivity to these changes.  
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(often assisted by family or support network members)
brings expertise related to understanding the individual’s
values, goals, supports, and preferences. Shared decision
making generally involves both partners presenting their
respective views and then negotiating a plan that both
agree is ethical, consistent with the evidence, congruent
with the patient’s preferences, and practical. Conceptually,
shared decision making falls between two extreme
approaches to medical decision making: the paternalis-
tic and the autonomous decision models.4 In the tradi-
tional, paternalistic model, the physician assesses what is
best for a particular patient, based on scientific evidence
and clinical judgment, and makes the decision. In the
autonomous decision model, the patient is presented with
information, weighs the information, and makes the
choice unilaterally.
As a simple example of shared decision making, con-
sider a young woman who suddenly develops radiating
pain as a result of a back injury. Her medical exam and
magnetic resonance imaging reveal a lumbar disk pro-
trusion. Her physician describes alternative approaches
that include surgery, nerve blocks, a back brace, physical
therapy, and watchful waiting. The patient and her par-
ents are averse to surgery, especially when they under-
stand the risks, and prefer conservative treatment. The
physician agrees that wearing a brace and waiting for 2
months to re-evaluate the injury is reasonable. Two
months later, she is much improved, and they agree that
exercise is the best strategy.
Now consider a more complex decision. A second young
woman develops a breast lump and is diagnosed with
uncomplicated early breast cancer. Her physician reviews
with her the surgical alternatives (lumpectomy vs breast
removal) as well as adjunctive chemotherapy and radi-
ation therapy, and describes the risks and benefits of
each. Due to the early stage of illness, the physician
clearly believes that the patient is an excellent candidate
for lumpectomy. Because of a strong family history and
the experience of watching her mother die of breast can-
cer, however, the young woman prefers bilateral mas-
tectomy. After further discussion with the patient and her
husband, the physician understands and accepts the
patient’s decision and performs the more radical surgery.
In this case, the physician initially disagrees with the
patient’s choice but accepts the patient’s preference and
right to make the decision.
The medical literature and research evidence on shared
decision making, decision supports, and decision aids are
extensive and growing rapidly.5 For example, there are
now literally hundreds of decision aids to help patients
make medical decisions. The diversity of these instru-
ments has led recently to the development of interna-
tional standards.6 The evidence shows that decision aids
help patients to make more informed decisions that are
more congruent with their values and preferences.7
Longer-term effects on basic health outcomes are not yet
well studied. 
Shared decision making in 
mental health: current status
Several arguments suggest the importance of shared
decision making in mental health. First and foremost,
effective mental health care should be person-centered.8,9
As is true with other long-term illnesses,10,11 empowering
people to be knowledgeable and active in managing their
own mental illnesses is critical.12 Decisions related to
chronic illnesses differ from acute-care decisions in sev-
eral ways: for example, there are many opportunities to
make and revisit the decisions, and the patient must take
much greater responsibility in carrying out decisions
daily.10 Because of personal values and subjective
responses, patients themselves can best evaluate trade-
offs in efficacy and side effects.13,14 In mental health,
shared decision making enhances the working relation-
ship needed to optimize long-term outcomes.15 For exam-
ple, learning to manage one’s illness with medications
involves a dynamic, longitudinal process that encom-
passes resolving decisional conflicts, conducting experi-
ments, balancing positive and negative effects, and mak-
ing changes. A close working alliance between
practitioner and client is the sine qua non of success.
In addition to these practical concerns, others have made
ethical and legal arguments for shared decision making.
Autonomy—the right to make decisions regarding one’s
body—has long been a fundamental principle of Western
medical ethics.16 Recognizing the importance of auton-
omy, the legal standard for medical care is shifting from
informed consent to informed choice among reasonable
alternatives.17 
Most mental health patients express a desire to partici-
pate in making decisions regarding medications and hos-
pitalizations.18-21 Nevertheless, shared decision making is
not prominent in widely disseminated psychiatric med-
ication algorithms22 and not usually practiced in daily
medication management.15 Patients with severe and per-
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sistent mental illnesses report that their perceived role in
making medical decisions is usually passive.18,21,23 Further,
many psychiatrists consistently report that shared deci-
sion making is not applicable to decisions regarding med-
ications and hospitalizations due to patients’ decisional
incapacity.24,25
At the same time, the evidence in support of shared deci-
sion making in mental health is expanding rapidly. First,
nearly all psychiatric patients, even the great majority of
those with the most severe disorders such as schizophre-
nia, are capable of understanding treatment choices and
making rational decisions.26-28 Like many other patients
with limited education, learning disorders, or other dis-
advantages, some require repetition of information or
multimodal sources of information.29 Also, some psychi-
atric patients experience temporary decisional incapac-
ity, such as during psychotic episodes, and may elect to
establish psychiatric advanced directives to cover such
periods of decisional incapacity.30
Second, shared decision making constitutes a core prin-
ciple of many effective mental health practices and may,
in part, explain their effectiveness.12,31-33 For example, hon-
oring the client’s preference for type of job is a funda-
mental principle of supported employment, and the
entire model follows the client’s decisions about when to
search for a job, how many hours to work, whether or not
to disclose illness to the potential employer, supports on
the job, manner of follow-up, and so on.34 Emphasis on
shared decision making is also built into illness manage-
ment and recovery,12 behavioral family therapy,35 inte-
grated dual disorders treatment,36 and systematic med-
ication management.37 Assertive community treatment,
which was historically criticized for paternalism, is also
becoming more client-centered.38
Third, although research on shared decision making in
mental health is in its infancy, seven initial randomized
controlled trials support its effectiveness. Malm et al39
provided multiple shared decision-making sessions within
a treatment program for schizophrenia patients, and
found that the experimental group had higher ratings of
patient satisfaction than controls at 2 years. Van Korff et
al40 provided multiple sessions of shared decision making
to depressed patients, and found better adherence and
depression symptom outcomes favoring experimental
over control participants at 3, 6, 9, and 12 months. Van Os
et al gave one session of shared decision making to
patients with schizophrenia and their doctors in a ran-
domized clinical trial and found that the experimental
patients reported improvements in quality of patient-
doctor communication and that the intervention induced
changes in medication management immediately.41
Hamann et al42 conducted a randomized controlled trial
with schizophrenia inpatients and found increased
knowledge and perceived involvement in decisions by
the experimental group during hospitalization. Priebe et
al43 used a cluster randomized design to study use of a
computer-mediated intervention to structure patient-clin-
ician interactions regarding quality of life and needs for
care every 2 months for a year. Schizophrenia patients in
the experimental group had better subjective quality of
life, fewer unmet needs, and greater satisfaction with
treatment at 1 year. Loh et al44 used a cluster randomized
design to study a shared decision-making intervention
with depressed patients. At 6- to 8-week follow-up, exper-
imental group patients reported greater participation in
decision making and greater satisfaction with care,
although the intervention did not impact severity of
depressive symptoms. Joosten et al45 used a cluster ran-
domized design to study shared decision making within
inpatient addiction treatment programs. Patients who
received shared decision making rather than traditional
decision making had greater reductions in drug use and
psychiatric symptoms at 3-month follow-up. Woltmann46
used a cluster randomized design to study shared deci-
sion making during one session of treatment planning
between case managers and clients with severe and per-
sistent mental illnesses. Clients and case managers in the
shared decision-making group were more likely to report
that decisions were collaborative. 
Thus, as in general medicine, the initial research in men-
tal health shows that shared decision making increases
the quality of decisions (knowledge, participation, and
congruence with values), but there is minimal evidence
regarding objective health outcomes. Long-term studies
of health outcomes related to greater knowledge, partic-
ipation in illness self-management, and better relation-
ships with practitioners need to be evaluated. 
The doctor’s role in shared decision making
In this section, we illustrate some of the barriers to imple-
menting shared decision making in mental health by
examining the outpatient psychiatrist’s role. The central
point is that practising shared decision making involves
much more than endorsing the concept. The complex
structure and process of care must support the desired
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practice. To achieve shared decisions, psychiatrists and
patients need significant time,4 facilitated communica-
tion,47 and easy access to clinically useful current scientific
knowledge.48 These conditions do not currently exist in
psychiatric office practice in the US. Therefore, the
process of care will need to be redesigned to make shared
decision making the easy and natural way to practice.49
Psychiatric office visits are complex and dynamic inter-
actions that are packed with psychological, interpersonal,
and practical tasks. These include establishing a trusting
relationship; identifying goals for the encounter; gather-
ing needed information, such as assessing and addressing
symptoms, function, and/or side effects of treatment;
planning the next steps; documenting the encounter; pre-
scribing medications; communicating with other
providers; and filling out forms.50 The time for shared
decision making must come from time usually spent on
these other tasks because expanding visit length is cur-
rently prohibited by costs.
Addressing the time dilemma will require re-engineering
office practice and using information technology.51 At the
microsystem level, a trained and organized team (an acti-
vated patient, support from other staff, and a well-designed
information system) can create efficiencies in the flow of
the office visit.52 Team members other than the psychiatrist
can elicit and record the patients’ current concerns, expe-
riences, and values.53 They can also obtain required vital
signs, track down lab values, fill out sections of forms the
psychiatrist needs to sign, prepare prescriptions for physi-
cian review and signature, and help the patient to be as
active as possible, including direct participation in collect-
ing information through patient portals to the electronic
medical record. A well-designed electronic medical record
can increase efficiency (and improve care) by collecting
and graphically displaying patient-entered information,
laying out evidenced-based treatment algorithms, and
streamlining common required tasks such as clinical doc-
umentation, prescription writing, and clinical communica-
tion to other health care providers.54
Many people, including both those with and without psy-
chiatric symptoms, find it difficult to express themselves
in doctors’ offices. The medical care process is not trans-
parent, and people do not naturally know what informa-
tion is relevant and important to communicate. Further,
medical settings are often intimidating, and people are
nervous. Nevertheless, the voice of the patient must be at
the heart of the decision-making process. Without hear-
ing the patient’s chief current concerns, subjective life
experiences, and core values, decisions lack both data and
salience to the patient’s life.55
Currently, all information about the patient’s perspective
comes from the dialog between the psychiatrist and the
patient during the busy office visit. Important issues, such
as whether the patient’s chief concerns for the session are
routinely elicited and whether the patient experience is
gathered in a valid, reliable manner, are up to self-
designed practice habits of the psychiatrist.55 Without a
system designed to elicit, organize, and amplify the voice
of the patient, the psychiatrist can easily miss information
that would make the clinical decisions much more
informed, relevant, and collaborative.
Re-engineering the office could facilitate communication
in three ways. First, the redesign could increase the con-
fidence and ability of patients to be active participants in
the care process by explicitly welcoming them when they
arrive for service, orienting them to the care process, and
providing accessible education on the illnesses and the
treatment options. Second, the patient’s voice could be
amplified by explicitly eliciting and documenting chief
concerns, experiences, and core values. If this inquiry
occurs before the actual encounter, the information is
more likely to be complete, the patient’s questions will
be written down so they are not forgotten, and the visit
time is freed up for double-checking understanding and
for in-depth discussion. Finally, symptoms, medication
side effects, and functional status questions can be asked
in a systematic fashion using standardized instruments by
computer,55,57,58 and the longitudinal results can be dis-
played graphically. Computerization allows the patient
and the psychiatrist to examine progress and base dis-
cussions on longitudinal standardized data as a team,
practising individualized evidence-based medicine.
The essence of evidence-based practice is to use knowl-
edge gained through research to inform specific clinical
choices. Decision supports are more likely to be used if
information is available in the regular flow of the office
visit. Connecting the patient and the psychiatrist with the
evidence at the time that it is needed and in a form that
both can understand is therefore another critical element
of redesigning the office visit to facilitate shared decision
making.49
Both patients and psychiatrists need timely access to
research findings. Patients can benefit from orienting
information about the illnesses and what is known about
options to minimize symptoms and maximize function.
Psychiatrists and patients together can benefit from
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research-supported charts and algorithms that condense
whole fields of knowledge into research-supported paths
for care.59,60 Psychiatrists also need direct access to
detailed information when it is too voluminous or com-
plex to remember. Currently, this includes decision sup-
port in the form of drug-drug interactions that appear as
safety warnings in electronic records. Soon, it will encom-
pass individualized medicine: historical, medical, physio-
logical, and genetic information that will summarize
patient-specific risk factors.
The needs of people with severe and persistent mental
illnesses do not vary radically from site to site. Therefore,
a transformational psychiatrist office visit process that
weaves together all the elements that are needed for effi-
cient evidence-based psychiatric practice could be
designed, tested, packaged, and implemented widely.
Doing so shifts the office visit process to one that is
specifically designed to meet the needs of people who
have an ongoing psychiatric illness or vulnerability using
principles that have been shown to be helpful in improv-
ing the care of people with other persistent health diffi-
culties.61
Personalized mental health care 
and shared decision making
Creating a flow of care that makes sharing decisions nat-
ural and efficient will be even more important when we
have access to tests that will provide us with person-level
information that is relevant to mental health care deci-
sions. The current state of treatment selection in mental
health is characterized by multiple choices, with little evi-
dence to guide decisions to select initial or subsequent
treatments.62,63 Genetic or molecular factors might help
inform treatment selection by identifying a priori people
likely to have side effects, such as treatment-emergent
suicidal ideation in response to antidepressants,64 or
metabolic syndromes with antipsychotic treatment.65
Genetic testing might also identify people needing par-
ticularly low or high doses of medications,66 people more
likely to attain remissions,67,68 or even people more likely
to respond to a certain medication mechanism of action.69
Identification of individual genetic or molecular factors,
in the future, may help establish diagnoses in people with
subsyndromal symptoms or unclear diagnoses, as well as
further inform asymptomatic relatives of people with
mental illnesses in making reproductive decisions and
personal lifestyle choices.70
At the same time, information of this type might also cre-
ate social and psychological risks and pessimism in regard
to the effectiveness of treatments.71 Potential adverse con-
sequences could affect emotional well-being, family rela-
tionships, employment, and insurance.72,73 Thus, the poten-
tial of psychiatric genomics has fueled ongoing ethical
and legal debates.74,75
The availability of such complex information needs to be
paired with a structured system of communicating the
benefits and the risks of testing to patients to allow its
effective incorporation into the process of shared med-
ical decision making. In other areas of medicine, studies
of communication of genetic information to patients have
identified the importance of education, risk communica-
tion, and emotional support.76-78
Genetic information dramatically increases the com-
plexity of risk. In cancer genetics, Huiart et al79 outlined
the difference between the individual risk of inheriting
or transmitting predisposing genes and the individual
risk of developing the disease. This is highly relevant for
mental health, as most neuropsychiatric disorders are
polygenic, and any single gene variation may have min-
imal impact on individual risk. Gene variations can have
additive effects on the expression of a phenotype,80 or a
certain gene variation might be expressed only through
interaction with the environment.81 The ability of a test
to identify gene variation might be different from 
its ability to identify the phenotype of interest.
Furthermore, for example in cytochrome system testing,
identifying a certain phenotype, such as slow metabo-
lizers, may or may not have clinical utility, depending on
other factors, such as ethnicity or the medication choice
involved.66
As in other areas of medicine, communicating the mean-
ings of uncertainty, risk, and statistics in mental health
conditions is difficult.82 Patient education needs to include
not only information about choices but also information
to enhance statistical literacy. Several research findings
have helped this field. For example, using absolute risks
rather than relative risks and transforming probabilities
into natural frequencies displayed as pictograms facili-
tate communication and understanding.83,84
Specialized genetic counselors have traditionally pro-
vided risk information in medical genetics. More
recently, decision aids focused on risk communication
and patient education have become prominent.77,85 A
recent review of risk communication interventions found
that decision aids improved knowledge, but did not nec-
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essarily decrease anxiety.77 Availability of decision aids
prior to the encounter with a clinician did, however,
increase time for discussion of personal risk rather than
education.86
Individual counseling has been identified as an important
element of genetic communication to improve risk per-
ception and to address the psychological and social
effects of genetic testing on the patient and the fam-
ily.71,77,87,88 Inaccurate perceptions of risk after communi-
cation were associated with the psychological health of
the individual.79 One-on-one counseling was associated
with reduced decision conflict in general medicine,89 but
research on counseling related to genetic risk in mental
health has not yet been done. Joint psychiatrist-genetic
counselor consultation and family–based approaches
have been proposed in mental health.90
Psychiatrists, as well as other medical providers, score low
on scales of patient involvement in decision making,91
perhaps in part because traditional genetic counseling
has been based on autonomous choice models.92
Increased patient activation was described when men-
tal health patients’ own strategies for well-being and
recovery were identified and supported.15 In general,
patients expect and prefer help with decision making in
studies of genetic information communication.78,93
Shared decision making in mental health will need to
incorporate, in the future, effective communication
regarding genetic and molecular testing. Structured
assessments prior to the consultation will facilitate
expression of the patient’s goals and values, including
goals for genetic testing. Decision aids provided prior
to the consultation could increase patients’ knowledge
and individualize information. The encounter with a
provider should facilitate risk communication and deci-
sion making. 
Limitations
The barriers to shared decision making are legion.94
Clinicians lack familiarity and training, sometimes dis-
agree with the concept, and often have concerns regard-
ing decisional capacity and legal responsibility. Patients
often lack the information, empowerment, motivation,
and self-efficacy needed to participate in shared decision
making. Mental health systems almost universally lack
the needed computer infrastructure. At a basic science
level, concerns involve communicating uncertainty and
risk, biases in many decision aids, and human biases in
decision making in general.95,96 For example, mental
health patients, like others, are biased by optimism
regarding their own health, are confused by too many
choices, have difficulties understanding statistical risks,
and are influenced by biased information from industry.
These issues need to be clarified by further research and
addressed at many levels: basic decision-making science,
clinician training, structural implementation, electronic
infrastructure, patient empowerment, and so forth. 
Summary and conclusions
Implementing shared decision making in routine mental
health care offers considerable promise in terms of ethics,
quality, informed decisions, patient satisfaction, enhanced
ability for self-management, improved adherence, and
meaningful outcomes. Putting these potentialities into
everyday practice will be fraught with difficulties. Now is
the time to address these barriers through research on
shared decision making, as the information explosion and
personalized medicine will require new educational
structures, communication patterns, and decision-making
forms.  ❏
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La toma de decisiones compartidas en salud
mental: perspectivas para la medicina 
personalizada
Este artículo describe el modelo de la toma de deci-
siones compartidas, revisa su situación actual en el
campo de la salud mental y discute su potencial
impacto en la medicina personalizada. La toma de
decisiones compartidas traduce un proceso estruc-
turado que fomenta la participación total del
paciente y del proveedor. La investigación actual
muestra que la toma de decisiones compartidas
puede mejorar la participación de los pacientes
mentales y la calidad de las decisiones en términos
del conocimiento y los valores. Se debe estudiar el
impacto de la toma de decisiones compartidas en la
adherencia, el auto manejo de la enfermedad y las
consecuencias en la salud. La implementación de la
toma de decisiones compartidas en líneas genera-
les requerirá de una reingeniería del circuito de la
atención clínica en los ambientes de práctica coti-
diana y un mayor empleo de la tecnología de la
información. Se necesitarán cambios similares para
combinar datos genómicos y otros datos biológicos
con los valores y preferencias de los pacientes, y con
la experiencia de los clínicos. El futuro de la medi-
cina personalizada está claramente relacionado con
nuestra capacidad de crear la infraestructura y la
receptividad cultural a estos cambios.   
Prise de décision partagée en santé 
mentale : en quête d’une médecine 
personnalisée
Cet article décrit le modèle de prise de décision par-
tagée, le resitue dans le cadre actuel de la santé
mentale et analyse son influence potentielle dans
la médecine personnalisée. La prise de décision par-
tagée est un processus structuré qui encourage la
participation entière du patient et du médecin. La
recherche actuelle montre que cette prise de déci-
sion peut favoriser la participation des patients psy-
chiatriques et la qualité des décisions en termes de
connaissances et de valeurs. Il faut en étudier l’in-
fluence sur l’adhésion au traitement, la prise  en
charge individuelle de la maladie par le patient et
l’évolution deson’état de santé. La mise en œuvre
étendue de cette prise de décision partagée néces-
sitera de réorganiser les soins cliniques dans le cadre
d’une pratique de routine et d’ utiliser de manière
plus importante les technologies de l’information.
Associer la génomique et les autres données biolo-
giques avec les préférences des patients et l’expé-
rience des médecins demandera également des
changements.  L’avenir de la médecine personnali-
sée dépend clairement de notre capacité à créer
l’infrastructure et la réceptivité culturelle à ces
changements.
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Personalized medicine: selected Web resources
Nancy F. Stimson, MLS
ince the completion of the Human Genome
Project in 2003, interest in “personalized medicine”
and the quantity of journal literature and Web
resources related to this topic has been burgeoning.
Former US Department of Health and Human
Services (HHS) Secretary, Michael O. Leavitt, made
personalized medicine one of his priorities, and the US
President, Barack Obama, was the author of the
Genomics and Personalized Medicine Acts of 2006 and
2007. The attention and energies of these two high-
level officials, as well as many others, have contributed
to the continued US support for this research agenda.
Kathleen Sebelius succeeded Michael O. Levitt as
HHS Secretary on April 28, 2009. On May 5, 2009, a
coalition representing more than a hundred genetic
testing laboratories, patient advocates, investors, and
health policy researchers sent the Secretary a letter
describing their issues and concerns regarding person-
alized medicine. 
As stated on the HHS personalized health care Web
site, “Virtually every agency in the US Department of
Health and Human Services participates actively in ini-
tiatives that are working toward the long-term goals of
personalized health care. The integration of these
efforts will act as a powerful force to achieve personal-
ized patient care.” The HHS issued two reports on US
efforts related to personalized medicine. The first
report (2007) “included summaries of federal efforts in
the areas of expanding the science base for personal-
ized health care; supporting health information tech-
nology; regulatory responsibilities; implementing per-
sonalized medical products and services in clinical
practice; and ethical, legal and social issues.” The sec-
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Information about personalized medicine abounds, yet it
is difficult to comprehensively search for information on
this topic due to the broadness of the term “personalized
medicine,” the variety of terms that are used to describe
this concept, the vast amount of pertinent journal articles
and Web sites, and the fast pace of developments in this
field. A selected list of Web sites is provided as a starting
place for information about concepts, terminology, pro-
jects, databases, tools, and stakeholders related to per-
sonalized medicine.
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:464-468.
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ond report (2008) “seeks to bring into focus a sampling
of activities that are now underway in different parts of
the private and academic health care sectors toward
integrating personalized health care into clinical prac-
tice.”
• HHS Personalized Health Care Initiative, US
Department of Health and Human Services
[http://www.hhs.gov/myhealthcare/] 
• HHS Secretary's Advisory Committee on Genetics,
Health & Society (SACGHS) 
[http://oba.od.nih.gov/sacghs/sacghs_home.html] 
• "Personalized Health Care: Opportunities, Pathways,
Resources," US Department of Health and Human
Services, September 2007 
[http://www.hhs.gov/myhealthcare/news/phc-report.pdf]
• "Personalized Health Care Pioneers, Partnerships,
Progress," US Department of Health and Human
Services, November 2008 
[http://www.hhs.gov/myhealthcare/news/
phc_2008_report.pdf] 
• Letter to HHS Secretary, Kathleen Sebelius, May 5,
2009
[http://www.dnapolicy.org/resources/LtrtoSecSebelius
rePersonalizedMedicine.pdf]
Another important milestone on the road to attaining
personalized medicine was the passage of the US
Genetic Information Nondiscrimination Act (GINA)
which was signed into law in May 2008, and was
designed to prohibit the improper use of genetic infor-
mation in health insurance and employment.
• H.R. 493, Genetic Information Nondiscrimination Act
of 2008 
[http://thomas.loc.gov/cgi-
bin/bdquery/z?d110:HR00493:@@@L&summ2=m&]
Terminology
How can researchers and clinicians sift through the
petabytes of information on the internet to find relevant
information about personalized medicine? At the time of
writing, a keyword search for “personalized medicine” in
PubMed reveals hundreds of articles published in the last
year alone, and that reflects just a tiny percentage of the
articles on this topic. A Google search for the phrase
“personalized medicine” now reveals over 500 000 results
and that, too, is just the tip of the iceberg. Why are these
search engines finding such a small percentage of the
available information? The concept of personalized med-
icine is a broad one, and one that can be represented by
many different terms and spellings such as personalized
medicine, personalised medicine, personalized health
care, personalized healthcare, individualized medicine,
etc. In addition, there are many narrower topics, or
related topics, covered by this umbrella term such as
pharmacogenomics, biomarkers, neuromarkers, microar-
ray analysis, single nucleotide polymorphism (SNP) pro-
filing, electronic health records, and many more. The pro-
liferation of “-omics” terms such as genomics,
pharmacogenomics, proteomics, epigenomics, nutrige-
nomics, agrigenomics, metabonomics—even neuroge-
nomics—is one signal of the infiltration of genomics into
many different fields.1 Another indicator is the number
of recently published journals specifically dedicated to
this topic that were started after 2002 (eg, Personalized
Medicine, Current Pharmacogenomics and Personalized
Medicine, Human Genomics and Proteomics, Genome
Medicine, Genomic Medicine, BMC Medical Genomics,
The Open Genomics Journal, etc). 
When searching PubMed for articles, it is often useful to
search using National Library of Medicine Medical
Subject Headings (MeSH) which are used to consis-
tently categorize article references, and bring together
references on a topic. If there is a good MeSH term (or
terms) for a particular topic, researchers do not have to
think of every single keyword and synonym that authors
might have used to describe that concept. However,
there is not a single MeSH term that covers the broad
topic of personalized medicine, and existing MeSH
terms such as “Pharmacogenetics,” “Patient-Centered
Care,” “Genomics,” “Genome, Human,” “Genetics,
Medical,” “Proteomics,” “Biomarkers,” and “Medical
Records Systems, Computerized” vary in how consis-
tently they are applied. 
Definitions of particular terms vary, also. It is hard to
find a standard definition of many terms, including “per-
sonalized medicine,” and sometimes people confuse one
term with another (eg, “pharmacogenetics” vs “pharma-
cogenomics”).2 The issue of terminology concerns every-
one: researchers, clinicians, public policy decision mak-
ers, bioinformaticists, and laypeople, as well as other
stakeholders. The US National Human Genome
Research Institute, and US National Cancer Institute
have created useful glossaries:
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• Talking Glossary of Genetic Terms, US National
Human Genome Research Institute 
[http://genome.gov/10002096] 
• Dictionary of Cancer Terms, US National Cancer
Institute 
[http://www.cancer.gov/dictionary/]
There is an excellent glossary in the new, comprehensive,
two-volume book set, Genomic and Personalized
Medicine, which was published by Elsevier/Academic
Press in 2009.3 This book set, available in print or elec-
tronically through ScienceDirect, is an excellent starting
place for people who are trying to get an understanding
of the many concepts and issues that comprise personal-
ized medicine. The former US HHS Secretary, Michael
O. Leavitt, wrote the foreword to this book. Section 12 of
this book, titled “Neuropsychiatric Disease Genomic
Medicine,” includes eight chapters that discuss dementia,
Parkinson's disease, epilepsy, ophthalmology, neuromus-
cular disorders, psychiatric disorders, depression, and
bipolar disorder.
• Genomic and Personalized Medicine
[http://www.science-direct.com/science/book/
9780123694201]
In short, the terminology that is used in article databases
such as PubMed as well as on various Web sites is wide-
ranging and makes it difficult to pull all of the relevant
information on this topic together. 
Additional Web resources
There are thousands of Web sites that pertain to personal-
ized medicine and its subtopics. Any collection, especially
one in a “brief report” such as this, is necessarily a “selected”
list. The following Web sites are provided as a sample of the
range of projects and Web sites that are available: 
US National Institutes of Health (NIH) 
• National Human Genome Research Institute 
(NHGRI) 
[http://genome.gov] 
• PhenX Toolkit, NHGRI 
[https://www.phenxtoolkit.org/] 
• ENCODE Project: ENCyclopedia of DNA Elements,
NHGRI 
[http://www.genome.gov/ENCODE/]
• Ethical, Legal, and Social Implications ELSI Research
Program, NHGRI 
[http://www.genome.gov/10001618] 
• Human Genome Project, NHGRI 
[http://www.genome.gov/10001772] 
• Pharmacogenetics Research Network, National
Institute of General Medical Sciences (NIGMS)
[http:www.nigms.nih.gov/pharmacogenetics]
• Environmental Genome Project, National Institute of
Environmental Health Sciences (NIEHS) 
[http://www.niehs.nih.gov/research/supported/
programs/egp/]
• NIH Chemical Genomics Center 
[http://www.ncgc.nih.gov/] 
• NIH Data Sharing Policy for Genome Wide
Association Studies (GWAS) 
[http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-07-088.html]
• NIH Roadmap for Medical Research 
[http://nihroadmap.nih.gov] 
NIH neurosciences-related resources
• NIH Blueprint for Neuroscience Research 
[http://neuroscienceblueprint.nih.gov/] 
• National Institute of Neurological Disorders and Stroke
(NINDS): Clinical and Translational Resources 
[http://www. ninds.nih.gov/research/scientific_resources/
clinical/] 
• Neuroscience Information Framework (NIF) 
[http://www.neuinfo.org/] 
National Center for Biotechnology Information
(NCBI) databases
• Entrez - All Databases 
[http://www.ncbi.nlm.nih.gov/sites/gquery]
• Human Genome Resources 
[http://www.ncbi.nlm.nih.gov/projects/genome/ 
guide/human/] 
• Online Mendelian Inheritance in Man (OMIM) 
[http://www.ncbi.nlm.nih.gov/omim/] 
• Entrez Gene 
[http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene]
• Database of Genotypes and Phenotypes 
(dbGaP)
[http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap]
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 466
467 www.dialogues-cns.org
Personalized medicine Web resources - Stimson Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
• Gene Expression Omnibus 
[http://www.ncbi.nlm.nih.gov/geo/]
• PubChem 
[http://pubchem.ncbi.nlm.nih.gov/]
• NCBI BioSystems 
[http://www.ncbi.nlm.nih.gov/biosystems/]
Other US federal government agency resources
• HHS Personalized Health Care: Federal Activities
[http://www.hhs.gov/myhealthcare/activities/]
• HHS CDS Collaboratory 
[http://healthit.hhs.gov/portal/server.pt?open=
512&objID=1230&parentname=CommunityPage&
parentid=1&mode=2&in_hi_userid=10741&cached=
true] 
• CDC Public Health Genomics 
[http://www.cdc.gov/genomics/] 
• CDC Evaluation of Genomic Applications in Practice
and Prevention Initiative 
[http://www.cdc.gov/genomics/gtesting/EGAPP/
about.htm] 
• CDC Human Genome Epidemiology Network 
(HuGENet) 
[http://www.cdc.gov/genomics/hugenet/default.htm] 
• CDC HuGE Navigator 
[http://www.hugenavigator.net/] 
• CDC Genomics Workforce Competencies 
[http://www.cdc.gov/genomics/training/competencies/]
Nonprofit organizations
• Personalized Medicine Coalition 
[http://www.personalizedmedicinecoalition.org/]
• Genetic Alliance 
[http://www.geneticalliance.org/]
• Coalition for 21st Century Medicine 
[http://www.twentyfirstcenturymedicine.org/
index.shtml]
Resources for the general public
• Genetics Home Reference 
[http://ghr.nlm.nih.gov/]
• "From Genes to Personalized Medicines," National
Institutes of Health 
[http://www.nih.gov/about/researchresultsforthe
public/Genes_PersonalizedMed.pdf]
• "Genetics, Disease Prevention and Treatment,"
National Human Genome Research Institute 
(NHGRI) 
[http://www.genome.gov/19016938] 
• MedlinePlus: Genes and Gene Therapy 
[http://www.nlm.nih.gov/medlineplus/
genesandgenetherapy.html]
Commercial companies targeting the general public
• deCODEme 
[http://www.decodeme.com/] 
• 23andMe 
[https://www.23andme.com/]
• Navigenics 
[http://www.navigenics.com/]
Miscellaneous resources
• Morningside Initiative, American Medical Informatics
Association (AMIA) 
[http://www.amia.org/inside/initiatives/cds]
• "The Roadmap for National Action on Clinical
Decision Support," AMIA 
[http://www.amia.org/files/cdsroadmap.pdf]
• National Coalition for Health Professional Education
in Genetics (NCHPEG) 
[http://www.nchpeg.org]
• BIG Health Consortium 
[http://bighealthconsortium.org/]
• J. Craig Venter Institute 
[http://www.jcvi.org/]
• UCSC Genome Bioinformatics 
[http://genome.ucsc.edu/]
• GenMAPP: Gene Map Annotator and Pathway
Profiler 
[http://www.genmapp.org/]
• Bioconductor: Open Source Software for
Bioinformatics 
[http://www.bioconductor.org/]
• Brain Research and Integrative Neuroscience
Network (BRAINet) 
[http://brainnet.net/]
• Allen Brain Atlas, Allen Institute for Brain Science
[http://www.brain-map.org/]
Although this article focuses primarily on US projects
and Web sites, progress towards making personalized
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medicine a reality is an international effort, as is
reflected by this sample of project and tool Web sites:
International and non-US resources
• 1000 Genomes Project 
[http://www.1000genomes.org/page.php]
• Human Variome Project 
[http://www.humanvariomeproject.org/]
• International HapMap Project 
[http://www.hapmap.org/index.html.en]
• Structural Genomics Consortium 
[http://www.thesgconline.org/]
• GeneCards 
[http://www.genecards.org/]
• Ensembl Human Genome Browser 
[http://www.ensembl.org/Homo_sapiens/Info/]
• ArrayExpress Database 
[http://www.ebi.ac.uk/microarray-as/ae/]
• International Sequencing Consortium 
[http://www.intlgenome.org/]
• European Bioinformatics Institute 
[http://www.ebi.ac.uk/]
• Swiss Institute of Bioinformatics 
[http://www.isb-sib.ch/]
• Max Planck Institute for Molecular Genetics 
[http://www.molgen.mpg.de/]
• Nationales Genomforschungsnetz (NGFN) 
[http://www.ngfn.de/]
• Riken Genomic Sciences Research Complex (GSC) 
[http://www.gsc.riken.go.jp/]
• Kyoto Encyclopedia of Genes and Genomes 
[http://www.genome.jp/kegg/]
• ExPASy Proteomics Server 
[http://expasy.org/]
• European Proteomics Association (EuPA) 
[http://www.eupa.org/]
• HUPO: Human Proteome Organisation 
[http://www.hupo.org/] 
• HUPO Brain Proteome Project 
[http://www.hbpp.org/5602.html]
Conclusion
Learning about the plethora of concepts, terminology, pro-
jects, databases, tools, and stakeholders involved in per-
sonalized medicine is a difficult task. For an overview with
both breadth and depth, consulting the book by Willard
and Ginsburg (mentioned above)3 is highly recommended.
Keeping up with new literature and other developments
in specific areas of personalized medicine is also challeng-
ing. It is possible to follow new journal literature, in
PubMed for example, by setting up search alerts for top-
ics of interest, or alerts for tables of contents from partic-
ular journals. Another strategy is to create Google alerts,
or to arrange with government agencies or other organi-
zations to receive their news alerts. While e-mail alerts are
one way to receive this information, an RSS (Really
Simple Syndication) reader such as Google Reader
(http://reader.google.com) is another way to easily and
efficiently read and manage alerts. Researchers at institu-
tions that are fortunate enough to have a librarian or other
information professional should consult them for advice
on searching for information, managing what they find,
and keeping informed about new developments, especially
in fast-paced fields such as personalized medicine. ❏
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Medicina personalizada: 
recursos seleccionados de la web
Aunque existe bastante información acerca de la
medicina personalizada, todavía es difícil buscar de
manera comprensible información sobre este tema
debido a la amplitud del término “medicina perso-
nalizada”, la variedad de términos que se utilizan
para describir este concepto, la gran cantidad de
artículos de revistas y sitios web, y el rápido avance
del progreso en este campo. Se provee una lista
seleccionada de sitios web como punto de partida
para obtener información acerca de conceptos, ter-
minología, proyectos, bases de datos, herramientas
y usuarios relacionados con la medicina personali-
zada. 
Médecine personnalisée : 
sélection de sources internet 
Le terme de « médecine personnalisée » est si large
qu’il est difficile d’effectuer une recherche complète
sur ce sujet qui regorge d’informations, qui est
décrit par une multitude de mots dans une grande
quantité d’articles de journaux et de sites internet
appropriés et dont le développement est rapide.
Nous avons sélectionné une liste de sites internet
qui permettent de débuter une recherche sur les
concepts, la terminologie, les projets, les données,
les outils et les partenaires de la médecine person-
nalisée.
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1999
• Bipolar Disorders
• Depression in the Elderly
• Nosology and Nosography
2000
• Posttraumatic Stress Disorder
• Alzheimer’s Disease
• From Research to Treatment in Clinical 
Neuroscience
• Schizophrenia: General Findings
2001
• Genetic Approach to Neuropsychiatric 
Disorders
• Schizophrenia: Specific Topics
• Cerebral Aging
• New Perspectives in Chronic Psychoses
2002
• Pathophysiology of Depression
• CNS Aspects of Reproductive Endocrinology
• Anxiety I
• Drug Development
2003
• Dementia
• Psychiatric Disorders in Somatic Medicine
• Anxiety II
• Chronobiology and Mood Disorders
2004
• Predictors of Response to Treatment 
in Neuropsychiatry
• Neuroplasticity
• Parkinson's Disease
• Mild Cognitive Impairment
2005 
• Early Stages of Schizophrenia
• New Psychiatric Classification based on 
Endophenotypes
• Pharmacology of Mood Disorders
• Sleep Disorders, Neuropsychiatry, and Psychotropics
2006 
• Diagnosis and Management of Schizophrenic 
Disorders
• Depression in Medicine
• Drug Discovery and Proof of Concept
• Stress
2007 
• Neuropsychiatry and Cardiovascular Disease
• Neuropsychiatric Manifestations of 
Neurodegenerative Disease
• Chronobiology in Psychiatry
• Addictive Substances
2008 
• Epilepsy and Psychiatry 
• Developments in Bipolar Disorder 
• The Core of Depression   
• Remission in Depression    
2009
•  Child and Adolescent Psychiatry  
•  Alzheimer's Disease and Mild Cognitive 
Impairment
•  Neurotoxicity and Neuroprotection
An interface between clinical neuropsychiatry and neuroscience,
providing state-of-the-art information and original insights into 
relevant clinical, biological, and therapeutic aspects
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